Novel drug linker, antibody-drug conjugate thereof and use thereof

By using camptothecin derivatives as novel drug linkers, the problem of ADC aggregation was solved, the stability and safety of ADCs were improved, the anti-tumor efficacy was enhanced, the toxicity was reduced, and the therapeutic window was expanded.

WO2026233411A1PCT designated stage Publication Date: 2026-11-12HANGZHOU ZHONGMEI HUADONG PHARMACEUTICAL CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/CN2026/095445
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-09
Filing Date
2026-05-08
Publication Date
2026-11-12

AI Technical Summary

Technical Problem

Existing antibody-drug conjugates (ADCs) tend to aggregate at high drug-to-antibody ratios (DARs), leading to rapid plasma clearance and increased toxicity, thus affecting efficacy.

Method used

A novel drug linker is employed, using a camptothecin derivative as a prodrug toxin, which combines a hydrophilic group and a stable lactone ring to form a compound structure that improves the stability and solubility of ADCs, reduces efflux rate, and enhances safety and therapeutic index.

Benefits of technology

It improves the in vitro and in vivo antitumor efficacy of ADCs, enhances physicochemical stability and tolerability, reduces toxic side effects, and expands the therapeutic window.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN2026095445_12112026_PF_FP_ABST
    Figure CN2026095445_12112026_PF_FP_ABST
Patent Text Reader

Abstract

Compounds or pharmaceutically acceptable salts, esters, stereoisomers, polymorphs, solvates, N-oxides, isotopically labeled compounds, metabolites or prodrugs thereof. The compounds have the structure of formula (I). The compounds have good activity, stable lactone rings, a low efflux rate and high safety, and has outstanding potential to be manufactured as drugs.
Need to check novelty before this filing date? Find Prior Art

Description

Novel drug linkers, their antibody-drug conjugates and their uses

[0001] This application claims priority to Chinese patent application 202510595004.7, filed on May 9, 2025, which is incorporated herein by reference in its entirety. Technical Field

[0002] This invention relates to a novel linker for antibody-drug conjugates (ADCs), as well as ADCs based on the linker, their preparation methods, and uses. Background Technology

[0003] Antibody-drug conjugates (ADCs) are a type of targeted cancer therapy. Antibodies targeting tumor antigens are covalently coupled to cytotoxic payloads via chemically synthesized linkers. The selection of both the drug linker and the payload plays a crucial role in the therapeutic efficacy and safety of ADCs.

[0004] Currently, most ADC molecules entering clinical development utilize cleavable linkers, including acid-labile linkers, peptide linkers, and disulfide linkers. Cleavable dipeptide linkers, formed by linking valine-citrulline (Val-Cit) to a self-cleavable spacer benzyl hydroxyl group (PAB), are widely used in ADC clinical development. However, due to the strong hydrophobicity of VC linkers, when combined with superhydrophobic payloads, they can form easily aggregated "surfactant-like" structures with the more hydrophilic portions of antibodies, especially when the drug-to-antibody ratio (DAR) is higher than 4. In vivo, ADC aggregation can lead to rapid plasma clearance, reduced efficacy, and increased toxicity, particularly for ADC molecules with high DAR values.

[0005] Therefore, there is an urgent need in the field to develop new, stable, hydrophilic, and non-aggregating linkers and payloads to obtain effectively targeted ADCs that achieve the highest therapeutic index. Summary of the Invention

[0006] Through extensive research, this invention has surprisingly discovered a camptothecin derivative, a prodrug toxin for preparing ADC drugs. This camptothecin derivative exhibits excellent activity, a more stable lactone ring, low efflux rate, and better safety, demonstrating significant drug development potential. Furthermore, the inventors have found that ADCs based on this prodrug toxin possess superior in vitro and in vivo antitumor efficacy, outperforming certain existing ADC agents or existing linker-drug toxin (LP)-based ADC agents. The ADC of this invention also has the potential to possess improved properties, such as good solubility and physicochemical stability, good stability in blood circulation, good tolerability, low toxicity, and a wide therapeutic window, etc.

[0007] Linker-toxin linker

[0008] One aspect of the present invention provides a compound or a pharmaceutically acceptable salt, ester, stereoisomer, polymorph, solvate, N-oxide, isotopically labeled compound, metabolite, or prodrug thereof, wherein the compound has the structure of formula (I):

[0009] in:

[0010] Q is a functional group that can couple with cysteine, lysine, non-natural amino acids, or glycosyl groups of antibody molecules.

[0011] D represents the drug unit;

[0012] B1, B2, and B3 are each independently selected from bonded or branched segments;

[0013] C1 is an independent spacer group;

[0014] S2, S3, S4, and S5 are each independently a hydrophilic group or a group selected from various hydrophilic groups;

[0015] F1 is selected from the direct bond or the group consisting of: optionally substituted alkylene, optionally substituted polyethylene glycol, optionally substituted alkenyl, optionally substituted ynylene, optionally substituted alicyclic, optionally substituted alicyclic, optionally substituted aryl, and optionally substituted heteroaryl; when substituted, the substituent is selected from halogen, hydroxyl, amino, carboxyl, carbonyl, sulfonic acid, sulfone, phosphate, and alkoxy.

[0016] L1 is selected from either a direct bond or an extended unit; the condition is that F1 and L1 are not both direct bonds at the same time.

[0017] a, b, c, and d are each independently 0, 1, 2, or 3, provided that a, b, c, and d are not all 0 at the same time;

[0018] The functional groups conjugated to the cysteine, lysine, non-natural amino acids, or glycosyl groups of the antibody molecule are selected from those with optional substitutions.

[0019] The drug structural unit is selected from the compounds shown in formula (A):

[0020] in:

[0021] X is CH2 or S;

[0022] Ring A is independently selected from C 3-6 cycloalkyl or 3-6 membered heterocycloalkyl;

[0023] R1 and R 2 Each is independently selected from halogens, -NH2, -OH, and C. 1-3 Alkyl or C 1-3 Alkoxy;

[0024] Or, R 1 R 2 Composition with adjacent carbon

[0025] R is independently selected from halogen, hydroxyl, amino, or thiol groups;

[0026] n is selected from 0, 1, 2, or 3;

[0027] m is selected from 1, 2, 3, or 4;

[0028] "---"for Or a mixture containing it.

[0029] In some implementations, "---" means

[0030] In the preferred embodiment, "---" means

[0031] In some embodiments, the present invention provides compounds of formula (I) or pharmaceutically acceptable salts, esters, stereoisomers, polymorphs, solvates, N-oxides, isotopically labeled compounds, metabolites, or prodrugs thereof, wherein said compounds have the structure of formula (Ia):

[0032] in:

[0033] Q is the functional group that can couple with cysteine, lysine, non-natural amino acids or glycosyl groups of antibody molecules.

[0034] D represents the drug unit;

[0035] C1 is the spacer group independently;

[0036] S3 is independently the hydrophilic group or selected from the group consisting of each of the hydrophilic groups;

[0037] F1 is selected from the direct bond or the group consisting of: optionally substituted alkylene, optionally substituted polyethylene glycol, optionally substituted alkenyl, optionally substituted ynylene, optionally substituted alicyclic, optionally substituted alicyclic, optionally substituted aryl, and optionally substituted heteroaryl; when substituted, the substituent is selected from halogen, hydroxyl, amino, carboxyl, carbonyl, sulfonic acid, sulfone, phosphate, and alkoxy.

[0038] L1 is selected from either a direct key or the extended unit; the condition is that F1 and L1 are not both direct keys at the same time.

[0039] a can be 1, 2, or 3 independently.

[0040] In some embodiments of compounds of formula (Ia), L1 is a direct bond.

[0041] In some embodiments of compounds of formula (Ia), a is 1.

[0042] In some embodiments, the present invention provides compounds of formula (I) or pharmaceutically acceptable salts, esters, stereoisomers, polymorphs, solvates, N-oxides, isotopically labeled compounds, metabolites, or prodrugs thereof, wherein said compounds have the structure of formula (Ib):

[0043] in:

[0044] Q is the functional group that can couple with cysteine, lysine, non-natural amino acids or glycosyl groups of antibody molecules.

[0045] D represents the drug unit;

[0046] B1 is selected from the branched segment;

[0047] C1 is either a direct bond or the spacer group;

[0048] S2 is independently the hydrophilic group or selected from the group consisting of each of the hydrophilic groups;

[0049] F1 is selected from the direct bond or the group consisting of: optionally substituted alkylene, optionally substituted polyethylene glycol, optionally substituted alkenyl, optionally substituted ynylene, optionally substituted alicyclic, optionally substituted alicyclic, optionally substituted aryl, and optionally substituted heteroaryl; when substituted, the substituent is selected from halogen, hydroxyl, amino, carboxyl, carbonyl, sulfonic acid, sulfone, phosphate, and alkoxy.

[0050] L1 is the extension unit;

[0051] b can be 1, 2, or 3 independently.

[0052] In some embodiments of compounds of formula (Ib), F1 is a direct bond.

[0053] In some embodiments of compounds of formula (Ib), b is 1.

[0054] In some embodiments, the present invention provides compounds of formula (I) or pharmaceutically acceptable salts, esters, stereoisomers, polymorphs, solvates, N-oxides, isotopically labeled compounds, metabolites, or prodrugs thereof, wherein said compounds have the structure of formula (Ic):

[0055] in:

[0056] Q is the functional group that can couple with cysteine, lysine, non-natural amino acids or glycosyl groups of antibody molecules.

[0057] D represents the drug unit;

[0058] B1 and B2 are independently selected from the branched segments;

[0059] C1 is the spacer group independently;

[0060] S3, S4 and S2 are independently the hydrophilic groups or selected from the group consisting of the hydrophilic groups;

[0061] F1 is selected from the direct bond or the group consisting of: optionally substituted alkylene, optionally substituted polyethylene glycol, optionally substituted alkenyl, optionally substituted ynylene, optionally substituted alicyclic, optionally substituted alicyclic, optionally substituted aryl, and optionally substituted heteroaryl; when substituted, the substituent is selected from halogen, hydroxyl, amino, carboxyl, carbonyl, sulfonic acid, sulfone, phosphate, and alkoxy.

[0062] L1 is selected from either a direct key or the extended unit; the condition is that F1 and L1 are not both direct keys at the same time.

[0063] b and c can each be 1, 2, or 3 independently;

[0064] a can be 0, 1, 2 or 3 independently.

[0065] In some embodiments of compounds of formula (Ic), neither F1 nor L1 is a direct bond.

[0066] In some embodiments of compounds of formula (Ic), a is 0. In some embodiments of compounds of formula (Ic), a is 1.

[0067] In some embodiments of compounds of formula (Ic), b is 1.

[0068] In some embodiments of compounds of formula (Ic), c is 1.

[0069] In some embodiments, the present invention provides compounds of formula (I) or pharmaceutically acceptable salts, esters, stereoisomers, polymorphs, solvates, N-oxides, isotopically labeled compounds, metabolites, or prodrugs thereof, wherein said compounds have the structure of formula (Id):

[0070] in:

[0071] Q is the functional group that can couple with cysteine, lysine, non-natural amino acids or glycosyl groups of antibody molecules.

[0072] D represents the drug unit;

[0073] B2 is independently selected from the branched segment;

[0074] C1 is the spacer group independently;

[0075] S3 and S4 are independently the hydrophilic groups or selected from the group consisting of the hydrophilic groups;

[0076] F1 is selected from the direct bond or the group consisting of: optionally substituted alkylene, optionally substituted polyethylene glycol, optionally substituted alkenyl, optionally substituted ynylene, optionally substituted alicyclic, optionally substituted alicyclic, optionally substituted aryl, and optionally substituted heteroaryl; when substituted, the substituent is selected from halogen, hydroxyl, amino, carboxyl, carbonyl, sulfonic acid, sulfone, phosphate, and alkoxy.

[0077] L1 is selected from either a direct key or the extended unit; the condition is that F1 and L1 are not both direct keys at the same time.

[0078] c can be 1, 2, or 3 independently;

[0079] a can be 0, 1, 2 or 3 independently.

[0080] In some embodiments of compounds of formula (Id), neither F1 nor L1 is a direct bond.

[0081] In some embodiments of compounds of formula (Id), a is 0. In some embodiments of compounds of formula (Id), a is 1.

[0082] In some embodiments of compounds of formula (Id), c is 1.

[0083] In some embodiments, the present invention provides compounds of formula (I) or pharmaceutically acceptable salts, esters, stereoisomers, polymorphs, solvates, N-oxides, isotopically labeled compounds, metabolites, or prodrugs thereof, wherein said compounds have the structure of formula (Ie):

[0084] in:

[0085] Q is the functional group that can couple with cysteine, lysine, non-natural amino acids or glycosyl groups of antibody molecules.

[0086] D represents the drug unit;

[0087] B3 is independently selected from the branched segment;

[0088] C1 is the spacer group independently;

[0089] S3 and S5 are independently the hydrophilic groups or selected from the group consisting of the hydrophilic groups;

[0090] F1 is selected from the direct bond or the group consisting of: optionally substituted alkylene, optionally substituted polyethylene glycol, optionally substituted alkenyl, optionally substituted ynylene, optionally substituted alicyclic, optionally substituted alicyclic, optionally substituted aryl, and optionally substituted heteroaryl; when substituted, the substituent is selected from halogen, hydroxyl, amino, carboxyl, carbonyl, sulfonic acid, sulfone, phosphate, and alkoxy.

[0091] L1 is selected from either a direct key or the extended unit; the condition is that F1 and L1 are not both direct keys at the same time.

[0092] d can be 1, 2, or 3 independently;

[0093] a can be 0, 1, 2 or 3 independently.

[0094] In some embodiments of compounds of formula (Ie), neither F1 nor L1 is a direct bond.

[0095] In some embodiments of compounds of formula (Ie), a is 0. In some embodiments of compounds of formula (Ie), a is 1.

[0096] In some embodiments of compounds of formula (Ie), d is 1.

[0097] In some embodiments, the present invention provides a compound of formula (I) or a pharmaceutically acceptable salt, ester, stereoisomer, polymorph, solvate, N-oxide, isotopically labeled compound, metabolite, or prodrug thereof, wherein:

[0098] Q is the functional group that can couple with cysteine, lysine, non-natural amino acids or glycosyl groups of antibody molecules.

[0099] D represents the drug unit;

[0100] B1 is selected from the branched segment;

[0101] C1 is either a direct bond or the spacer group;

[0102] S2 and S3 are each independently the hydrophilic group or selected from the group consisting of each of the hydrophilic groups;

[0103] F1 is selected from the direct bond or the group consisting of: optionally substituted alkylene, optionally substituted polyethylene glycol, optionally substituted alkenyl, optionally substituted ynylene, optionally substituted alicyclic, optionally substituted alicyclic, optionally substituted aryl, and optionally substituted heteroaryl; when substituted, the substituent is selected from halogen, hydroxyl, amino, carboxyl, carbonyl, sulfonic acid, sulfone, phosphate, and alkoxy.

[0104] L1 is selected from either a direct key or the extended unit; the condition is that F1 and L1 are not both direct keys at the same time.

[0105] a and b can be 1, 2, or 3 independently.

[0106] In some such embodiments, the compound has the structure of formula (If):

[0107] In some embodiments, in any of formula I, Ia, Ib, Ic, Id, Ie, or If, F1 is selected from a direct bond or the group consisting of: optionally substituted alkylene, optionally substituted polyethylene glycol, optionally substituted alkenyl, optionally substituted ynylene, optionally substituted alicyclic, optionally substituted alicyclic, optionally substituted aryl, and optionally substituted heteroaryl; when substituted, the substituent is selected from halogen, hydroxyl, amino, carboxyl, sulfonic acid, sulfone, phosphate, and alkoxy.

[0108] In some implementations, B1, B2, and B3, when present, are each keys in any of Equations I, Ia, Ib, Ic, Id, Ie, or If.

[0109] In a preferred embodiment, in any of formulas I, Ia, Ib, Ic, Id, Ie, or If, B1, B2, and B3, when present, are each: in:

[0110] Connection point 3 This indicates that B1, B2, or B3 are connected to S2, S4, or S5 respectively; and

[0111] R 8 Selected from H or hydrophilic groups.

[0112] In the preferred embodiment, R 8The hydrophilic groups in S2, S4, or S5 are each selected from: optionally substituted polysarcosine residues, polyglycerols, polyols, glycosyl groups, cyclodextrins, substituted ethylene glycol fragments, substituted glycosylated polyethylene glycol fragments, substituted glycosylated polyglycerols, substituted cyclodextrin polyethylene glycols, or combinations thereof.

[0113] In some such embodiments, the optionally substituted polysarcosine residue is Wherein n2 is an integer between 4 and 20, 4 and 16, or 8 and 12, preferably 10; R0 is selected from C1-C6 alkyl, C1-C6 cycloalkyl, and C1-C6 alkoxy, preferably methyl; preferably, the optionally substituted polysarcosine residue is

[0114] In some embodiments, the substituted glycosylated polyglycerol fragment is Where n4 is an integer between 4 and 12, or between 4 and 10.

[0115] In some embodiments, the substituted polyethylene glycol fragment is Where n5 is an integer between 4 and 24, between 7 and 20, or between 8 and 18, preferably, the substituted polyethylene glycol fragment is...

[0116] In some embodiments, the substituted glycosylated polyethylene glycol fragment is Where n3 is an integer between 4 and 18, or between 4 and 12. Preferably, the substituted glycosylated polyethylene glycol fragment is...

[0117] In some embodiments, the hydrophilic group is selected from the group consisting of optionally substituted polyethylene glycol segments and substituted polysarcosine segments, preferably. Wherein n7 is an integer between 4 and 20, 4 and 16, or 8 and 12, preferably 10; R0 is selected from C1-C6 alkyl, C1-C6 cycloalkyl, and C1-C6 alkoxy, preferably methyl; n5 is an integer between 4 and 24, 7 and 20, or 8 and 18. Preferably, the hydrophilic group is:

[0118] In some embodiments, the polyol is Preferred

[0119] In some embodiments, the glycosyl group is

[0120] In a preferred embodiment, in any of formulas I, Ia, Ib, Ic, Id, Ie, or If, B1, B2, and B3, when present, are each selected from the following group: "Connection point 3" means that B1, B2 or B3 are respectively connected to S2, S4 or S5.

[0121] In a preferred embodiment, in any of formulas I, Ia, Ib, Ic, Id, Ie, or If, B1, B2, and B3, when present, are each: Where "connection point 3" means that B1, B2, or B3 are respectively connected to S2, S4, or S5, and R 8 The hydrophilic group is mentioned above.

[0122] In a preferred embodiment, in any of Formula I, Ia, Ib, Ic, Id, Ie, or If, the hydrophilic group is independently selected each time it appears from: optionally substituted polysarcosine residues, polyglycerols, polyols, glycosyl groups, cyclodextrins, substituted ethylene glycol fragments, substituted glycosylated polyethylene glycol fragments, substituted glycosylated polyglycerols, substituted cyclodextrin polyethylene glycols, or combinations thereof.

[0123] In some preferred embodiments, in any of formulas I, Ia, Ib, Ic, Id, Ie, or If, the optionally substituted polysarcosine residue is Wherein: n2 is an integer between 4 and 20, for example an integer between 4 and 16, preferably an integer between 8 and 12, more preferably 10; R0 is selected from: C1-C6 alkyl, C1-C6 cycloalkyl and C1-C6 alkoxy, preferably methyl.

[0124] Preferably, the optionally substituted polysarcosine residues are:

[0125] In some preferred embodiments, in any of formulas I, Ia, Ib, Ic, Id, Ie, or If, the substituted glycosylated polyglycerol fragment is Where n4 is an integer between 4 and 12, for example, an integer between 4 and 10.

[0126] In some preferred embodiments, in any of formulas I, Ia, Ib, Ic, Id, Ie, or If, the substituted polyethylene glycol segment is Wherein, n5 is an integer between 4 and 24, for example, between 7 and 20, or between 8 and 18, for example, the substituted polyethylene glycol fragment is...

[0127] In other preferred embodiments, in any of formulas I, Ia, Ib, Ic, Id, Ie, or If, the substituted...

[0128] Glycosylated polyethylene glycol fragments are Where n3 is an integer between 4 and 18, for example, an integer between 4 and 12; preferably, the substituted glycosylated polyethylene glycol fragment is:

[0129] In some preferred embodiments, in any of formulas I, Ia, Ib, Ic, Id, Ie, or If, the hydrophilic group may also be selected from the group consisting of optionally substituted polyethylene glycol segments and substituted polysarcosine segments, preferably. Wherein n7 is an integer between 4 and 20, for example, an integer between 4 and 16, preferably an integer between 8 and 12, more preferably 10; R0 is selected from: C1-C6 alkyl, C1-C6 cycloalkyl, and C1-C6 alkoxy, preferably methyl; n5 is an integer between 4 and 24, for example, an integer between 7 and 20, or an integer between 8 and 18; further preferred

[0130] In some preferred embodiments, the polyol is Preferred

[0131] In some preferred embodiments, the glycosyl group is

[0132] In some preferred embodiments, in any of equations I, Ia, Ib, Ic, Id, Ie, or If, when B1, B2, or B is present, -B1-[S2] b -B2-[S4] c 、or -B3-[S2] a Each part is independently selected from:

[0133] In some preferred embodiments, in any of formulas I, Ia, Ib, Ic, Id, Ie, or If, L1, when present, may independently be an optionally substituted amino acid. Preferably, the amino acid is selected from: phenylalanine, isoleucine, leucine, tryptophan, valine, methionine, tyrosine, alanine, threonine, histidine, serine, glutamine, arginine, lysine, asparagine, glutamic acid, proline, citrulline, aspartic acid, and glycine. More preferably, the amino acid is valine, particularly... include

[0134] In some preferred embodiments, L1 may also be an optionally substituted polypeptide residue in any of Formula I, Ia, Ib, Ic, Id, Ie, or If, when present.

[0135] In some such embodiments, in any of formulas I, Ia, Ib, Ic, Id, Ie, or If, L1, when present, independently comprises optionally substituted polypeptide residues consisting of amino acids selected from the group consisting of: phenylalanine, isoleucine, leucine, tryptophan, valine, methionine, tyrosine, alanine, threonine, histidine, serine, glutamine, arginine, lysine, asparagine, glutamic acid, proline, citrulline, aspartic acid, and glycine.

[0136] In a preferred embodiment, in any of formulas I, Ia, Ib, Ic, Id, Ie, or If, L1, when present, independently comprises a polypeptide residue consisting of optionally substituted amino acids selected from the group consisting of glycine, phenylalanine, valine, alanine, arginine, citrulline, aspartic acid, asparagine, and lysine.

[0137] In a preferred embodiment, in any of Formula I, Ia, Ib, Ic, Id, Ie, or If, L1, when present, independently comprises optionally substituted polypeptide residues selected from the group consisting of: phenylalanine-lysine (Phe-Lys), valine-alanine (Val-Ala), valine-citrulline (Val-Cit), glutamic acid-valine-alanine (Glu-Val-Ala), glutamic acid-valine-citrulline (Glu-Val-Cit), valine-lysine (Val-Lys), alanine-alanine (Ala-Ala), alanine-alanine-alanine (Ala-Ala-Ala), alanine-alanine-asparagine (Ala-Ala-Asn), alanine-leucine (Ala-Leu), leucine-leucine (Leu-Leu), phenylalanine-arginine (Phe-Arg), and phenylalanine-lysine (Phe-Lys). Glycine-glycine-phenylalanine-glycine (Gly-Gly-Phe-Gly), glycine-proline (Gly-Pro).

[0138] In a preferred embodiment, in any of formulas I, Ia, Ib, Ic, Id, Ie, or If, L1 is independently phenylalanine-lysine (Phe-Lys), valine-alanine (Val-Ala), valine-citrulline (Val-Cit), alanine-alanine (Ala-Ala), or glycine-glycine-phenylalanine-glycine (Gly-Gly-Phe-Gly).

[0139] In a more preferred embodiment, in any of formulas I, Ia, Ib, Ic, Id, Ie, or If, L1, when present, is independently valine-alanine (Val-Ala), valine-citrulline (Val-Cit), or alanine-alanine (Ala-Ala), particularly include

[0140] In some implementations, in any of equations I, Ia, Ib, Ic, Id, Ie, or If, each C1 is independently:

[0141] Preferred

[0142] More

[0143] Where: Connection point 1 Connect to B3 or L1 (where applicable), and connect point 2. Connected to the drug unit D.

[0144] In some preferred embodiments, in any of formulas I, Ia, Ib, Ic, Id, Ie, or If, when a is present and not zero, each S3 is independently the glycosyl or cyclodextrin, preferably the glycosyl, more preferably the glycosyl. include

[0145] In some implementations, C1 is selected from the group consisting of any of Equations I, Ia, Ib, Ic, Id, Ie, or If: and optional replacement Here, connection point 1 is connected to L1, and connection point 2 is connected to the drug unit D.

[0146] In some preferred embodiments, in any of formulas I, Ia, Ib, Ic, Id, Ie, or If, when B1 is selected from... When S2 is a glycosyl group, the -B1-S2 portion is selected from...

[0147] In some preferred embodiments, in any of formulas I, Ia, Ib, Ic, Id, Ie, or If, when B1 is selected from... And when S2 is a polyol, the -B1-S2 portion is selected from...

[0148] In some preferred embodiments, in any of formulas I, Ia, Ib, Ic, Id, Ie, or If, -C1-[S3] a Part of

[0149] In some preferred embodiments, in any of formulas I, Ia, Ib, Ic, Id, Ie, or If, when C1 is selected from... When S3 is a glycosyl group, the -C1-S3 portion is selected from...

[0150] In some implementations, F1 is an independent direct key in any of Equations I, Ia, Ib, Ic, Id, Ie, or If, when it exists.

[0151] In some preferred embodiments, in any of formulas I, Ia, Ib, Ic, Id, Ie, or If, F1, when present, is independently selected from directly bonded or optionally substituted polyethylene glycol groups. In a preferred embodiment, the optionally substituted polyethylene glycol group is... Where n6 is an integer between 1 and 18, preferably between 1 and 12 or between 1 and 10, such as 1, 2, 3, 4, 5, 6, 7, 8 or 9.

[0152] In a preferred embodiment, F1, when present in any of equations I, Ia, Ib, Ic, Id, Ie, or If, is independently [equation missing]. Where n6 is 1, 3 or 7.

[0153] In a preferred embodiment, F1, when present in any of equations I, Ia, Ib, Ic, Id, Ie, or If, is independently [equation missing]. Where n6 is 1, 3 or 7.

[0154] In some embodiments, the amino terminus (-NH-) of the polyethylene glycol group is connected to L1.

[0155] In a preferred embodiment, the carbonyl end (-C(O)-) of the polyethylene glycol group is connected to L1.

[0156] In a preferred embodiment, in any of formulas I, Ia, Ib, Ic, Id, Ie, or If, the C in the pharmaceutical unit D... 3~6 The cycloalkyl group can be a monocyclic, spirocyclic, fused, or bridged ring; preferably, the C 3~6 cycloalkyl groups are selected from C 3~6 Monocyclic cycloalkyl or C 5~6 Bridged cycloalkyl rings.

[0157] In a preferred embodiment, in any of formulas I, Ia, Ib, Ic, Id, Ie, or If, the C in the pharmaceutical unit D... 3~6 The cycloalkyl group is selected from cyclopropane, cyclobutane, cyclopentane, cyclohexane, Preferred materials include cyclopropane, cyclobutane, cyclohexane, or... More

[0158] In a preferred embodiment, in any of Formula I, Ia, Ib, Ic, Id, Ie, or If, the 3-6 membered heterocyclic alkyl group in the pharmaceutical unit D may be ethylene oxide, aziridinyl, aziridine, oxacyclobutyl, tetrahydrofuranyl, dioxacyclopentenyl, pyrrolylalkyl, pyrrolidoneyl, imidazoalkyl, pyrazolylalkyl, pyrrolinyl, tetrahydropyranyl, piperidinyl, morpholinyl, dithiaalkyl, thiomorpholinyl, piperazine, or trithiaalkyl.

[0159] In a preferred embodiment, in any of formulas I, Ia, Ib, Ic, Id, Ie, or If, the R in the pharmaceutical unit D 1 Selected from halogens, -NH2, -OH, C 1-3 Alkyl or C 1-3 Alkyl group.

[0160] In a preferred embodiment, in any of formulas I, Ia, Ib, Ic, Id, Ie, or If, the R in the pharmaceutical unit D... 1 It is selected from F, Cl, Br, I, -NH2, -OH, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy or propoxy, preferably methyl, methoxy, Cl, -OH or -NH2, more preferably methyl or methoxy.

[0161] In a preferred embodiment, in any of formulas I, Ia, Ib, Ic, Id, Ie, or If, the R in the pharmaceutical unit D... 2 Selected from halogens, -NH2, -OH, C 1-3 Alkyl or C 1-3 Alkyl group.

[0162] In a preferred embodiment, in any of formulas I, Ia, Ib, Ic, Id, Ie, or If, the R in the pharmaceutical unit D... 2 It is selected from F, Cl, Br, I, -NH2, -OH, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy or propoxy, with F being preferred.

[0163] In a preferred embodiment, in any of formulas I, Ia, Ib, Ic, Id, Ie, or If, the R in the pharmaceutical unit D is selected from F, Cl, Br, or I, preferably F.

[0164] In a preferred embodiment, in any of formulas I, Ia, Ib, Ic, Id, Ie, or If, the n in the pharmaceutical unit D is selected from 1 or 2, preferably 1.

[0165] In a preferred embodiment, in any of formulas I, Ia, Ib, Ic, Id, Ie, or If, the m in the pharmaceutical unit D is selected from 1 or 2, preferably 1.

[0166] In a preferred embodiment, in any of formulas I, Ia, Ib, Ic, Id, Ie, or If, the compound of formula (A) is selected from the structure represented by the following formula (A-1):

[0167] in:

[0168] Ring A can be cyclopropane, cyclobutane, cyclopentane, or cyclohexane.

[0169] The R 2 Preferred option: F;

[0170] The R 1 Preferably methyl or methoxy (in some embodiments, R 1 For methyl; in some embodiments, R 1 (Methoxylated);

[0171] Other definitions are as described above.

[0172] In a preferred embodiment, in any one of formula I, Ia, Ib, Ic, Id, Ie, or If, the compound of formula (A) is a compound of formula (A-1-1):

[0173] in:

[0174] R 1Selected from methyl, Cl, -OH or -NH2, methoxy;

[0175] R 2 Selected from F;

[0176] Or, R 1 R 2 Composition with adjacent carbon

[0177] R is selected from F; and

[0178] n is selected from 1;

[0179] Preferably, it is a compound of formula (AA)

[0180] In a preferred embodiment, in any one of formula I, Ia, Ib, Ic, Id, Ie, or If, the compound of formula (A) is a compound of formula (A-1-2):

[0181] in:

[0182] R 1 Selected from methyl, Cl, -OH or -NH2, methoxy;

[0183] R 2 Selected from F;

[0184] Or, R 1 R 2 Composition with adjacent carbon

[0185] R is selected from F; and

[0186] n is selected from 1.

[0187] In a preferred embodiment, in any one of formulas I, Ia, Ib, Ic, Id, Ie, or If, the compound of formula (A) is a compound of formula (A-1-3):

[0188] in:

[0189] R 1 Selected from methyl, Cl, -OH or -NH2, methoxy;

[0190] R 2 Selected from F;

[0191] Or, R 1 R 2 Composition with adjacent carbon

[0192] R is selected from F; and

[0193] n is selected from 1.

[0194] In a preferred embodiment, in any one of formulas I, Ia, Ib, Ic, Id, Ie, or If, the compound of formula (A) is a compound of formula (A-1-4):

[0195] in:

[0196] R 1 Selected from methyl, Cl, -OH or -NH2, methoxy;

[0197] R 2 Selected from F; and

[0198] n is selected from 0.

[0199] In some embodiments, in any of formulas I, Ia, Ib, Ic, Id, Ie, or If, the compound of formula (A) is selected from the structures shown in Table A below:

[0200] In a preferred embodiment, the pharmaceutical unit D is compound 11a or 17a from Table A above.

[0201] The pharmaceutical unit D of this application, namely the compound of any formula (A) described above, is also described in the applicant's international patent application PCT / CN2025 / 097909, which is incorporated herein by reference in its entirety.

[0202] According to IUPAC nomenclature, the compound of any formula (A) described above has an imino group (-NH-) at position 1 and an OH group at position 9. In some embodiments, the compound of any formula (A) described above is connected to C1 via a carboxamide bond (-C(O)-N-) or a phosphoramide bond (-P(O)(OH)-N-) through the -NH- group at position 1. In some embodiments, the compound of any formula (A) described above is connected to C1 via a carboxylic acid ester group (-C(O)-O-) or a phosphate ester group (-P(O)(OH)-O-) through the OH group at position 9.

[0203] In this invention, the embodiments or preferred embodiments of the above components (such as Q, C1, B1, F1, L1, S2, S3, D) can be applied individually to any of formulas I, Ia, Ib, Ic, Id, Ie or If, or in various combinations to any of formulas I, Ia, Ib, Ic, Id, Ie or If.

[0204] Where combinations are applicable, the implementation schemes or preferred implementation schemes of the components may be combined in whole or in part.

[0205] In a preferred embodiment, the present invention provides compounds selected from formulas A1 to A18, or pharmaceutically acceptable salts, esters, stereoisomers, polymorphs, solvates, N-oxides, isotopically labeled compounds, metabolites, or prodrugs thereof:

[0206] Drug-connector fragments

[0207] Another aspect of the present invention provides a linker or a pharmaceutically acceptable salt, ester, stereoisomer, polymorph, solvate, N-oxide, isotopically labeled compound, metabolite, or prodrug thereof, wherein the linker has the structure of formula (II):

[0208] in:

[0209] Q1 is a functional group that can couple with cysteine, lysine, non-natural amino acids or glycosyl groups of antibody molecules.

[0210] D represents the drug unit;

[0211] B1, B2, and B3 are independently selected from bonded or branched segments;

[0212] C1 is an independent spacer group;

[0213] S2, S3, S4 and S5 are each independently a hydrophilic group or selected from the group consisting of each of the aforementioned hydrophilic groups;

[0214] F1 is selected from the direct bond or the group consisting of: optionally substituted alkylene, optionally substituted polyethylene glycol, optionally substituted alkenyl, optionally substituted ynylene, optionally substituted alicyclic, optionally substituted alicyclic, optionally substituted aryl, and optionally substituted heteroaryl; when substituted, the substituent is selected from halogen, hydroxyl, amino, carboxyl, carbonyl, sulfonic acid, sulfone, phosphate, and alkoxy.

[0215] L1 is selected from either a direct bond or an extended unit; the condition is that F1 and L1 are not both direct bonds at the same time.

[0216] a, b, c, and d are each independently 0, 1, 2, or 3, provided that a, b, c, and d are not all 0 at the same time;

[0217] The functional groups conjugated to the cysteine, lysine, non-natural amino acids, or glycosyl groups of the antibody molecule are selected from those with optional substitutions. Or optional replacement

[0218] The drug structural unit is selected from the compounds shown in formula (A):

[0219] in:

[0220] X is CH2 or S;

[0221] Ring A is independently selected from C 3-6 cycloalkyl or 3-6 membered heterocycloalkyl;

[0222] R 1 and R 2 Each is independently selected from halogens, -NH2, -OH, and C. 1-3 Alkyl or C 1-3 Alkoxy;

[0223] Or, R 1 R 2 Composition with adjacent carbon

[0224] R is independently selected from halogen, hydroxyl, amino, or thiol groups;

[0225] n is selected from 0, 1, 2, or 3;

[0226] m is selected from 1, 2, 3, or 4;

[0227] "---"for Or a mixture containing it.

[0228] In some embodiments, the functional groups conjugated to the cysteine, lysine, non-natural amino acids, or glycosyl groups of the antibody molecule are optionally substituted.

[0229] In a preferred embodiment, the functional group coupled to the cysteine, lysine, non-natural amino acid, or glycosyl group of the antibody molecule is selected from optionally substituted groups. More

[0230] It should be understood that the * in the structure of Q1 above represents the position where it is connected to the rest of the compound molecule.

[0231] In some implementations, "---" means

[0232] In the preferred embodiment, "---" means

[0233] In some embodiments, the present invention provides compounds of formula (II) or pharmaceutically acceptable salts, esters, stereoisomers, polymorphs, solvates, N-oxides, isotopically labeled compounds, metabolites, or prodrugs thereof, wherein said compounds have the structure of formula (II-a):

[0234] in:

[0235] Q1 is the functional group that can couple with cysteine, lysine, non-natural amino acids or glycosyl groups of antibody molecules.

[0236] D represents the drug unit;

[0237] C1 is the spacer group independently;

[0238] S3 is each independently the hydrophilic group or selected from the group consisting of each of the hydrophilic groups;

[0239] F1 is selected from the direct bond or the group consisting of: optionally substituted alkylene, optionally substituted polyethylene glycol, optionally substituted alkenyl, optionally substituted ynylene, optionally substituted alicyclic, optionally substituted alicyclic, optionally substituted aryl, and optionally substituted heteroaryl; when substituted, the substituent is selected from halogen, hydroxyl, amino, carboxyl, carbonyl, sulfonic acid, sulfone, phosphate, and alkoxy.

[0240] L1 is selected from either a direct key or the extended unit; the condition is that F1 and L1 are not both direct keys at the same time.

[0241] a can be 1, 2, or 3 independently.

[0242] In some embodiments of compounds of formula (II-a), L1 is a direct bond.

[0243] In some embodiments of compounds of formula (II-a), a is 1.

[0244] In some embodiments, the present invention provides compounds of formula (II) or pharmaceutically acceptable salts, esters, stereoisomers, polymorphs, solvates, N-oxides, isotopically labeled compounds, metabolites, or prodrugs thereof, wherein said compounds have the structure of formula (II-b):

[0245] in:

[0246] Q1 is the functional group that can couple with cysteine, lysine, non-natural amino acids or glycosyl groups of antibody molecules.

[0247] D represents the drug unit;

[0248] B1 is selected from the branched segment;

[0249] C1 is either a direct bond or the spacer group;

[0250] S2 is independently the hydrophilic group or selected from the group consisting of each of the hydrophilic groups;

[0251] F1 is selected from the direct bond or the group consisting of: optionally substituted alkylene, optionally substituted polyethylene glycol, optionally substituted alkenyl, optionally substituted ynylene, optionally substituted alicyclic, optionally substituted alicyclic, optionally substituted aryl, and optionally substituted heteroaryl; when substituted, the substituent is selected from halogen, hydroxyl, amino, carboxyl, carbonyl, sulfonic acid, sulfone, phosphate, and alkoxy.

[0252] L1 is the extension unit;

[0253] b can be 1, 2, or 3 independently.

[0254] In some embodiments of compounds of formula (II-b), F1 is a direct bond.

[0255] In some embodiments of compounds of formula (II-b), b is 1.

[0256] In some embodiments, the present invention provides compounds of formula (II) or pharmaceutically acceptable salts, esters, stereoisomers, polymorphs, solvates, N-oxides, isotopically labeled compounds, metabolites, or prodrugs thereof, wherein said compounds have the structure of formula (II-c):

[0257] in:

[0258] Q1 is the functional group that can couple with cysteine, lysine, non-natural amino acids or glycosyl groups of antibody molecules.

[0259] D represents the drug unit;

[0260] B1 and B2 are independently selected from the branched segments;

[0261] C1 is the spacer group independently;

[0262] S3, S4 and S2 are independently the hydrophilic groups or selected from the group consisting of the hydrophilic groups;

[0263] F1 is selected from the direct bond or the group consisting of: optionally substituted alkylene, optionally substituted polyethylene glycol, optionally substituted alkenyl, optionally substituted ynylene, optionally substituted alicyclic, optionally substituted alicyclic, optionally substituted aryl, and optionally substituted heteroaryl; when substituted, the substituent is selected from halogen, hydroxyl, amino, carboxyl, carbonyl, sulfonic acid, sulfone, phosphate, and alkoxy.

[0264] L1 is selected from either a direct key or the extended unit; the condition is that F1 and L1 are not both direct keys at the same time.

[0265] b and c can each be 1, 2, or 3 independently;

[0266] a can be 0, 1, 2 or 3 independently.

[0267] In some embodiments of compounds of formula (II-c), neither F1 nor L1 is a direct bond.

[0268] In some embodiments of compounds of formula (II-c), a is 0. In some embodiments of compounds of formula (II-c), a is 1.

[0269] In some embodiments of compounds of formula (II-c), b is 1.

[0270] In some embodiments of compounds of formula (II-c), c is 1.

[0271] In some embodiments, the present invention provides compounds of formula (II) or pharmaceutically acceptable salts, esters, stereoisomers, polymorphs, solvates, N-oxides, isotopically labeled compounds, metabolites, or prodrugs thereof, wherein said compounds have the structure of formula (II-d):

[0272] in:

[0273] Q1 is the functional group that can couple with cysteine, lysine, non-natural amino acids or glycosyl groups of antibody molecules.

[0274] D represents the drug unit;

[0275] B2 is independently selected from the branched segment;

[0276] C1 is the spacer group independently;

[0277] S3 and S4 are independently the hydrophilic groups or selected from the group consisting of the hydrophilic groups;

[0278] F1 is selected from the direct bond or the group consisting of: optionally substituted alkylene, optionally substituted polyethylene glycol, optionally substituted alkenyl, optionally substituted ynylene, optionally substituted alicyclic, optionally substituted alicyclic, optionally substituted aryl, and optionally substituted heteroaryl; when substituted, the substituent is selected from halogen, hydroxyl, amino, carboxyl, carbonyl, sulfonic acid, sulfone, phosphate, and alkoxy.

[0279] L1 is selected from either a direct key or the extended unit; the condition is that F1 and L1 are not both direct keys at the same time.

[0280] c can be 1, 2, or 3 independently;

[0281] a can be 0, 1, 2 or 3 independently.

[0282] In some embodiments of compounds of formula (II-d), neither F1 nor L1 is a direct bond.

[0283] In some embodiments of compounds of formula (II-d), a is 0. In some embodiments of compounds of formula (II-c), a is 1.

[0284] In some embodiments of compounds of formula (II-d), c is 1.

[0285] In some embodiments, the present invention provides compounds of formula (II) or pharmaceutically acceptable salts, esters, stereoisomers, polymorphs, solvates, N-oxides, isotopically labeled compounds, metabolites, or prodrugs thereof, wherein said compounds have the structure of formula (II-e):

[0286] in:

[0287] Q1 is the functional group that can couple with cysteine, lysine, non-natural amino acids or glycosyl groups of antibody molecules.

[0288] D represents the drug unit;

[0289] B3 is independently selected from the branched segment;

[0290] C1 is the spacer group independently;

[0291] S3 and S5 are independently the hydrophilic groups or selected from the group consisting of the hydrophilic groups;

[0292] F1 is selected from the direct bond or the group consisting of: optionally substituted alkylene, optionally substituted polyethylene glycol, optionally substituted alkenyl, optionally substituted ynylene, optionally substituted alicyclic, optionally substituted alicyclic, optionally substituted aryl, and optionally substituted heteroaryl; when substituted, the substituent is selected from halogen, hydroxyl, amino, carboxyl, carbonyl, sulfonic acid, sulfone, phosphate, and alkoxy.

[0293] L1 is selected from either a direct key or the extended unit; the condition is that F1 and L1 are not both direct keys at the same time.

[0294] d can be 1, 2, or 3 independently;

[0295] a can be 0, 1, 2 or 3 independently.

[0296] In some embodiments of compounds of formula (II-e), neither F1 nor L1 is a direct bond.

[0297] In some embodiments of compounds of formula (II-e), a is 0. In some embodiments of compounds of formula (II-e), a is 1.

[0298] In some embodiments of compounds of formula (II-e), d is 1.

[0299] In some embodiments, the present invention provides a compound of formula (II) or a pharmaceutically acceptable salt, ester, stereoisomer, polymorph, solvate, N-oxide, isotopically labeled compound, metabolite, or prodrug thereof, wherein:

[0300] Q1 is the functional group that can couple with cysteine, lysine, non-natural amino acids or glycosyl groups of antibody molecules.

[0301] D represents the drug unit;

[0302] B1 is selected from the branched segment;

[0303] C1 is the spacer group independently;

[0304] S2 and S3 are each independently the hydrophilic group or selected from the group consisting of each of the hydrophilic groups;

[0305] F1 is selected from the direct bond or the group consisting of: optionally substituted alkylene, optionally substituted polyethylene glycol, optionally substituted alkenyl, optionally substituted ynylene, optionally substituted alicyclic, optionally substituted alicyclic, optionally substituted aryl, and optionally substituted heteroaryl; when substituted, the substituent is selected from halogen, hydroxyl, amino, carboxyl, carbonyl, sulfonic acid, sulfone, phosphate, and alkoxy.

[0306] L1 is selected from either a direct key or the extended unit; the condition is that F1 and L1 are not both direct keys at the same time.

[0307] a and b can be 1, 2, or 3 independently.

[0308] In some such embodiments, the compound has the structure of formula (II-f):

[0309] In some embodiments, in any of formula II, II-a, II-b, II-c, II-d, II-e, or II-f, F1 is selected from a direct bond or the group consisting of: optionally substituted alkylene groups, optionally substituted polyethylene glycol groups, optionally substituted alkenyl groups, optionally substituted ynylene groups, optionally substituted alicyclic groups, optionally substituted alicyclic heterocyclic groups, optionally substituted aryl groups, and optionally substituted heteroaryl groups; when substituted, the substituent is selected from halogens, hydroxyl groups, amino groups, carboxyl groups, sulfonic acid groups, sulfone groups, phosphate groups, and alkoxy groups.

[0310] In some implementations, B1, B2, and B3, when present, are each bonds in any of formulas II, II-a, II-b, II-c, II-d, II-e, or II-f.

[0311] In a preferred embodiment, in any of formulas II, II-a, II-b, II-c, II-d, II-e, or II-f, B1, B2, and B3, when present, are each: in:

[0312] Connection point 3 This indicates that B1, B2, or B3 are connected to S2, S4, or S5 respectively; and

[0313] R 8 Selected from H or hydrophilic groups.

[0314] In the preferred embodiment, R 8 The hydrophilic groups in S2, S4, or S5 are each selected from: optionally substituted polysarcosine residues, polyglycerols, polyols, glycosyl groups, cyclodextrins, substituted ethylene glycol fragments, substituted glycosylated polyethylene glycol fragments, substituted glycosylated polyglycerols, substituted cyclodextrin polyethylene glycols, or combinations thereof.

[0315] In some such embodiments, the optionally substituted polysarcosine residue is Wherein n2 is an integer between 4 and 20, 4 and 16, or 8 and 12, preferably 10; R0 is selected from C1-C6 alkyl, C1-C6 cycloalkyl, and C1-C6 alkoxy, preferably methyl; preferably, the optionally substituted polysarcosine residue is

[0316] In some embodiments, the substituted glycosylated polyglycerol fragment is Where n4 is an integer between 4 and 12, or between 4 and 10.

[0317] In some embodiments, the substituted polyethylene glycol fragment is Where n5 is an integer between 4 and 24, between 7 and 20, or between 8 and 18, preferably, the substituted polyethylene glycol fragment is...

[0318] In some embodiments, the substituted glycosylated polyethylene glycol fragment is Where n3 is an integer between 4 and 18, or between 4 and 12. Preferably, the substituted glycosylated polyethylene glycol fragment is...

[0319] In some embodiments, the hydrophilic group is selected from the group consisting of optionally substituted polyethylene glycol segments and substituted polysarcosine segments, preferably. Wherein n7 is an integer between 4 and 20, 4 and 16, or 8 and 12, preferably 10; R0 is selected from C1-C6 alkyl, C1-C6 cycloalkyl, and C1-C6 alkoxy, preferably methyl; n5 is an integer between 4 and 24, 7 and 20, or 8 and 18. Preferably, the hydrophilic group is:

[0320] In some embodiments, the polyol is Preferred

[0321] In some embodiments, the glycosyl group is

[0322] In a preferred embodiment, in any of formulas II, II-a, II-b, II-c, II-d, II-e, or II-f, B1, B2, and B3, when present, are each: in:

[0323] Connection point 3 This indicates that B1, B2, or B3 are connected to S2, S4, or S5 respectively; and

[0324] R 8 Selected from H or hydrophilic groups.

[0325] In a preferred embodiment, in any of formulas II, II-a, II-b, II-c, II-d, II-e, or II-f, B1, B2, and B3, when present, are each independently selected from the group consisting of: "Connection point 3" means that B1, B2 or B3 are respectively connected to S2, S4 or S5.

[0326] In a preferred embodiment, in any of formulas II, II-a, II-b, II-c, II-d, II-e, or II-f, B1, B2, and B3, when present, are each: Where "connection point 3" means that B1, B2, or B3 are respectively connected to S2, S4, or S5, and R 8 The hydrophilic group is mentioned above.

[0327] In a preferred embodiment, in any of formula II, II-a, II-b, II-c, II-d, II-e, or II-f, the hydrophilic group is independently selected each time it appears from: optionally substituted polysarcosine residues, polyglycerols, polyols, glycosyl groups, cyclodextrins, substituted ethylene glycol fragments, substituted glycosylated polyethylene glycol fragments, substituted glycosylated polyglycerols, substituted cyclodextrin polyethylene glycols, or combinations thereof.

[0328] In some preferred embodiments, in any of formula II, II-a, II-b, II-c, II-d, II-e, or II-f, the optionally substituted polysarcosine residue is Wherein: n2 is an integer between 4 and 20, for example an integer between 4 and 16, preferably an integer between 8 and 12, more preferably 10; R0 is selected from: C1-C6 alkyl, C1-C6 cycloalkyl and C1-C6 alkoxy, preferably methyl.

[0329] Preferably, the optionally substituted polysarcosine residues are:

[0330] In some preferred embodiments, in any of formula II, II-a, II-b, II-c, II-d, II-e, or II-f, the substituted glycosylated polyglycerol fragment is Where n4 is an integer between 4 and 12, for example, an integer between 4 and 10.

[0331] In some preferred embodiments, the substituted polyethylene glycol segment in any of formula II, II-a, II-b, II-c, II-d, II-e, or II-f is Wherein, n5 is an integer between 4 and 24, for example, between 7 and 20, or between 8 and 18, for example, the substituted polyethylene glycol fragment is...

[0332]

[0333] In other preferred embodiments, in any of formulas II, II-a, II-b, II-c, II-d, II-e, or II-f, the substituted glycosylated polyethylene glycol fragment is Where n3 is an integer between 4 and 18, for example, an integer between 4 and 12; preferably, the substituted glycosylated polyethylene glycol fragment is:

[0334] In some preferred embodiments, in any of formulas II, II-a, II-b, II-c, II-d, II-e, or II-f, the hydrophilic group may also be selected from the group consisting of optionally substituted polyethylene glycol segments and substituted polysarcosine segments, preferably... Wherein n7 is an integer between 4 and 20, for example, an integer between 4 and 16, preferably an integer between 8 and 12, more preferably 10; R0 is selected from: C1-C6 alkyl, C1-C6 cycloalkyl, and C1-C6 alkoxy, preferably methyl; n5 is an integer between 4 and 24, for example, an integer between 7 and 20, or an integer between 8 and 18; further preferred

[0335] In some preferred embodiments, the polyol is Preferred

[0336] In some preferred embodiments, the glycosyl group is

[0337] In some preferred embodiments, in any of formulas II, II-a, II-b, II-c, II-d, II-e, or II-f, when B1, B2, or B is present, -B1-[S2] b -B2-[S4] c 、or -B3-[S2] a Each part is independently selected from:

[0338] In some preferred embodiments, L1, when present, may independently be an optionally substituted amino acid in any of formulas II, II-a, II-b, II-c, II-d, II-e, or II-f. Preferably, the amino acid is selected from: phenylalanine, isoleucine, leucine, tryptophan, valine, methionine, tyrosine, alanine, threonine, histidine, serine, glutamine, arginine, lysine, asparagine, glutamic acid, proline, citrulline, aspartic acid, and glycine. More preferably, the amino acid is valine, particularly... include

[0339] In some preferred embodiments, L1 may also be an optionally substituted polypeptide residue in any of formulas II, II-a, II-b, II-c, II-d, II-e, or II-f.

[0340] In some such embodiments, in any of formulas II, II-a, II-b, II-c, II-d, II-e, or II-f, L1, when present, independently comprises optionally substituted polypeptide residues consisting of amino acids selected from the group consisting of: phenylalanine, isoleucine, leucine, tryptophan, valine, methionine, tyrosine, alanine, threonine, histidine, serine, glutamine, arginine, lysine, asparagine, glutamic acid, proline, citrulline, aspartic acid, and glycine.

[0341] In a preferred embodiment, in any of formula II, II-a, II-b, II-c, II-d, II-e, or II-f, L1, when present, independently comprises a polypeptide residue consisting of optionally substituted amino acids selected from the group consisting of glycine, phenylalanine, valine, alanine, arginine, citrulline, aspartic acid, asparagine, and lysine.

[0342] In a preferred embodiment, in any of formulas II, II-a, II-b, II-c, II-d, II-e, or II-f, L1, when present, independently comprises optionally substituted polypeptide residues selected from the group consisting of: phenylalanine-lysine (Phe-Lys), valine-alanine (Val-Ala), valine-citrulline (Val-Cit), glutamic acid-valine-alanine (Glu-Val-Ala), glutamic acid-valine-citrulline (Glu-Val-Cit), valine-lysine (Val-Lys), alanine-alanine (Ala-Ala), alanine-alanine-alanine (Ala-Ala-Ala), alanine-alanine-asparagine (Ala-Ala-Asn), alanine-leucine (Ala-Leu), leucine-leucine (Leu-Leu), phenylalanine-arginine (Phe-Arg), and phenylalanine-lysine (Phe-Lys). Glycine-glycine-phenylalanine-glycine (Gly-Gly-Phe-Gly), glycine-proline (Gly-Pro).

[0343] In a preferred embodiment, in any of formulas II, II-a, II-b, II-c, II-d, II-e, or II-f, L1 is independently phenylalanine-lysine (Phe-Lys), valine-alanine (Val-Ala), valine-citrulline (Val-Cit), alanine-alanine (Ala-Ala), or glycine-glycine-phenylalanine-glycine (Gly-Gly-Phe-Gly).

[0344] In a more preferred embodiment, in any of formulas II, II-a, II-b, II-c, II-d, II-e, or II-f, L1, when present, is independently valine-alanine (Val-Ala), valine-citrulline (Val-Cit), or alanine-alanine (Ala-Ala), particularly include

[0345] In some implementations, in any of formulas II, II-a, II-b, II-c, II-d, II-e, or II-f, each C1 is independently:

[0346] Preferred

[0347] More

[0348] Where: Connection point 1 Connect to B3 or L1 (where applicable), and connect point 2. Connected to the drug unit D.

[0349] In some preferred embodiments, in any of formulas II, II-a, II-b, II-c, II-d, II-e, or II-f, when a is present and not zero, each S3 is independently the glycosyl or cyclodextrin, preferably glycosyl, more preferably glycosyl. include

[0350] In some embodiments, in any of formulas II, II-a, II-b, II-c, II-d, II-e, or II-f, C1 is selected from the group consisting of: and optional replacement Here, connection point 1 is connected to L1, and connection point 2 is connected to the drug unit D.

[0351] In some preferred embodiments, in any of formulas II, II-a, II-b, II-c, II-d, II-e, or II-f, when B1 is selected from... When S2 is a glycosyl group, the -B1-S2 portion is selected from...

[0352] In some preferred embodiments, in any of formulas II, II-a, II-b, II-c, II-d, II-e, or II-f, when B1 is selected from... And when S2 is a polyol, the -B1-S2 portion is selected from...

[0353] In some preferred embodiments, in any of formulas II, II-a, II-b, II-c, II-d, II-e, or II-f, the -C1-S3 portion is

[0354] In some preferred embodiments, in any of formulas II, II-a, II-b, II-c, II-d, II-e, or II-f, when C1 is selected from... When S3 is a glycosyl group, the -C1-S3 portion is selected from...

[0355] In some implementations, F1 is an independent direct bond in any of formulas II, II-a, II-b, II-c, II-d, II-e, or II-f, when present.

[0356] In some preferred embodiments, in any of formulas II, II-a, II-b, II-c, II-d, II-e, or II-f, F1, when present, is independently selected from directly bonded or optionally substituted polyethylene glycol groups. In a preferred embodiment, the optionally substituted polyethylene glycol group is an amino-substituted polyethylene glycol group, more preferably... Where n6 is an integer between 1 and 18, preferably between 1 and 12 or between 1 and 10, such as 1, 2, 3, 4, 5, 6, 7, 8 or 9.

[0357] In a preferred embodiment, in any of formulas II, II-a, II-b, II-c, II-d, II-e, or II-f, F1, when present, is independently […]. Where n6 is 1, 3 or 7.

[0358] In a preferred embodiment, in any of formulas II, II-a, II-b, II-c, II-d, II-e, or II-f, F1, when present, is independently […]. Where n6 is 1, 3 or 7.

[0359] In some embodiments, the amino terminus (-NH-) of the polyethylene glycol group is connected to L1.

[0360] In a preferred embodiment, the carbonyl end (-C(O)-) of the polyethylene glycol group is connected to L1.

[0361] In a preferred embodiment, in any of formulas II, II-a, II-b, II-c, II-d, II-e, or II-f, the C in the pharmaceutical unit D 3~6 The cycloalkyl group can be a monocyclic, spirocyclic, fused, or bridged ring; preferably, the C 3~6 cycloalkyl groups are selected from C 3~6 Monocyclic cycloalkyl or C 5~6 Bridged cycloalkyl rings.

[0362] In a preferred embodiment, in any of formulas II, II-a, II-b, II-c, II-d, II-e, or II-f, the C in the pharmaceutical unit D 3~6 The cycloalkyl group is selected from cyclopropane, cyclobutane, cyclopentane, cyclohexane, Preferred materials include cyclopropane, cyclobutane, cyclohexane, or... More

[0363] In a preferred embodiment, in any of formula II, II-a, II-b, II-c, II-d, II-e, or II-f, the 3-6 membered heterocyclic alkyl group in the pharmaceutical unit D may be ethylene oxide, aziridinyl, aziridine, oxacyclobutyl, tetrahydrofuranyl, dioxacyclopentenyl, pyrrolylalkyl, pyrrolidoneyl, imidazoalkyl, pyrazolylalkyl, pyrrolinyl, tetrahydropyranyl, piperidinyl, morpholinyl, dithiaalkyl, thiomorpholinyl, piperazine, or trithiaalkyl.

[0364] In a preferred embodiment, in any of formulas II, II-a, II-b, II-c, II-d, II-e, or II-f, the R in the pharmaceutical unit D 1 Selected from halogens, -NH2, -OH, C 1-3 Alkyl or C 1-3 Alkyl group.

[0365] In a preferred embodiment, in any of formulas II, II-a, II-b, II-c, II-d, II-e, or II-f, the R in the pharmaceutical unit D... 1The derivatives are selected from F, Cl, Br, I, -NH2, -OH, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, or propoxy, preferably methyl, methoxy, Cl, -OH, or -NH2, and more preferably methyl or methoxy. 。

[0366] In a preferred embodiment, in any of formulas II, II-a, II-b, II-c, II-d, II-e, or II-f, the R in the pharmaceutical unit D... 2 Selected from halogens, -NH2, -OH, C 1-3 Alkyl or C 1-3 Alkyl group.

[0367] In a preferred embodiment, in any of formulas II, II-a, II-b, II-c, II-d, II-e, or II-f, the R in the pharmaceutical unit D... 2 It is selected from F, Cl, Br, I, -NH2, -OH, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy or propoxy, with F being preferred.

[0368] In a preferred embodiment, in any one of formula II, II-a, II-b, II-c, II-d, II-e, or II-f, the R in the pharmaceutical unit D is selected from F, Cl, Br, or I, preferably F.

[0369] In a preferred embodiment, in any one of formulas II, II-a, II-b, II-c, II-d, II-e, or II-f, the n in the pharmaceutical unit D is selected from 1 or 2, preferably 1.

[0370] In a preferred embodiment, in any one of formula II, II-a, II-b, II-c, II-d, II-e, or II-f, the m in the pharmaceutical unit D is selected from 1 or 2, preferably 1.

[0371] In a preferred embodiment, in any one of formulas II, II-a, II-b, II-c, II-d, II-e, or II-f, the compound of formula (A) is selected from the structure represented by the following formula (A-1):

[0372] in:

[0373] Ring A can be cyclopropane, cyclobutane, cyclopentane, or cyclohexane.

[0374] The R 2 Preferred option: F;

[0375] The R 1Preferably methyl or methoxy (in some embodiments, R 1 For methyl; in some embodiments, R 1 (Methoxylated);

[0376] Other definitions are as described above.

[0377] In a preferred embodiment, in any one of formula II, II-a, II-b, II-c, II-d, II-e, or II-f, the compound of formula (A) is a compound of formula (A-1-1):

[0378] in:

[0379] R 1 Selected from methyl, Cl, -OH or -NH2, methoxy;

[0380] R 2 Selected from F;

[0381] Or, R 1 R 2 Composition with adjacent carbon

[0382] R is selected from F; and

[0383] n is selected from 1;

[0384] Preferably, it is a compound of formula (AA)

[0385] In a preferred embodiment, in any one of formulas II, II-a, II-b, II-c, II-d, II-e, or II-f, the compound of formula (A) is a compound of formula (A-1-2):

[0386] in:

[0387] R 1 Selected from methyl, Cl, -OH or -NH2, methoxy;

[0388] R 2 Selected from F;

[0389] Or, R 1 R 2 Composition with adjacent carbon

[0390] R is selected from F; and

[0391] n is selected from 1.

[0392] In a preferred embodiment, in any one of formulas II, II-a, II-b, II-c, II-d, II-e, or II-f, the compound of formula (A) is a compound of formula (A-1-3):

[0393] in:

[0394] R 1 Selected from methyl, Cl, -OH or -NH2, methoxy;

[0395] R 2 Selected from F;

[0396] Or, R 1 R 2 Composition with adjacent carbon

[0397] R is selected from F; and

[0398] n is selected from 1.

[0399] In a preferred embodiment, in any one of formulas II, II-a, II-b, II-c, II-d, II-e, or II-f, the compound of formula (A) is a compound of formula (A-1-4):

[0400] in:

[0401] R 1 Selected from methyl, Cl, -OH or -NH2, methoxy;

[0402] R 2 Selected from F; and

[0403] n is selected from 0.

[0404] In some embodiments, in any one of formula II, II-a, II-b, II-c, II-d, II-e, or II-f, the compound of formula (A) is selected from the structures shown in Table A above.

[0405] In a preferred embodiment, the pharmaceutical unit D is compound 11a or 17a from Table A above.

[0406] In some embodiments, the compound of any formula (A) described above is connected to C1 via a carboxamide bond (-C(O)-N-) or a phosphoramide bond (-P(O)(OH)-N-) through a -NH- group at position 1. In some embodiments, the compound of any formula (A) described above is connected to C1 via a carboxylic acid ester group (-C(O)-O-) or a phosphate ester group (-P(O)(OH)-O-) through an OH- group at position 9.

[0407] In this invention, the embodiments or preferred embodiments of each of the above components (such as Q1, C1, B1, B2, B3, F1, L1, S2, S3, S4, S5, D, a, b, c, d) can be applied individually to any of formulas II, II-a, II-b, II-c, II-d, II-e, or II-f, or in various combinations to any of formulas II, II-a, II-b, II-c, II-d, II-e, or II-f.

[0408] Where combinations are applicable, the implementation schemes or preferred implementation schemes of the components may be combined in whole or in part.

[0409] In a preferred embodiment, the present invention provides compounds selected from formulas B1 to B18, or pharmaceutically acceptable salts, esters, stereoisomers, polymorphs, solvates, N-oxides, isotopically labeled compounds, metabolites, or prodrugs thereof:

[0410]

[0411] In this invention, any of formulas II, II-a, II-b, II-c, II-d, II-e, or II-f and the structures shown in their respective embodiments are also referred to as "drug-linker fragments", "linker-drug fragments", or "LP".

[0412] Connector

[0413] Another aspect of the present invention provides a linker, which can serve as an intermediate, or a pharmaceutically acceptable salt, ester, stereoisomer, polymorph, solvate, N-oxide, isotopically labeled compound, metabolite, or prodrug thereof, wherein the linker has the structure of formula (III):

[0414] in:

[0415] Q1 is a functional group that can couple with cysteine, lysine, non-natural amino acids or glycosyl groups of antibody molecules.

[0416] Connection point Connected to the antibody

[0417] Connection point Connect to the drug delivery unit;

[0418] B1, B2, and B3 are each independently selected from branched segments;

[0419] C1 is an independent spacer group;

[0420] S2, S3, S4 and S5 are each independently a hydrophilic group or selected from the group consisting of each of the aforementioned hydrophilic groups;

[0421] F1 is selected from the direct bond or the group consisting of: optionally substituted alkylene, optionally substituted polyethylene glycol, optionally substituted alkenyl, optionally substituted ynylene, optionally substituted alicyclic, optionally substituted alicyclic, optionally substituted aryl, and optionally substituted heteroaryl; when substituted, the substituent is selected from halogen, hydroxyl, amino, carboxyl, carbonyl, sulfonic acid, sulfone, phosphate, and alkoxy.

[0422] L1 is selected from either a direct bond or an extended unit; the condition is that F1 and L1 are not both direct bonds at the same time.

[0423] a, b, c, and d are each independently 0, 1, 2, or 3, provided that a, b, c, and d are not all 0 at the same time;

[0424] The functional groups conjugated to the cysteine, lysine, non-natural amino acids, or glycosyl groups of the antibody molecule are selected from those with optional substitutions.

[0425] It is easy to understand that, in some implementations, the Q1 functional group here is... The form (as described above in compounds of formula (II)) is coupled to the cysteine, lysine or non-natural amino acid of the antibody molecule, for example by forming a disulfide bond, as shown in compounds of formulas D1-D18 below.

[0426] In some embodiments, the present invention provides a linker of formula (III) or a pharmaceutically acceptable salt, ester, stereoisomer, polymorph, solvate, N-oxide, isotopically labeled compound, metabolite, or prodrug thereof, wherein said intermediate has the structure of formula (III-a):

[0427] in:

[0428] Q1 is the functional group that can couple with cysteine, lysine, non-natural amino acids or glycosyl groups of antibody molecules.

[0429] Connection point Connected to the antibody;

[0430] Connection point Connected to the drug unit;

[0431] C1 is the spacer group independently;

[0432] S3 is independently the hydrophilic group or selected from the group consisting of each of the hydrophilic groups;

[0433] F1 is selected from the direct bond or the group consisting of: optionally substituted alkylene, optionally substituted polyethylene glycol, optionally substituted alkenyl, optionally substituted ynylene, optionally substituted alicyclic, optionally substituted alicyclic, optionally substituted aryl, and optionally substituted heteroaryl; when substituted, the substituent is selected from halogen, hydroxyl, amino, carboxyl, carbonyl, sulfonic acid, sulfone, phosphate, and alkoxy.

[0434] L1 is selected from either a direct key or the extended unit; the condition being that F1 and L1 are not both direct keys.

[0435] a can be 1, 2, or 3 independently.

[0436] In some implementations of the connector of formula (III-a), L1 is a direct bond.

[0437] In some implementations of the connector of formula (III-a), a is 1.

[0438] In some embodiments, the present invention provides a linker of formula (III) or a pharmaceutically acceptable salt, ester, stereoisomer, polymorph, solvate, N-oxide, isotopically labeled compound, metabolite, or prodrug thereof, wherein said intermediate has the structure of formula (III-b):

[0439] in:

[0440] Q1 is the functional group that can couple with cysteine, lysine, non-natural amino acids or glycosyl groups of antibody molecules.

[0441] Connection point Connected to the antibody;

[0442] Connection point Connected to the drug unit;

[0443] B1 is selected from the branching groups mentioned above;

[0444] C1 is the spacer group independently;

[0445] S2 is independently the hydrophilic group or selected from the group consisting of each of the hydrophilic groups;

[0446] F1 is selected from the direct bond or the group consisting of: optionally substituted alkylene, optionally substituted polyethylene glycol, optionally substituted alkenyl, optionally substituted ynylene, optionally substituted alicyclic, optionally substituted alicyclic, optionally substituted aryl, and optionally substituted heteroaryl; when substituted, the substituent is selected from halogen, hydroxyl, amino, carboxyl, carbonyl, sulfonic acid, sulfone, phosphate, and alkoxy.

[0447] L1 is the extension unit;

[0448] b can be 1, 2, or 3 independently.

[0449] In some implementations of the connector of formula (III-b), F1 is a direct bond.

[0450] In some implementations of the connector of formula (III-b), b is 1.

[0451] In some embodiments, the present invention provides a linker of formula (III) or a pharmaceutically acceptable salt, ester, stereoisomer, polymorph, solvate, N-oxide, isotopically labeled compound, metabolite, or prodrug thereof, wherein said intermediate has the structure of formula (III-c):

[0452] in:

[0453] Q1 is a functional group that can couple with cysteine, lysine, non-natural amino acids or glycosyl groups of antibody molecules.

[0454] B1 and B2 are independently selected from the branched segments;

[0455] C1 is the spacer group independently;

[0456] S3, S4 and S2 are independently the hydrophilic groups or selected from the group consisting of the hydrophilic groups;

[0457] F1 is selected from the direct bond or the group consisting of: optionally substituted alkylene, optionally substituted polyethylene glycol, optionally substituted alkenyl, optionally substituted ynylene, optionally substituted alicyclic, optionally substituted alicyclic, optionally substituted aryl, and optionally substituted heteroaryl; when substituted, the substituent is selected from halogen, hydroxyl, amino, carboxyl, carbonyl, sulfonic acid, sulfone, phosphate, and alkoxy.

[0458] L1 is selected from either a direct key or the extended unit; the condition is that F1 and L1 are not both direct keys at the same time.

[0459] b and c can each be 1, 2, or 3 independently;

[0460] a can be 0, 1, 2 or 3 independently.

[0461] In some implementations of the linker of formula (III-c), neither F1 nor L1 is a direct bond.

[0462] In some embodiments of the connector of formula (III-c), a is 0. In some embodiments of the connector of formula (III-c), a is 1.

[0463] In some implementations of the connector of formula (III-c), b is 1.

[0464] In some implementations of the connector of formula (III-c), c is 1.

[0465] In some embodiments, the present invention provides a linker of formula (III) or a pharmaceutically acceptable salt, ester, stereoisomer, polymorph, solvate, N-oxide, isotopically labeled compound, metabolite, or prodrug thereof, wherein the intermediate has a structure of formula (III-d):

[0466] in:

[0467] Q1 is the functional group that can couple with cysteine, lysine, non-natural amino acids or glycosyl groups of antibody molecules.

[0468] D represents the drug unit;

[0469] B2 is independently selected from the branched segment;

[0470] C1 is the spacer group independently;

[0471] S3 and S4 are independently the hydrophilic groups or selected from the group consisting of the hydrophilic groups;

[0472] F1 is selected from the direct bond or the group consisting of: optionally substituted alkylene, optionally substituted polyethylene glycol, optionally substituted alkenyl, optionally substituted ynylene, optionally substituted alicyclic, optionally substituted alicyclic, optionally substituted aryl, and optionally substituted heteroaryl; when substituted, the substituent is selected from halogen, hydroxyl, amino, carboxyl, carbonyl, sulfonic acid, sulfone, phosphate, and alkoxy.

[0473] L1 is selected from either a direct key or the extended unit; the condition is that F1 and L1 are not both direct keys at the same time.

[0474] c can be 1, 2, or 3 independently;

[0475] a can be 0, 1, 2 or 3 independently.

[0476] In some implementations of the (III-d) connector, neither F1 nor L1 is a direct bond.

[0477] In some embodiments of the connector of formula (III-d), a is 0. In some embodiments of the connector of formula (III-d), a is 1.

[0478] In some implementations of the connector of formula (III-d), c is 1.

[0479] In some embodiments, the present invention provides a linker of formula (III) or a pharmaceutically acceptable salt, ester, stereoisomer, polymorph, solvate, N-oxide, isotopically labeled compound, metabolite, or prodrug thereof, wherein said intermediate has a structure of formula (III-e):

[0480] in:

[0481] Q1 is the functional group that can couple with cysteine, lysine, non-natural amino acids or glycosyl groups of antibody molecules.

[0482] B3 is independently selected from the branched segment;

[0483] C1 is the spacer group independently;

[0484] S3 and S5 are independently the hydrophilic groups or selected from the group consisting of the hydrophilic groups;

[0485] F1 is selected from the direct bond or the group consisting of: optionally substituted alkylene, optionally substituted polyethylene glycol, optionally substituted alkenyl, optionally substituted ynylene, optionally substituted alicyclic, optionally substituted alicyclic, optionally substituted aryl, and optionally substituted heteroaryl; when substituted, the substituent is selected from halogen, hydroxyl, amino, carboxyl, carbonyl, sulfonic acid, sulfone, phosphate, and alkoxy.

[0486] L1 is selected from either a direct key or the extended unit; the condition is that F1 and L1 are not both direct keys at the same time.

[0487] d can be 1, 2, or 3 independently;

[0488] a can be 0, 1, 2 or 3 independently.

[0489] In some implementations of the linker of formula (III-e), neither F1 nor L1 is a direct bond.

[0490] In some embodiments of the connector of formula (III-e), a is 0. In some embodiments of the connector of formula (III-e), a is 1.

[0491] In some implementations of the connector of formula (III-e), d is 1.

[0492] In some embodiments, the present invention provides a linker of formula (III) or a pharmaceutically acceptable salt, ester, stereoisomer, polymorph, solvate, N-oxide, isotopically labeled compound, metabolite, or prodrug thereof, wherein:

[0493] Q1 is the functional group that can couple with cysteine, lysine, non-natural amino acids or glycosyl groups of antibody molecules.

[0494] B1 is selected from the branched segment;

[0495] C1 is the spacer group independently;

[0496] S2 and S3 are each independently the hydrophilic group or selected from the group consisting of each of the hydrophilic groups;

[0497] F1 is selected from the direct bond or the group consisting of: optionally substituted alkylene, optionally substituted polyethylene glycol, optionally substituted alkenyl, optionally substituted ynylene, optionally substituted alicyclic, optionally substituted alicyclic, optionally substituted aryl, and optionally substituted heteroaryl; when substituted, the substituent is selected from halogen, hydroxyl, amino, carboxyl, carbonyl, sulfonic acid, sulfone, phosphate, and alkoxy.

[0498] L1 is selected from either a direct key or the extended unit; the condition is that F1 and L1 are not both direct keys at the same time.

[0499] a and b can be 1, 2, or 3 independently.

[0500] In some such embodiments, the connector has a structure of formula (III-f):

[0501] In some embodiments, in any of formula III, III-a, III-b, III-c, III-d, III-e, or III-f, F1 is selected from a direct bond or the group consisting of: optionally substituted alkylene, optionally substituted polyethylene glycol, optionally substituted alkenyl, optionally substituted ynylene, optionally substituted alicyclic, optionally substituted alicyclic, optionally substituted aryl, and optionally substituted heteroaryl; when substituted, the substituent is selected from halogen, hydroxyl, amino, carboxyl, sulfonic acid, sulfone, phosphate, and alkoxy.

[0502] In some implementations, B1, B2, and B3, when present, are each bonds in any of formulas III, III-a, III-b, III-c, III-d, III-e, or III-f.

[0503] In a preferred embodiment, in any of formulas III, III-a, III-b, III-c, III-d, III-e, or III-f, B1, B2, and B3, when present, are each: in:

[0504] Connection point 3 This indicates that B1, B2, or B3 are connected to S2, S4, or S5 respectively; and

[0505] R8 Selected from H or hydrophilic groups.

[0506] In the preferred embodiment, R 8 The hydrophilic groups in S2, S4, or S5 are each selected from: optionally substituted polysarcosine residues, polyglycerols, polyols, glycosyl groups, cyclodextrins, substituted ethylene glycol fragments, substituted glycosylated polyethylene glycol fragments, substituted glycosylated polyglycerols, substituted cyclodextrin polyethylene glycols, or combinations thereof.

[0507] In some such embodiments, the optionally substituted polysarcosine residue is Wherein n2 is an integer between 4 and 20, 4 and 16, or 8 and 12, preferably 10; R0 is selected from C1-C6 alkyl, C1-C6 cycloalkyl, and C1-C6 alkoxy, preferably methyl; preferably, the optionally substituted polysarcosine residue is

[0508] In some embodiments, the substituted glycosylated polyglycerol fragment is Where n4 is an integer between 4 and 12, or between 4 and 10.

[0509] In some embodiments, the substituted polyethylene glycol fragment is Where n5 is an integer between 4 and 24, between 7 and 20, or between 8 and 18, preferably, the substituted polyethylene glycol fragment is...

[0510] In some embodiments, the substituted glycosylated polyethylene glycol fragment is Where n3 is an integer between 4 and 18, or between 4 and 12. Preferably, the substituted glycosylated polyethylene glycol fragment is...

[0511] In some embodiments, the hydrophilic group is selected from the group consisting of optionally substituted polyethylene glycol segments and substituted polysarcosine segments, preferably. Wherein n7 is an integer between 4 and 20, 4 and 16, or 8 and 12, preferably 10; R0 is selected from C1-C6 alkyl, C1-C6 cycloalkyl, and C1-C6 alkoxy, preferably methyl; n5 is an integer between 4 and 24, 7 and 20, or 8 and 18. Preferably, the hydrophilic group is:

[0512] In some embodiments, the polyol is Preferred

[0513] In some embodiments, the glycosyl group is

[0514] In a preferred embodiment, in any of formulas III, III-a, III-b, III-c, III-d, III-e, or III-f, B1, B2, and B3, when present, are each selected from the group consisting of: "Connection point 3" means that B1, B2 or B3 are respectively connected to S2, S4 or S5.

[0515] In a preferred embodiment, in any of formulas III, III-a, III-b, III-c, III-d, III-e, or III-f, B1, B2, and B3, when present, are each: Where "connection point 3" means that B1, B2, or B3 are respectively connected to S2, S4, or S5, and R 8 The hydrophilic group is mentioned above.

[0516] In a preferred embodiment, in any of formula III, III-a, III-b, III-c, III-d, III-e, or III-f, the hydrophilic group is independently selected each time it appears from: optionally substituted polysarcosine residues, polyglycerols, polyols, glycosyl groups, cyclodextrins, substituted ethylene glycol fragments, substituted glycosylated polyethylene glycol fragments, substituted glycosylated polyglycerols, substituted cyclodextrin polyethylene glycols, or combinations thereof.

[0517] In some preferred embodiments, in any of formula III, III-a, III-b, III-c, III-d, III-e, or III-f, the optionally substituted polysarcosine residue is Wherein: n2 is an integer between 4 and 20, for example an integer between 4 and 16, preferably an integer between 8 and 12, more preferably 10; R0 is selected from: C1-C6 alkyl, C1-C6 cycloalkyl and C1-C6 alkoxy, preferably methyl.

[0518] Preferably, the optionally substituted polysarcosine residues are:

[0519] In some preferred embodiments, the substituted glycosylated polyglycerol fragment in any of formula III, III-a, III-b, III-c, III-d, III-e, or III-f is Where n4 is an integer between 4 and 12, for example, an integer between 4 and 10.

[0520] In some preferred embodiments, the substituted polyethylene glycol segment in any of formula III, III-a, III-b, III-c, III-d, III-e, or III-f is Wherein, n5 is an integer between 4 and 24, for example, between 7 and 20, or between 8 and 18, for example, the substituted polyethylene glycol fragment is...

[0521] In other preferred embodiments, in any of formula III, III-a, III-b, III-c, III-d, III-e, or III-f, the substituted glycosylated polyethylene glycol fragment is Where n3 is an integer between 4 and 18, for example, an integer between 4 and 12; preferably, the substituted glycosylated polyethylene glycol fragment is:

[0522] In some preferred embodiments, in any of formula III, III-a, III-b, III-c, III-d, III-e, or III-f, the hydrophilic group may also be selected from the group consisting of optionally substituted polyethylene glycol segments and substituted polysarcosine segments, preferably... Wherein n7 is an integer between 4 and 20, for example, an integer between 4 and 16, preferably an integer between 8 and 12, more preferably 10; R0 is selected from: C1-C6 alkyl, C1-C6 cycloalkyl, and C1-C6 alkoxy, preferably methyl; n5 is an integer between 4 and 24, for example, an integer between 7 and 20, or an integer between 8 and 18; further preferred

[0523] In some preferred embodiments, the polyol is Preferred

[0524] In some preferred embodiments, the glycosyl group is

[0525] In some preferred embodiments, in any of formulas III, III-a, III-b, III-c, III-d, III-e, or III-f, when B1, B2, or B is present, -B1-[S2] b -B2-[S4] c 、or -B3-[S2] a Each part is independently selected from:

[0526] In some preferred embodiments, L1, when present, may independently be an optionally substituted amino acid in any of formulas III, III-a, III-b, III-c, III-d, III-e, or III-f. Preferably, the amino acid is selected from: phenylalanine, isoleucine, leucine, tryptophan, valine, methionine, tyrosine, alanine, threonine, histidine, serine, glutamine, arginine, lysine, asparagine, glutamic acid, proline, citrulline, aspartic acid, and glycine. More preferably, the amino acid is valine, particularly... include

[0527] In some preferred embodiments, L1 may also be an optionally substituted polypeptide residue in any of formulas III, III-a, III-b, III-c, III-d, III-e, or III-f.

[0528] In some such embodiments, in any of formula III, III-a, III-b, III-c, III-d, III-e, or III-f, L1, when present, independently comprises optionally substituted polypeptide residues consisting of amino acids selected from the group consisting of: phenylalanine, isoleucine, leucine, tryptophan, valine, methionine, tyrosine, alanine, threonine, histidine, serine, glutamine, arginine, lysine, asparagine, glutamic acid, proline, citrulline, aspartic acid, and glycine.

[0529] In a preferred embodiment, in any of formula III, III-a, III-b, III-c, III-d, III-e, or III-f, L1, when present, independently comprises a polypeptide residue consisting of optionally substituted amino acids selected from the group consisting of glycine, phenylalanine, valine, alanine, arginine, citrulline, aspartic acid, asparagine, and lysine.

[0530] In a preferred embodiment, in any of formulas III, III-a, III-b, III-c, III-d, III-e, or III-f, L1, when present, independently comprises optionally substituted polypeptide residues selected from the group consisting of: phenylalanine-lysine (Phe-Lys), valine-alanine (Val-Ala), valine-citrulline (Val-Cit), glutamic acid-valine-alanine (Glu-Val-Ala), glutamic acid-valine-citrulline (Glu-Val-Cit), valine-lysine (Val-Lys), alanine-alanine (Ala-Ala), alanine-alanine-alanine (Ala-Ala-Ala), alanine-alanine-asparagine (Ala-Ala-Asn), alanine-leucine (Ala-Leu), leucine-leucine (Leu-Leu), phenylalanine-arginine (Phe-Arg), and phenylalanine-lysine (Phe-Lys). Glycine-glycine-phenylalanine-glycine (Gly-Gly-Phe-Gly), glycine-proline (Gly-Pro).

[0531] In a preferred embodiment, in any of formula III, III-a, III-b, III-c, III-d, III-e, or III-f, L1 is independently phenylalanine-lysine (Phe-Lys), valine-alanine (Val-Ala), valine-citrulline (Val-Cit), alanine-alanine (Ala-Ala), or glycine-glycine-phenylalanine-glycine (Gly-Gly-Phe-Gly).

[0532] In a more preferred embodiment, in any of formula III, III-a, III-b, III-c, III-d, III-e, or III-f, L1, when present, is independently valine-alanine (Val-Ala), valine-citrulline (Val-Cit), or alanine-alanine (Ala-Ala), particularly include

[0533] In some implementations, in any of formulas III, III-a, III-b, III-c, III-d, III-e, or III-f, each C1 is independently:

[0534] Preferred

[0535] More

[0536] Where: Connection point 1 Connect to B3 or L1 (where applicable), and connect point 2. Connected to the drug unit D.

[0537] In some preferred embodiments, in any of formulas III, III-a, III-b, III-c, III-d, III-e, or III-f, when a is present and not zero, each S3 is independently the glycosyl or cyclodextrin, preferably glycosyl, more preferably glycosyl. include

[0538] In some embodiments, in any of formulas III, III-a, III-b, III-c, III-d, III-e, or III-f, C1 is selected from the group consisting of: and optional replacement Here, connection point 1 is connected to L1, and connection point 2 is connected to the drug unit D.

[0539] In some preferred embodiments, in any of formulas III, III-a, III-b, III-c, III-d, III-e, or III-f, when B1 is selected from... When S2 is a glycosyl group, the -B1-S2 portion is selected from...

[0540] In some preferred embodiments, in any of formulas III, III-a, III-b, III-c, III-d, III-e, or III-f, when B1 is selected from... And when S2 is a polyol, the -B1-S2 portion is selected from...

[0541] In some preferred embodiments, in any of formula III, III-a, III-b, III-c, III-d, III-e, or III-f, the -C1-S3 portion is

[0542] In some preferred embodiments, in any of formulas III, III-a, III-b, III-c, III-d, III-e, or III-f, when C1 is selected from... When S3 is a glycosyl group, the -C1-S3 portion is selected from...

[0543] In some implementations, F1 is an independent direct bond in any of formulas III, III-a, III-b, III-c, III-d, III-e, or III-f, when present.

[0544] In some preferred embodiments, in any of formulas III, III-a, III-b, III-c, III-d, III-e, or III-f, F1, when present, is independently selected from directly bonded or optionally substituted polyethylene glycol groups. In a preferred embodiment, the optionally substituted polyethylene glycol group is an amino-substituted polyethylene glycol group, more preferably... Where n6 is an integer between 1 and 18, preferably between 1 and 12 or between 1 and 10, such as 1, 2, 3, 4, 5, 6, 7, 8 or 9.

[0545] In a preferred embodiment, in any of formulas III, III-a, III-b, III-c, III-d, III-e, or III-f, F1, when present, is independently […]. Where n6 is 1, 3 or 7.

[0546] In a preferred embodiment, in any of formulas III, III-a, III-b, III-c, III-d, III-e, or III-f, F1, when present, is independently […]. Where n6 is 1, 3 or 7.

[0547] In some embodiments, the amino terminus (-NH-) of the polyethylene glycol group is connected to L1.

[0548] In a preferred embodiment, the carbonyl end (-C(O)-) of the polyethylene glycol group is connected to L1.

[0549] In a preferred embodiment, in any of formulas III, III-a, III-b, III-c, III-d, III-e, or III-f, the C in the pharmaceutical unit D 3~6 The cycloalkyl group can be a monocyclic, spirocyclic, fused, or bridged ring; preferably, the C 3~6 cycloalkyl groups are selected from C 3~6 Monocyclic cycloalkyl or C 5~6 Bridged cycloalkyl rings.

[0550] In a preferred embodiment, in any of formulas III, III-a, III-b, III-c, III-d, III-e, or III-f, the C in the pharmaceutical unit D 3~6 The cycloalkyl group is selected from cyclopropane, cyclobutane, cyclopentane, cyclohexane, Preferred materials include cyclopropane, cyclobutane, cyclohexane, or... More

[0551] In a preferred embodiment, in any of formula III, III-a, III-b, III-c, III-d, III-e, or III-f, the 3-6 membered heterocyclic alkyl group in the pharmaceutical unit D may be ethylene oxide, aziridinyl, aziridine, oxacyclobutyl, tetrahydrofuranyl, dioxacyclopentenyl, pyrrolylalkyl, pyrrolidoneyl, imidazoalkyl, pyrazolylalkyl, pyrrolinyl, tetrahydropyranyl, piperidinyl, morpholinyl, dithiaalkyl, thiomorpholinyl, piperazine, or trithiaalkyl.

[0552] In a preferred embodiment, in any of formulas III, III-a, III-b, III-c, III-d, III-e, or III-f, the R in the pharmaceutical unit D 1 Selected from halogens, -NH2, -OH, C 1-3 Alkyl or C 1-3 Alkyl group.

[0553] In a preferred embodiment, in any of formulas III, III-a, III-b, III-c, III-d, III-e, or III-f, the R in the pharmaceutical unit D 1 The derivatives are selected from F, Cl, Br, I, -NH2, -OH, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, or propoxy, preferably methyl, methoxy, Cl, -OH, or -NH2, and more preferably methyl or methoxy. 。

[0554] In a preferred embodiment, in any of formulas III, III-a, III-b, III-c, III-d, III-e, or III-f, the R in the pharmaceutical unit D 2 Selected from halogens, -NH2, -OH, C 1-3 Alkyl or C 1-3 Alkyl group.

[0555] In a preferred embodiment, in any of formulas III, III-a, III-b, III-c, III-d, III-e, or III-f, the R in the pharmaceutical unit D 2 It is selected from F, Cl, Br, I, -NH2, -OH, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy or propoxy, with F being preferred.

[0556] In a preferred embodiment, in any of formula III, III-a, III-b, III-c, III-d, III-e, or III-f, the R in the pharmaceutical unit D is selected from F, Cl, Br, or I, preferably F.

[0557] In a preferred embodiment, in any of formulas III, III-a, III-b, III-c, III-d, III-e, or III-f, the n in the pharmaceutical unit D is selected from 1 or 2, preferably 1.

[0558] In a preferred embodiment, in any one of formula III, III-a, III-b, III-c, III-d, III-e, or III-f, the m in the pharmaceutical unit D is selected from 1 or 2, preferably 1.

[0559] In a preferred embodiment, the present invention provides intermediates selected from formulas C1 to C18, or pharmaceutically acceptable salts, esters, stereoisomers, polymorphs, solvates, N-oxides, isotopically labeled compounds, metabolites, or prodrugs thereof:

[0560] Linkers of any of formulas III, III-a, III-b, III-c, III-d, III-e, or III-f described above, including linkers of formulas C1 to C18, can be linked to any suitable pharmaceutical unit, including but not limited to any compound of formula (A) described above, as described above in compounds of formula (I) or linkers of formula (II). In some embodiments, linkers of any of formulas III, III-a, III-b, III-c, III-d, III-e, or III-f described above, including linkers of formulas C1 to C18, are linked via their C1 group to the -NH- group at the 1-position of the compound of formula (A) through a carboxamide bond (-C(O)-N-) or a phosphoramide bond (-P(O)(OH)-N-). In some embodiments, the linker of any of the formulas III, III-a, III-b, III-c, III-d, III-e, or III-f described above, including the linkers of formulas C1 to C18, is connected to the OH at the 9-position of the compound of formula (A) via its C1 group through a carboxylic acid ester group (-C(O)-O-) or a phosphate ester group (-P(O)(OH)-O-).

[0561] Antibody-drug conjugates

[0562] Another aspect of the invention provides antibody-drug conjugates as compounds or their pharmaceutically acceptable salts, esters, stereoisomers, polymorphs, solvates, N-oxides, isotopically labeled compounds, metabolites, or prodrugs, wherein said compounds have the structure of formula (IV):

[0563] in:

[0564] Ab is an antibody molecule;

[0565] q is an integer or decimal from 1 to 8;

[0566] Q1 is a functional group capable of coupling with cysteine, lysine, non-natural amino acids, or glycosyl groups of the antibody molecule.

[0567] D represents the drug unit;

[0568] B1, B2, and B3 are each independently selected from bonded or branched segments;

[0569] C1 is an independent spacer group;

[0570] S2, S3, S4 and S5 are each independently a hydrophilic group or selected from the group consisting of each of the aforementioned hydrophilic groups;

[0571] F1 is selected from the direct bond or the group consisting of: optionally substituted alkylene, optionally substituted polyethylene glycol, optionally substituted alkenyl, optionally substituted ynylene, optionally substituted alicyclic, optionally substituted alicyclic, optionally substituted aryl, and optionally substituted heteroaryl; when substituted, the substituent is selected from halogen, hydroxyl, amino, carboxyl, carbonyl, sulfonic acid, sulfone, phosphate, and alkoxy.

[0572] L1 is selected from either a direct bond or an extended unit; the condition is that F1 and L1 are not both direct bonds at the same time.

[0573] a, b, c, and d are each independently 0, 1, 2, or 3, provided that a, b, c, and d are not all 0 at the same time;

[0574] The functional groups conjugated to the cysteine, lysine, non-natural amino acids, or glycosyl groups of the antibody molecule are selected from those with optional substitutions.

[0575] The drug structural unit is selected from the compounds shown in formula (A):

[0576] in:

[0577] X is CH2 or S;

[0578] Ring A is independently selected from C 3-6 cycloalkyl or 3-6 membered heterocycloalkyl;

[0579] R 1 and R 2 Each is independently selected from halogens, -NH2, -OH, and C. 1-3 Alkyl or C 1-3 Alkoxy;

[0580] Or, R 1 R 2 Composition with adjacent carbon

[0581] R is independently selected from halogen, hydroxyl, amino, or thiol groups;

[0582] n is selected from 0, 1, 2, or 3;

[0583] m is selected from 1, 2, 3, or 4;

[0584] "---"for Or a mixture containing it.

[0585] In some implementations, "---" means

[0586] In the preferred embodiment, "---" means

[0587] It can be readily understood that, in some embodiments, in the compound of formula (IV), the Q1 functional group here is... The form (as described above in compounds of formula (II)) is coupled to the cysteine, lysine, or non-natural amino acids of the antibody molecule, for example by forming disulfide bonds, as shown in compounds of formulas D1-D18 below.

[0588] In some embodiments, the present invention provides compounds of formula (IV) or pharmaceutically acceptable salts, esters, stereoisomers, polymorphs, solvates, N-oxides, isotopically labeled compounds, metabolites, or prodrugs thereof, wherein said compounds have the structure of formula (IV-a):

[0589] in:

[0590] Ab is the antibody molecule;

[0591] q is an integer or decimal from 1 to 8;

[0592] Q1 is the functional group that can couple with the cysteine, lysine, non-natural amino acid, or glycosyl group of the antibody molecule.

[0593] D represents the drug unit;

[0594] C1 is the spacer group independently;

[0595] S3 is each independently the hydrophilic group or selected from the group consisting of each of the hydrophilic groups;

[0596] F1 is selected from the direct bond or the group consisting of: optionally substituted alkylene, optionally substituted polyethylene glycol, optionally substituted alkenyl, optionally substituted ynylene, optionally substituted alicyclic, optionally substituted alicyclic, optionally substituted aryl, and optionally substituted heteroaryl; when substituted, the substituent is selected from halogen, hydroxyl, amino, carboxyl, carbonyl, sulfonic acid, sulfone, phosphate, and alkoxy.

[0597] L1 is the extension unit;

[0598] a can be 1, 2, or 3 independently.

[0599] In some embodiments of compounds of formula (IV-a), L1 is a direct bond.

[0600] In some embodiments of compounds of formula (IV-a), a is 1.

[0601] In some embodiments, the present invention provides compounds of formula (IV) or pharmaceutically acceptable salts, esters, stereoisomers, polymorphs, solvates, N-oxides, isotopically labeled compounds, metabolites, or prodrugs thereof, wherein said compounds have the structure of formula (IV-b):

[0602] in:

[0603] Ab is the antibody molecule;

[0604] q is an integer or decimal from 1 to 8;

[0605] Q1 is the functional group that can couple with the cysteine, lysine, non-natural amino acid, or glycosyl group of the antibody molecule.

[0606] D represents the drug unit;

[0607] B1 is selected from the branched segment;

[0608] C1 is either a direct bond or the spacer group;

[0609] S2 and S3 are each independently the hydrophilic group or selected from the group consisting of each of the hydrophilic groups;

[0610] F1 is selected from the direct bond or the group consisting of: optionally substituted alkylene, optionally substituted polyethylene glycol, optionally substituted alkenyl, optionally substituted ynylene, optionally substituted alicyclic, optionally substituted alicyclic, optionally substituted aryl, and optionally substituted heteroaryl; when substituted, the substituent is selected from halogen, hydroxyl, amino, carboxyl, carbonyl, sulfonic acid, sulfone, phosphate, and alkoxy.

[0611] L1 is the extension unit;

[0612] b can be 1, 2, or 3 independently.

[0613] In some embodiments of compounds of formula (IV-b), F1 is a direct bond.

[0614] In some embodiments of compounds of formula (IV-b), b is 1.

[0615] In some embodiments, the present invention provides compounds of formula (IV) or pharmaceutically acceptable salts, esters, stereoisomers, polymorphs, solvates, N-oxides, isotopically labeled compounds, metabolites, or prodrugs thereof, wherein said compounds have the structure of formula (IV-c):

[0616] in:

[0617] Ab is the antibody molecule;

[0618] q is an integer or decimal from 1 to 8;

[0619] Q1 is the functional group that can couple with the cysteine, lysine, non-natural amino acid, or glycosyl group of the antibody molecule.

[0620] D represents the drug unit;

[0621] B1 and B2 are independently selected from the branched fragments;

[0622] C1 is the spacer group independently;

[0623] S3, S4 and S2 are independently the hydrophilic groups or selected from the group consisting of the hydrophilic groups;

[0624] F1 is selected from the direct bond or the group consisting of: optionally substituted alkylene, optionally substituted polyethylene glycol, optionally substituted alkenyl, optionally substituted ynylene, optionally substituted alicyclic, optionally substituted alicyclic, optionally substituted aryl, and optionally substituted heteroaryl; when substituted, the substituent is selected from halogen, hydroxyl, amino, carboxyl, carbonyl, sulfonic acid, sulfone, phosphate, and alkoxy.

[0625] L1 is selected from either a direct key or the extended unit; the condition is that F1 and L1 are not both direct keys at the same time.

[0626] b and c can be 1, 2 or 3 independently;

[0627] a can be 0, 1, 2 or 3 independently.

[0628] In some embodiments of compounds of formula (IV-c), neither F1 nor L1 is a direct bond.

[0629] In some embodiments of compounds of formula (IV-c), a is 0. In some embodiments of compounds of formula (IV-c), a is 1.

[0630] In some embodiments of compounds of formula (IV-c), b is 1.

[0631] In some embodiments of compounds of formula (IV-c), c is 1.

[0632] In some embodiments, the present invention provides compounds of formula (IV) or pharmaceutically acceptable salts, esters, stereoisomers, polymorphs, solvates, N-oxides, isotopically labeled compounds, metabolites, or prodrugs thereof, wherein said compounds have the structure of formula (IV-d):

[0633] in:

[0634] Ab is the antibody molecule;

[0635] q is an integer or decimal from 1 to 8;

[0636] Q1 is the functional group that can couple with the cysteine, lysine, non-natural amino acid, or glycosyl group of the antibody molecule.

[0637] D represents the drug unit;

[0638] B2 is independently selected from the branched segment;

[0639] C1 is the spacer group independently;

[0640] S3 and S4 are independently the hydrophilic groups or selected from the group consisting of the hydrophilic groups;

[0641] F1 is selected from the direct bond or the group consisting of: optionally substituted alkylene, optionally substituted polyethylene glycol, optionally substituted alkenyl, optionally substituted ynylene, optionally substituted alicyclic, optionally substituted alicyclic, optionally substituted aryl, and optionally substituted heteroaryl; when substituted, the substituent is selected from halogen, hydroxyl, amino, carboxyl, carbonyl, sulfonic acid, sulfone, phosphate, and alkoxy.

[0642] L1 is selected from either a direct key or the extended unit; the condition is that F1 and L1 are not both direct keys at the same time.

[0643] c can be 1, 2, or 3 independently;

[0644] a can be 0, 1, 2 or 3 independently.

[0645] In some embodiments of compounds of formula (IV-d), neither F1 nor L1 is a direct bond.

[0646] In some embodiments of compounds of formula (IV-d), a is 0. In some embodiments of compounds of formula (IV-d), a is 1.

[0647] In some embodiments of compounds of formula (IV-d), c is 1.

[0648] In some embodiments, the present invention provides compounds of formula (IV) or pharmaceutically acceptable salts, esters, stereoisomers, polymorphs, solvates, N-oxides, isotopically labeled compounds, metabolites, or prodrugs thereof, wherein said compounds have the structure of formula (IV-e):

[0649] in:

[0650] Ab is the antibody molecule;

[0651] q is an integer or decimal from 1 to 8;

[0652] Q1 is the functional group that can couple with the cysteine, lysine, non-natural amino acid, or glycosyl group of the antibody molecule.

[0653] D represents the drug unit;

[0654] B3 is independently selected from the branched segment;

[0655] C1 is the spacer group independently;

[0656] S3 and S5 are independently the hydrophilic groups or selected from the group consisting of the hydrophilic groups;

[0657] F1 is selected from the direct bond or the group consisting of: optionally substituted alkylene, optionally substituted polyethylene glycol, optionally substituted alkenyl, optionally substituted ynylene, optionally substituted alicyclic, optionally substituted alicyclic, optionally substituted aryl, and optionally substituted heteroaryl; when substituted, the substituent is selected from halogen, hydroxyl, amino, carboxyl, carbonyl, sulfonic acid, sulfone, phosphate, and alkoxy.

[0658] L1 is selected from either a direct key or the extended unit; the condition is that F1 and L1 are not both direct keys at the same time.

[0659] d can be 1, 2, or 3 independently;

[0660] a can be 0, 1, 2 or 3 independently.

[0661] In some embodiments of compounds of formula (IV-e), neither F1 nor L1 is a direct bond.

[0662] In some embodiments of compounds of formula (IV-e), a is 0. In some embodiments of compounds of formula (IV-e), a is 1.

[0663] In some embodiments of compounds of formula (IV-e), d is 1.

[0664] In some embodiments, the present invention provides compounds of formula (IV) or pharmaceutically acceptable salts, esters, stereoisomers, polymorphs, solvates, N-oxides, isotopically labeled compounds, metabolites, or prodrugs thereof, wherein:

[0665] Q1 is the functional group that can couple with the cysteine, lysine, non-natural amino acid, or glycosyl group of the antibody molecule.

[0666] D represents the drug unit;

[0667] B1 is selected from the branched segment;

[0668] C1 is either a direct bond or the spacer group;

[0669] S2 and S3 are each independently the hydrophilic group or selected from the group consisting of each of the hydrophilic groups;

[0670] F1 is selected from the direct bond or the group consisting of: optionally substituted alkylene, optionally substituted polyethylene glycol, optionally substituted alkenyl, optionally substituted ynylene, optionally substituted alicyclic, optionally substituted alicyclic, optionally substituted aryl, and optionally substituted heteroaryl; when substituted, the substituent is selected from halogen, hydroxyl, amino, carboxyl, carbonyl, sulfonic acid, sulfone, phosphate, and alkoxy.

[0671] L1 is the extension unit;

[0672] a and b can be 1, 2, or 3 independently.

[0673] In some such embodiments, the compound has the structure of formula (IV-f):

[0674] In some embodiments, in any of formula IV, IV-a, IV-b, IV-c, IV-d, IV-e, or IV-f, F1 is selected from a direct bond or the group consisting of: optionally substituted alkylene, optionally substituted polyethylene glycol, optionally substituted alkenyl, optionally substituted ynylene, optionally substituted alicyclic, optionally substituted alicyclic, optionally substituted aryl, and optionally substituted heteroaryl; when substituted, the substituent is selected from halogen, hydroxyl, amino, carboxyl, sulfonic acid, sulfone, phosphate, and alkoxy.

[0675] In some implementations, B1, B2, and B3, when present, are each bonds in any of formulas IV, IV-a, IV-b, IV-c, IV-d, IV-e, or IV-f.

[0676] In a preferred embodiment, in any of formulas IV, IV-a, IV-b, IV-c, IV-d, IV-e, or IV-f, B1, B2, and B3, when present, are each: in:

[0677] Connection point 3 This indicates that B1, B2, or B3 are connected to S2, S4, or S5 respectively; and

[0678] R 8 Selected from H or hydrophilic groups.

[0679] In the preferred embodiment, R 8 The hydrophilic groups in S2, S4, or S5 are each selected from: optionally substituted polysarcosine residues, polyglycerols, polyols, glycosyl groups, cyclodextrins, substituted ethylene glycol fragments, substituted glycosylated polyethylene glycol fragments, substituted glycosylated polyglycerols, substituted cyclodextrin polyethylene glycols, or combinations thereof.

[0680] In some such embodiments, the optionally substituted polysarcosine residue is Wherein n2 is an integer between 4 and 20, 4 and 16, or 8 and 12, preferably 10; R0 is selected from C1-C6 alkyl, C1-C6 cycloalkyl, and C1-C6 alkoxy, preferably methyl; preferably, the optionally substituted polysarcosine residue is

[0681] In some embodiments, the substituted glycosylated polyglycerol fragment is Where n4 is an integer between 4 and 12, or between 4 and 10.

[0682] In some embodiments, the substituted polyethylene glycol fragment is Where n5 is an integer between 4 and 24, between 7 and 20, or between 8 and 18, preferably, the substituted polyethylene glycol fragment is...

[0683] In some embodiments, the substituted glycosylated polyethylene glycol fragment is Where n3 is an integer between 4 and 18, or between 4 and 12. Preferably, the substituted glycosylated polyethylene glycol fragment is...

[0684] In some embodiments, the hydrophilic group is selected from the group consisting of optionally substituted polyethylene glycol segments and substituted polysarcosine segments, preferably. Wherein n7 is an integer between 4 and 20, 4 and 16, or 8 and 12, preferably 10; R0 is selected from C1-C6 alkyl, C1-C6 cycloalkyl, and C1-C6 alkoxy, preferably methyl; n5 is an integer between 4 and 24, 7 and 20, or 8 and 18. Preferably, the hydrophilic group is:

[0685] In some embodiments, the polyol is Preferred

[0686] In some embodiments, the glycosyl group is

[0687] In a preferred embodiment, in any of formulas IV, IV-a, IV-b, IV-c, IV-d, IV-e, or IV-f, B1, B2, and B3, when present, are each selected from the group consisting of: "Connection point 3" means that B1, B2 or B3 are respectively connected to S2, S4 or S5.

[0688] In a preferred embodiment, in any of formulas IV, IV-a, IV-b, IV-c, IV-d, IV-e, or IV-f, B1, B2, and B3, when present, are each: Where "connection point 3" means that B1, B2, or B3 are respectively connected to S2, S4, or S5, and R 8 The hydrophilic group is mentioned above.

[0689] In a preferred embodiment, in any of formula IV, IV-a, IV-b, IV-c, IV-d, IV-e, or IV-f, the hydrophilic group is independently selected each time it appears from: optionally substituted polysarcosine residues, polyglycerols, polyols, glycosyl groups, cyclodextrins, substituted ethylene glycol fragments, substituted glycosylated polyethylene glycol fragments, substituted glycosylated polyglycerols, substituted cyclodextrin polyethylene glycols, or combinations thereof.

[0690] In some preferred embodiments, in any of formula IV, IV-a, IV-b, IV-c, IV-d, IV-e, or IV-f, the optionally substituted polysarcosine residue is Wherein: n2 is an integer between 4 and 20, for example an integer between 4 and 16, preferably an integer between 8 and 12, more preferably 10; R0 is selected from: C1-C6 alkyl, C1-C6 cycloalkyl and C1-C6 alkoxy, preferably methyl.

[0691] Preferably, the optionally substituted polysarcosine residues are:

[0692] In some preferred embodiments, the substituted glycosylated polyglycerol fragment in any of formulas IV, IV-a, IV-b, IV-c, IV-d, IV-e, or IV-f is Where n4 is an integer between 4 and 12, for example, an integer between 4 and 10.

[0693] In some preferred embodiments, the substituted polyethylene glycol fragment in any of formula IV, IV-a, IV-b, IV-c, IV-d, IV-e, or IV-f is Wherein, n5 is an integer between 4 and 24, for example, between 7 and 20, or between 8 and 18, for example, the substituted polyethylene glycol fragment is...

[0694] In other preferred embodiments, in any of formulas IV, IV-a, IV-b, IV-c, IV-d, IV-e, or IV-f, the substituted glycosylated polyethylene glycol fragment is Where n3 is an integer between 4 and 18, for example, an integer between 4 and 12; preferably, the substituted glycosylated polyethylene glycol fragment is:

[0695] In some preferred embodiments, in any of formulas IV, IV-a, IV-b, IV-c, IV-d, IV-e, or IV-f, the hydrophilic group may also be selected from the group consisting of optionally substituted polyethylene glycol segments and substituted polysarcosine segments, preferably... Wherein n7 is an integer between 4 and 20, for example, an integer between 4 and 16, preferably an integer between 8 and 12, more preferably 10; R0 is selected from: C1-C6 alkyl, C1-C6 cycloalkyl, and C1-C6 alkoxy, preferably methyl; n5 is an integer between 4 and 24, for example, an integer between 7 and 20, or an integer between 8 and 18; further preferred

[0696] In some preferred embodiments, the polyol is Preferred

[0697] In some preferred embodiments, the glycosyl group is

[0698] In some preferred embodiments, in any of formulas IV, IV-a, IV-b, IV-c, IV-d, IV-e, or IV-f, when B1, B2, or B is present, -B1-[S2] b -B2-[S4] c 、or -B3-[S2] a Each part is independently selected from:

[0699] In some preferred embodiments, L1, when present, may independently be an optionally substituted amino acid in any of formulas IV, IV-a, IV-b, IV-c, IV-d, IV-e, or IV-f. Preferably, the amino acid is selected from: phenylalanine, isoleucine, leucine, tryptophan, valine, methionine, tyrosine, alanine, threonine, histidine, serine, glutamine, arginine, lysine, asparagine, glutamic acid, proline, citrulline, aspartic acid, and glycine. More preferably, the amino acid is valine, particularly... include

[0700] In some preferred embodiments, L1 may also be an optionally substituted polypeptide residue in any of formulas IV, IV-a, IV-b, IV-c, IV-d, IV-e, or IV-f.

[0701] In some such embodiments, in any of formula IV, IV-a, IV-b, IV-c, IV-d, IV-e, or IV-f, L1, when present, independently comprises optionally substituted polypeptide residues consisting of amino acids selected from the group consisting of: phenylalanine, isoleucine, leucine, tryptophan, valine, methionine, tyrosine, alanine, threonine, histidine, serine, glutamine, arginine, lysine, asparagine, glutamic acid, proline, citrulline, aspartic acid, and glycine.

[0702] In a preferred embodiment, in any of formula IV, IV-a, IV-b, IV-c, IV-d, IV-e, or IV-f, L1, when present, independently comprises a polypeptide residue consisting of optionally substituted amino acids selected from the group consisting of glycine, phenylalanine, valine, alanine, arginine, citrulline, aspartic acid, asparagine, and lysine.

[0703] In a preferred embodiment, in any of formulas IV, IV-a, IV-b, IV-c, IV-d, IV-e, or IV-f, L1, when present, independently comprises optionally substituted polypeptide residues selected from the group consisting of: phenylalanine-lysine (Phe-Lys), valine-alanine (Val-Ala), valine-citrulline (Val-Cit), glutamic acid-valine-alanine (Glu-Val-Ala), glutamic acid-valine-citrulline (Glu-Val-Cit), valine-lysine (Val-Lys), alanine-alanine (Ala-Ala), alanine-alanine-alanine (Ala-Ala-Ala), alanine-alanine-asparagine (Ala-Ala-Asn), alanine-leucine (Ala-Leu), leucine-leucine (Leu-Leu), phenylalanine-arginine (Phe-Arg), and phenylalanine-lysine (Phe-Lys). Glycine-glycine-phenylalanine-glycine (Gly-Gly-Phe-Gly), glycine-proline (Gly-Pro).

[0704] In a preferred embodiment, in any of formulas IV, IV-a, IV-b, IV-c, IV-d, IV-e, or IV-f, L1 is independently phenylalanine-lysine (Phe-Lys), valine-alanine (Val-Ala), valine-citrulline (Val-Cit), alanine-alanine (Ala-Ala), or glycine-glycine-phenylalanine-glycine (Gly-Gly-Phe-Gly).

[0705] In a more preferred embodiment, in any of formula IV, IV-a, IV-b, IV-c, IV-d, IV-e, or IV-f, L1, when present, is independently valine-alanine (Val-Ala), valine-citrulline (Val-Cit), or alanine-alanine (Ala-Ala), particularly include

[0706] In some implementations, in any of formulas IV, IV-a, IV-b, IV-c, IV-d, IV-e, or IV-f, each C1 is independently:

[0707] Preferred

[0708] More

[0709] Where: Connection point 1 Connect to B3 or L1 (where applicable), and connect point 2. Connected to the drug unit D.

[0710] In some preferred embodiments, in any of formulas IV, IV-a, IV-b, IV-c, IV-d, IV-e, or IV-f, when a is present and not zero, each S3 is independently the glycosyl or cyclodextrin, preferably glycosyl, more preferably glycosyl. include

[0711] In some implementations, in any of formulas IV, IV-a, IV-b, IV-c, IV-d, IV-e, or IV-f, C1 is selected from the group consisting of: and optional replacement Here, connection point 1 is connected to L1, and connection point 2 is connected to the drug unit D.

[0712] In some preferred embodiments, in any of formulas IV, IV-a, IV-b, IV-c, IV-d, IV-e, or IV-f, when B1 is selected from... When S2 is a glycosyl group, the -B1-S2 portion is selected from...

[0713] In some preferred embodiments, in any of IV, IV-a, IV-b, IV-c, IV-d, IV-e, or IV-f, when B1 is selected from... And when S2 is a polyol, the -B1-S2 portion is selected from...

[0714] In some preferred embodiments, in any of formulas IV, IV-a, IV-b, IV-c, IV-d, IV-e, or IV-f, the -C1-S3 portion is

[0715] In some preferred embodiments, in any of formulas IV, IV-a, IV-b, IV-c, IV-d, IV-e, or IV-f, when C1 is selected from... When S3 is a glycosyl group, the -C1-S3 portion is selected from...

[0716] In some implementations, F1 is an independent direct bond in any of formulas IV, IV-a, IV-b, IV-c, IV-d, IV-e, or IV-f, when present.

[0717] In some preferred embodiments, in any of formulas IV, IV-a, IV-b, IV-c, IV-d, IV-e, or IV-f, F1, when present, is independently selected from directly bonded or optionally substituted polyethylene glycol groups. In a preferred embodiment, the optionally substituted polyethylene glycol group is an amino-substituted polyethylene glycol group, more preferably... Where n6 is an integer between 1 and 18, preferably between 1 and 12 or between 1 and 10, such as 1, 2, 3, 4, 5, 6, 7, 8 or 9.

[0718] In a preferred embodiment, in any of formulas IV, IV-a, IV-b, IV-c, IV-d, IV-e, or IV-f, F1, when present, is independently [value missing]. Where n6 is 1, 3 or 7.

[0719] In a preferred embodiment, in any of formulas IV, IV-a, IV-b, IV-c, IV-d, IV-e, or IV-f, F1, when present, is independently [value missing]. Where n6 is 1, 3 or 7.

[0720] In some embodiments, the amino terminus (-NH-) of the polyethylene glycol group is connected to L1.

[0721] In a preferred embodiment, the carbonyl end (-C(O)-) of the polyethylene glycol group is connected to L1.

[0722] In a preferred embodiment, in any of formulas IV, IV-a, IV-b, IV-c, IV-d, IV-e, or IV-f, the C in the pharmaceutical unit D 3~6 The cycloalkyl group can be a monocyclic, spirocyclic, fused, or bridged ring; preferably, the C 3~6 cycloalkyl groups are selected from C 3~6 Monocyclic cycloalkyl or C 5~6 Bridged cycloalkyl rings.

[0723] In a preferred embodiment, in any of formulas IV, IV-a, IV-b, IV-c, IV-d, IV-e, or IV-f, the C in the pharmaceutical unit D 3~6 The cycloalkyl group is selected from cyclopropane, cyclobutane, cyclopentane, cyclohexane, Preferred materials include cyclopropane, cyclobutane, cyclohexane, or... More

[0724] In a preferred embodiment, in any of formula IV, IV-a, IV-b, IV-c, IV-d, IV-e, or IV-f, the 3-6 membered heterocyclic alkyl group in the pharmaceutical unit D may be ethylene oxide, aziridinyl, aziridine, oxacyclobutyl, tetrahydrofuranyl, dioxacyclopentenyl, pyrrolylalkyl, pyrrolidoneyl, imidazoalkyl, pyrazolylalkyl, pyrrolinyl, tetrahydropyranyl, piperidinyl, morpholinyl, dithiaalkyl, thiomorpholinyl, piperazine, or trithiaalkyl.

[0725] In a preferred embodiment, in any of formulas IV, IV-a, IV-b, IV-c, IV-d, IV-e, or IV-f, the R in the pharmaceutical unit D 1 Selected from halogens, -NH2, -OH, C 1-3 Alkyl or C 1-3 Alkyl group.

[0726] In a preferred embodiment, in any of formulas IV, IV-a, IV-b, IV-c, IV-d, IV-e, or IV-f, the R in the pharmaceutical unit D 1 The derivatives are selected from F, Cl, Br, I, -NH2, -OH, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, or propoxy, preferably methyl, methoxy, Cl, -OH, or -NH2, and more preferably methyl or methoxy. 。

[0727] In a preferred embodiment, in any of formulas IV, IV-a, IV-b, IV-c, IV-d, IV-e, or IV-f, the R in the pharmaceutical unit D 2 Selected from halogens, -NH2, -OH, C1-3 Alkyl or C 1-3 Alkyl group.

[0728] In a preferred embodiment, in any of formulas IV, IV-a, IV-b, IV-c, IV-d, IV-e, or IV-f, the R in the pharmaceutical unit D 2 It is selected from F, Cl, Br, I, -NH2, -OH, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy or propoxy, with F being preferred.

[0729] In a preferred embodiment, in any one of formula IV, IV-a, IV-b, IV-c, IV-d, IV-e, or IV-f, the R in the pharmaceutical unit D is selected from F, Cl, Br, or I, preferably F.

[0730] In a preferred embodiment, in any one of formula IV, IV-a, IV-b, IV-c, IV-d, IV-e, or IV-f, the n in the pharmaceutical unit D is selected from 1 or 2, preferably 1.

[0731] In a preferred embodiment, in any one of formula IV, IV-a, IV-b, IV-c, IV-d, IV-e, or IV-f, the m in the pharmaceutical unit D is selected from 1 or 2, preferably 1.

[0732] In a preferred embodiment, in any one of formulas IV, IV-a, IV-b, IV-c, IV-d, IV-e, or IV-f, the compound of formula (A) is selected from the structure represented by the following formula (A-1):

[0733] in:

[0734] Ring A can be cyclopropane, cyclobutane, cyclopentane, or cyclohexane.

[0735] The R 2 Preferred option: F;

[0736] The R 1 Preferably methyl or methoxy (in some embodiments, R 1 For methyl; in some embodiments, R 1 (Methoxylated);

[0737] Other definitions are as described above.

[0738] In a preferred embodiment, in any one of formula IV, IV-a, IV-b, IV-c, IV-d, IV-e, or IV-f, the compound of formula (A) is a compound of formula (A-1-1):

[0739] in:

[0740] R 1 Selected from methyl, Cl, -OH or -NH2, methoxy;

[0741] R 2 Selected from F;

[0742] Or, R 1 R 2 Composition with adjacent carbon

[0743] R is selected from F; and

[0744] n is selected from 1;

[0745] Preferably, it is a compound of formula (AA)

[0746] In a preferred embodiment, in any one of formula IV, IV-a, IV-b, IV-c, IV-d, IV-e, or IV-f, the compound of formula (A) is a compound of formula (A-1-2):

[0747] in:

[0748] R 1 Selected from methyl, Cl, -OH or -NH2, methoxy;

[0749] R 2 Selected from F;

[0750] Or, R 1 R 2 Composition with adjacent carbon

[0751] R is selected from F; and

[0752] n is selected from 1.

[0753] In a preferred embodiment, in any one of formula IV, IV-a, IV-b, IV-c, IV-d, IV-e, or IV-f, the compound of formula (A) is a compound of formula (A-1-3):

[0754] in:

[0755] R 1 Selected from methyl, Cl, -OH or -NH2, methoxy;

[0756] R 2 Selected from F;

[0757] Or, R1 R 2 Composition with adjacent carbon

[0758] R is selected from F; and

[0759] n is selected from 1.

[0760] In a preferred embodiment, in any one of formulas IV, IV-a, IV-b, IV-c, IV-d, IV-e, or IV-f, the compound of formula (A) is a compound of formula (A-1-4):

[0761] in:

[0762] R 1 Selected from methyl, Cl, -OH or -NH2, methoxy;

[0763] R 2 Selected from F; and

[0764] n is selected from 0.

[0765] In a preferred embodiment, in any one of formula IV, IV-a, IV-b, IV-c, IV-d, IV-e, or IV-f, the compound of formula (A) is selected from the structures shown in Table A above.

[0766] In a preferred embodiment, the pharmaceutical unit D is compound 11a or 17a from Table A above.

[0767] In some embodiments, the compound of any formula (A) described above is connected to C1 via a carboxamide bond (-C(O)-N-) or a phosphoramide bond (-P(O)(OH)-N-) through a -NH- group at position 1. In some embodiments, the compound of any formula (A) described above is connected to C1 via a carboxylic acid ester group (-C(O)-O-) or a phosphate ester group (-P(O)(OH)-O-) through an OH- group at position 9.

[0768] In this invention, embodiments or preferred embodiments of each of the above components (such as Ab, Q1, C1, B1, B2, B3, F1, L1, S2, S3, S5, S4, a, b, c, d, D) can be applied individually to any one of formulas IV, IV-a, IV-b, IV-c, IV-d, IV-e, or IV-f, or in various combinations to any one of formulas IV, IV-a, IV-b, IV-c, IV-d, IV-e, or IV-f. Where combinations are applicable, embodiments or preferred embodiments of each component can be combined in whole or in part.

[0769] In a preferred embodiment, the present invention provides compounds selected from formulas D1 to D18, or pharmaceutically acceptable salts, esters, stereoisomers, polymorphs, solvates, N-oxides, isotopically labeled compounds, metabolites, or prodrugs thereof:

[0770] In this invention, in formulas IV, IV-a, IV-b, IV-c, IV-d, IV-e, IV-f, D1 to D18, q can be 1 to 7.5, 1 to 7, 1 to 6.5, 1 to 6, 1 to 5.5, 1 to 5, 1 to 4.5, 1 to 4, 1 to 3.5, 1 to 2.5, 1 to 2, 1 to 1.5, 1.5 to 9, 1.5 to 8.5, 1-5 to 8, 1-5 to 7.5, 1-5 to 5.5, 1.5 to 5, 1.5 to 4.5, 1.5 to 4, 1.5 to 3.5, 1.5 to 3, 1.5 to 2.5, 1.5 to 2, 2 to 7.5, 2 to 7, 2 to 6.5, 2 to 6, 2 to 5.5, 2 to 5, 2 to 4 0.5, 2 to 4, 2 to 3.5, 2 to 3, 2 to 2.5, 2.5 to 8, 2.5 to 7.5, 2.5 to 7, 2.5 to 6.5, 2.5 to 6, 2.5 to 5.5, 2.5 to 4.5, 2.5 to 5, 2.5 to 2.5, 2.5 to 3.5, 3 to 7.5, 3 to 7, 3 to 6.5, 3 to 6, 3 to 5.5, 3 to 4.5, 3 to 4, 3 to 3.5, 3.5 to 7.5, 3.5 to 7, 3.5 to 6, 3.5 to 5.5, 3.5 to 5, 3.5 to 4.5, 3.5 to 4, 4 to 8, 4 to 7.5, 4 to 7, 4 to 6.5, 4 to 6, 4 to 5.5, 4 to 5 or 4 to 4.5. For example, q can be approximately 1, approximately 1.5, approximately 2, approximately 2.5, approximately 3, approximately 3.5, approximately 4, approximately 4.5, approximately 5, approximately 5.5, approximately 6, approximately 6.5, approximately 7, approximately 7.5, or approximately 8.

[0771] In this invention, in formulas IV, IV-a, IV-b, IV-c, IV-d, IV-e, IV-f, D1 to D18, Ab is a monoclonal antibody or its antigen-binding fragment. In a preferred embodiment, the monoclonal antibody is an antibody against the following antigens: HER2, HER3, TROP2, B7-H3, B7-H4, GPC20, GPRC5D, CDH6, EGFR, EGFRvIII, AXL, Nectin-4, Tissue factor, TIM-1, PSMA, PTK7, EpCAM, MUC1, STEAP1, GPNMB, FGF2, FOLR1, c-MET, GFR, AGS-16, Guanylyl cyclase C, Mesothelin, SLC44A4, EphA2, AGS-5, GPC-3, c-KIT, ROR1, ROR2, PD-L1, CD27L, 5T4, MerTK, and Mucin 16. 16) NaPi2b, STEAP, SLITRK6, ETBR, BCMA, CEACAM5, ICAM1, SC-16, SLC39A6, Delta-like protein 3, Claudin 18.2, Claudin 3, Claudin 6, Claudin9, CD19, CD20, CD22, CD30, CD33, CD37, CD45, CD56, CD66e, CD70, CD73, CD74, CD79b, CD123, CD138, CD147, CD166, CD223, MUC16, MSLN, ENPP3, SLTRK6, FGFR, LIV-1, Lewis Y, integrin αV, integrin β6 beta-6, ITGB6), ASCT2, C4.4a, CA-IX, CD324, CD352, CD44v6, CD48a, CLL-1, Cripto, CS1, DPEP3, Ephrin-A2, Ephrin-A4, ETBR, FGFR2, FGFR3, FLT3, GD3, Globo H, GPC3, LAMP-1, LRRC15, Ly6E, TM4SF1, MFI2, NOTCH3, p-cadherin, PRLR, CLDN1, CD228, CUB domain-containing protein 1 (CDCP1), CXCR4, LGR4, FZD7, CTR, GPR56, CCR7, DDR1, and RNF43.

[0772] In a preferred embodiment, the monoclonal antibody is an anti-HER2 antibody or an anti-TROP2 antibody. In some embodiments, the anti-HER2 antibody is trastuzumab, pertuzumab, or magtucizab. In some embodiments, the anti-TROP2 antibody is datopotamab or sacituzumab. In some embodiments, the anti-HER2 antibody comprises a heavy chain as shown in SEQ ID NO:1 and a light chain as shown in SEQ ID NO:2.

[0773] In a preferred embodiment, the monoclonal antibody may also be an antifolate receptor α (FRα) antibody. In some embodiments, the antiHER2 antibody comprises a heavy chain as shown in SEQ ID NO:3 and a light chain as shown in SEQ ID NO:4.

[0774] In this invention, embodiments or preferred embodiments of each of the above components (such as Q1, C1, B1, B2, B3, F1, L1, D, S3, S2, S4, S5, q, and Ab) can be applied individually to any of formulas IV, IV-a, IV-b, IV-c, IV-d, IV-e, or IV-f, or in various combinations thereof. Where combinations are applicable, embodiments or preferred embodiments of each component can be combined in whole or in part.

[0775] Another aspect of the present invention provides a compound, or a tautomer, meso compound, racemic compound, enantiomer, diastereomer, or deuterated compound thereof, or a mixture thereof, or a pharmaceutically acceptable salt, prodrug, or solvate thereof, wherein the compound is an antibody-drug conjugate comprising an antibody molecule and at least two compounds linked to the antibody molecule, said at least two compounds linked to the antibody molecule being independently selected from the linker-drug fragment provided by the present invention, or a tautomer, meso compound, racemic compound, enantiomer, diastereomer, or deuterated compound thereof, or a mixture thereof, or a pharmaceutically acceptable salt, prodrug, or solvate thereof.

[0776] Pharmaceutical Compositions, Uses and Methods

[0777] One aspect of the invention also provides a pharmaceutical composition comprising any compound of the invention, or a tautomer, meso compound, racemic compound, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt, prodrug, or solvate thereof, and a pharmaceutically acceptable carrier.

[0778] Pharmaceutically acceptable carriers are selected from the group consisting of fillers (diluents), binders, wetting agents, disintegrants, and excipients. Depending on the method of administration, the composition may contain 0.1 to 99% by weight of the compound of the present invention.

[0779] The pharmaceutical composition may be in an oral form, such as tablets, lozenges, tablets, aqueous or oil suspensions, dispersible powders or granules, emulsions, hard or soft capsules, or syrups. Oral compositions may be prepared according to any method known in the art for preparing pharmaceutical compositions, and may contain binders, fillers, lubricants, disintegrants, or pharmaceutically acceptable wetting agents, and may also contain one or more ingredients selected from the group consisting of sweeteners, flavoring agents, colorants, and preservatives. The pharmaceutical composition may be in the form of a sterile injectable aqueous solution. Acceptable solvents or media that can be used include water, Ringer's solution, and isotonic sodium chloride solution. A sterile injectable formulation may be a sterile injectable oil-in-water microemulsion in which the active ingredient is dissolved in the oil phase. For example, the active ingredient is dissolved in a mixture of soybean oil and lecithin. The oil solution can then be treated with a mixture of water and glycerin to form a microemulsion. The injection or microemulsion can be injected into the patient's bloodstream by local large-volume injection. Alternatively, the solution and microemulsion can be administered in a manner that maintains a constant circulating concentration of the compounds of the present invention. To maintain this constant concentration, a continuous intravenous delivery device can be used. For example, the device could be an intravenous infusion pump.

[0780] The pharmaceutical composition may be in the form of a sterile injectable aqueous or oil suspension for intramuscular and subcutaneous administration. This suspension may be formulated using suitable dispersants or wetting agents and suspending agents as described above, according to known techniques. The sterile injectable formulation may also be a sterile injectable solution or suspension prepared in a parenteral-acceptable, non-toxic diluent or solvent. Alternatively, a sterile fixative oil may be conveniently used as a solvent or suspension medium.

[0781] The compounds of the present invention can be administered in suppository form for rectal administration. These pharmaceutical compositions can be prepared by mixing the drug with a suitable, non-irritating excipient that is solid at normal temperatures but liquid in the rectum, and thus dissolves in the rectum to release the drug. Such substances include cocoa butter, glycerin gelatin, hydrogenated vegetable oils, polyethylene glycol of various molecular weights, and mixtures of fatty acid esters of polyethylene glycol.

[0782] As is well known to those skilled in the art, the dosage of a drug depends on a variety of factors, including but not limited to: the activity of the specific compound used, the patient's age, the patient's weight, the patient's health status, the patient's behavior, the patient's diet, the timing of administration, the route of administration, the rate of excretion, and the combination of drugs; in addition, the optimal mode of treatment, such as the treatment regimen, the compound described in this invention or its tautomers, mesosomes, racemates, enantiomers, diastereomers, or mixtures thereof, or pharmaceutically acceptable salts thereof, and / or the daily dosage or type of pharmaceutically acceptable salt of the compound or its tautomers, mesosomes, racemates, enantiomers, diastereomers, or mixtures thereof, or pharmaceutically acceptable salts thereof, can be verified based on conventional treatment protocols.

[0783] The pharmaceutical compositions of the present invention may contain a safe and effective amount of the antibody-drug conjugate of the present invention and a pharmaceutically acceptable carrier. Such carriers may include (but are not limited to): saline, buffer solution, glucose, water, glycerol, ethanol, and combinations thereof. The effective amount of the antibody-drug conjugate of the present invention may vary depending on the administration method and the severity of the disease to be treated. The selection of the effective amount can be determined by those skilled in the art based on various factors (e.g., through clinical trials). These factors may include, but are not limited to: pharmacokinetic parameters of the antibody-drug conjugate, such as bioavailability, metabolism, half-life, etc.; the severity of the disease to be treated, the patient's weight, the patient's immune status, the route of administration, etc. Generally, satisfactory results can be obtained when the antibody-drug conjugate of the present invention is administered daily at an appropriate dose. For example, due to the urgency of the treatment condition, several separate doses may be administered daily, or the dose may be reduced proportionally.

[0784] The compounds of the present invention can be administered alone or in combination with other pharmaceutically acceptable therapeutic agents. When using the pharmaceutical composition, a safe and effective amount of the compound of the present invention can be applied to a mammal (such as a human) requiring treatment, wherein the dose administered can be a pharmaceutically considered effective dose, and the specific dose can also take into account factors such as the route of administration and the patient's health condition.

[0785] Another aspect of the invention provides the use of the compounds of the invention, or tautomers, mesosomes, racemates, enantiomers, diastereomers, or deuterated compounds thereof, or mixtures thereof, or pharmaceutically acceptable salts, prodrugs, or solvates thereof, or pharmaceutical compositions thereof, in the preparation of medicaments for treating and / or preventing tumors.

[0786] Another aspect of the invention provides compounds of the invention, or tautomers, mesosomes, racemates, enantiomers, diastereomers, or deuterated compounds thereof, or mixtures thereof, or pharmaceutically acceptable salts, prodrugs, or solvates thereof, or pharmaceutical compositions thereof, for the treatment and / or prevention of tumors.

[0787] Another aspect of the invention provides a method for treating and / or preventing tumors in a subject, the method comprising administering to the subject a therapeutically effective amount of a compound of the invention, or a tautomer, meso compound, racemic compound, enantiomer, diastereomer, or deuterated compound thereof, or a mixture thereof, or a pharmaceutically acceptable salt, prodrug, or solvate thereof, or a pharmaceutical composition of the invention.

[0788] In any of the foregoing embodiments, the tumor is a solid tumor or a hematoma. In any of the foregoing embodiments, in a preferred embodiment, the tumor is a homologous recombination repair deficiency (HRD)-associated tumor.In any of the foregoing aspects, in a more preferred embodiment, the tumor is selected from tumors that are positive for or highly express the following targets: HER2, HER3, TROP2, B7-H3, B7-H4, GPC20, GPRC5D, CDH6, EGFR, EGFRvIII, AXL, Nectin-4, Tissue factor, TIM-1, PSMA, PTK7, EpCAM, MUC1, STEAP1, GPNMB, FGF2, FOLR1, c-MET, GFR, AGS-16, Guanylyl cyclase C, Mesothelin, SLC44A4, EphA2, AGS-5, GPC-3, c-KIT, ROR1, ROR2, PD-L1, CD27L, 5T4, MerTK, Mucin 16. 16) NaPi2b, STEAP, SLITRK6, ETBR, BCMA, CEACAM5, ICAM1, SC-16, SLC39A6, Delta-like protein 3, Claudin 18.2, Claudin 3, Claudin 6, Claudin9, CD19, CD20, CD22, CD30, CD33, CD37, CD45, CD56, CD66e, CD70, CD73, CD74, CD79b, CD123, CD138, CD147, CD166, CD223, MUC16, MSLN, ENPP3, SLTRK6, FGFR, LIV-1, Lewis Y, integrin αV, integrin β6 beta-6, ITGB6), ASCT2, C4.4a, CA-IX, CD324, CD352, CD44v6, CD48a, CLL-1, Cripto, CS1, DPEP3, Ephrin-A2, Ephrin-A4, ETBR, FGFR2, FGFR3, FLT3, GD3, Globo H, GPC3, LAMP-1, LRRC15, Ly6E, TM4SF1, MFI2, NOTCH3, p-cadherin, PRLR, CLDN1, CD228, CUB domain-containing protein 1 (CDCP1), CXCR4, LGR4, FZD7, CTR, GPR56, CCR7, DDR1, and RNF43.

[0789] In any of the foregoing embodiments, the tumor is selected from breast cancer, ovarian cancer, non-Hodgkin lymphoma, Hodgkin lymphoma, acute lymphoblastic leukemia, anaplastic large cell lymphoma, multiple myeloma, prostate cancer, non-small cell lung cancer, small cell lung cancer, malignant melanoma, squamous cell carcinoma, glioblastoma, renal cell carcinoma, gastrointestinal tumors, pancreatic cancer, prostate cancer, rectal cancer, gastric cancer, bladder cancer, gastrointestinal stromal tumor, cervical cancer, esophageal cancer, peritoneal cancer, liver cancer, colon cancer, glioma, mesothelioma, rectal cancer, colorectal cancer, uterine cancer, salivary gland cancer, kidney cancer, vulvar cancer, thyroid cancer, penile cancer, malignant lymphoma, plasmacytoma, myeloma, and sarcoma.

[0790] Pharmaceutical compositions and treatment methods

[0791] In some embodiments, the present invention provides pharmaceutical compositions comprising a preventatively or therapeutically effective amount of the compound of the present invention or a pharmaceutically acceptable salt, ester, stereoisomer, polymorph, solvate, N-oxide, isotopically labeled compound, metabolite, or prodrug, and one or more pharmaceutically acceptable carriers, wherein the pharmaceutical composition is preferably a solid, semi-solid, liquid, or gaseous formulation. In some embodiments, the pharmaceutical composition may further comprise one or more other therapeutic agents. In preferred embodiments, the pharmaceutical composition is preferably administered orally, intravenously, intraarterially, subcutaneously, intraperitoneally, intramuscularly, or transdermally.

[0792] In some embodiments, the present invention provides the use of the compounds of the present invention or pharmaceutically acceptable salts, esters, stereoisomers, polymorphs, solvates, N-oxides, isotopically labeled compounds, metabolites or prodrugs, or pharmaceutical compositions of the present invention in the preparation of medicaments for the prevention or treatment of cancer and / or tumors and related conditions.

[0793] In some embodiments, the present invention provides compounds of the present invention or pharmaceutically acceptable salts, esters, stereoisomers, polymorphs, solvates, N-oxides, isotopically labeled compounds, metabolites or prodrugs of the present invention, or pharmaceutical compositions of the present invention, for the prevention or treatment of cancer and / or tumors and related conditions.

[0794] In some embodiments, the present invention provides a method for preventing or treating cancer and / or tumors and related conditions, the method comprising administering to an individual in need an effective amount of a compound of the present invention or a pharmaceutically acceptable salt, ester, stereoisomer, polymorph, solvate, N-oxide, isotopically labeled compound, metabolite or prodrug of the present invention, or a pharmaceutical composition of the present invention.

[0795] In some embodiments, the cancer and / or tumor and related conditions are preferably cancers of the esophagus, stomach, intestines, rectum, mouth, pharynx, larynx, lungs, colon, breast, uterus, endometrium, ovary, prostate, testis, bladder, kidney, liver, pancreas, bone, connective tissue, skin, eye, brain and central nervous system, as well as thyroid cancer, leukemia, Hodgkin's disease, lymphoma and myeloma.

[0796] Other aspects of the invention can be readily obtained from the above embodiments.

[0797] definition

[0798] In this invention, the term "alkyl" generally refers to a residue derived from an alkane by removing a hydrogen atom. Alkyl groups can be substituted or unsubstituted, substituted or non-substituted. The term "alkyl" generally refers to a saturated straight-chain or branched aliphatic hydrocarbon group having residues derived from the removal of hydrogen atoms from the same carbon atom or two different carbon atoms of the parent alkane. It can be a straight-chain or branched group containing 1 to 20 carbon atoms, for example, containing 1 to 12 carbon atoms, such as a chain alkyl containing 1 to 6 carbon atoms. Non-limiting examples of alkyl groups include, but are not limited to, methyl, ethyl, propyl, propyl, butyl, etc. Alkyl groups can be substituted or unsubstituted, alternative or non-substituted. For example, when substituted, the substituent can be replaced at any usable connection point. The substituent can be independently selected from one or more substituents chosen from alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, mercapto, hydroxyl, nitro, cyano, cycloalkyl, heterocyclic, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio, heterocycloalkylthio, and oxo, for example, it can be hydrogen, protium, deuterium, tritium, halogen, -NO2, -CN, -OH, -SH, -NH2, -C(O)H, -CO2H, -C(O)C(O)H, -C(O)CH2C(O)H, -S(O)H, -S(O)2H, -C(O)NH2, -SO2NH2, -OC(O)H, -N(H)SO2H or C 1-6 Aliphatic groups.

[0799] In this invention, the term "alkylene" generally refers to a saturated straight-chain or branched aliphatic hydrocarbon group having two residues derived from the removal of two hydrogen atoms from the same carbon atom or two different carbon atoms of a parent alkane. It can be a straight-chain or branched group containing 1 to 20 carbon atoms. For example, the term "methylene" can refer to a residue derived from the removal of two hydrogen atoms from a group containing one carbon atom. The methylene group can be substituted or unsubstituted, substituted or non-substituted; for example, containing 1 to 12 carbon atoms, such as an alkylene group containing 1 to 6 carbon atoms. Non-limiting examples of alkylene groups include, but are not limited to, methylene (-CH2-), 1,1-ethylene (-CH(CH3)-), 1,2-ethylene (-CH2CH2)-, 1,1-propylene (-CH(CH2CH3)-), 1,2-propylene (-CH2CH(CH3)-), 1,3-propylene (-CH2CH2CH2-), 1,4-butylene (-CH2CH2CH2CH2-), and 1,5-butylene (-CH2CH2CH2CH2CH2-). The alkylene group can be substituted or unsubstituted, alternative or non-substituted. For example, when substituted, the substituent can be replaced at any usable connection point. The substituent can be independently selected from one or more substituents chosen from alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, mercapto, hydroxyl, nitro, cyano, cycloalkyl, heterocyclic, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio, heterocycloalkylthio, and oxo, for example, it can be hydrogen, protium, deuterium, tritium, halogen, -NO2, -CN, -OH, -SH, -NH2, -C(O)H, -CO2H, -C(O)C(O)H, -C(O)CH2C(O)H, -S(O)H, -S(O)2H, -C(O)NH2, -SO2NH2, -OC(O)H, -N(H)SO2H or C 1-6 Aliphatic groups. Methylene or alkylene groups can be substituted or unsubstituted.

[0800] In this invention, the term "alkenyl" generally refers to a straight-chain or branched hydrocarbon group containing one or more double bonds. Exemplary examples of alkenyl groups include allyl, homoallyl, vinyl, crotonyl, butenyl, pentenyl, and hexenyl. Exemplary examples of C2-6 chain alkenyl groups having more than one double bond include butadienyl, pentadienyl, hexadienyl, and hextrienyl, as well as their branched forms. The unsaturated bond (double bond) can be located at any position on the carbon chain. Alkenyl groups can be substituted or unsubstituted. In this invention, the term "alkenylene" generally refers to a residue derived from the removal of two hydrogen atoms from a carbon atom of an alkene. For example, it can be allylene, vinylene, butenylene, pentenylene, and hexenylene. Alkenylene groups can be substituted or unsubstituted.

[0801] In this invention, the term "alkynyl" generally refers to an unsaturated straight-chain or branched alkynyl group, such as ethynyl, L-propynyl, propynyl, butynyl, etc. The alkynyl group can be substituted or unsubstituted. In this invention, the term "ynynyl" generally refers to a residue derived from the removal of two hydrogen atoms from a carbon atom of an alkyne. For example, it can be ethynylene, propynylene, propynylene, butynyl, etc. The ynynyl group can be substituted or unsubstituted.

[0802] In this invention, the term "aryl" generally refers to a residue derived from the removal of a hydrogen atom from an aromatic ring. The term "aromatic ring" can refer to a 6- to 14-membered all-carbon monocyclic or fused polycyclic (i.e., a ring sharing adjacent carbon atom pairs) having a conjugated π-electron system, and can be 6- to 10-membered, such as benzene and naphthalene. The aromatic ring can be fused to a heteroaryl, heterocyclic, or cycloalkyl ring, wherein the ring attached to the parent structure is an aryl ring. The aryl group can be substituted or unsubstituted, and when substituted, the substituent can be one or more of the following groups, independently selected from the group consisting of: alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, mercapto, hydroxyl, nitro, cyano, cycloalkyl, heterocyclic alkyl, aryl, heteroaryl, cycloalkoxy, heterocyclic alkoxy, cycloalkylthio, and heterocyclic alkylthio. The aryl group can be substituted or unsubstituted.

[0803] In this invention, the term "arylene" generally refers to a residue derived by removing two hydrogen atoms from a carbon atom of an aromatic ring. For example, it could be phenylene or naphthylene. The arylene can be substituted or unsubstituted.

[0804] In this invention, the term "heteroaryl" generally refers to a residue derived from the removal of a hydrogen atom from a carbon atom of a heteroaryl ring. The term "heteroaryl ring" refers to a heteroaryl system comprising 1 to 4 heteroatoms and 5 to 14 ring atoms, wherein the heteroatoms can be selected from the group consisting of oxygen, sulfur, and nitrogen. The heteroaryl group can be 5 to 10-membered, or 5- or 6-membered, such as furanyl, thiophene, pyridinyl, pyrroleyl, N-alkylpyrroleyl, pyrimidinyl, pyrazinyl, imidazolyl, tetrazolyl, etc. The heteroaryl ring can be fused to an aryl, heterocyclic, or cycloalkyl ring, wherein the ring connected to the parent structure is the heteroaryl ring. The heteroaryl group can be optionally substituted or unsubstituted. When substituted, the substituent can be one or more of the following groups, independently selected from the group consisting of: alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, mercapto, hydroxyl, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio, and heterocycloalkylthio. The heteroaryl group can be substituted or unsubstituted. In this invention, the term "heteroaryl" generally refers to a residue having two hydrogen atoms removed from a carbon atom of a heteroaryl ring. For example, it can be furanyl, thiopheneyl, pyridinyl, pyrrolithyl, pyrimidinyl, pyrazinyl, imidazolyl, tetrazolyl, etc. The heteroaryl group can be substituted or unsubstituted.

[0805] In this invention, the term "alicyclic group" generally refers to a residue derived by removing a hydrogen atom from the same carbon atom or multiple different carbon atoms of an aliphatic ring. The term "cycloalkane" generally refers to a saturated or partially unsaturated monocyclic or polycyclic hydrocarbon, the carbide ring containing 3 to 20 carbon atoms, or containing 3 to 12 carbon atoms, or containing 3 to 10 carbon atoms, or containing 3 to 8 carbon atoms. Non-limiting examples of alicyclic groups include cyclopropane, cyclobutane, cyclopentane, cyclopentenyl, cyclohexane, cyclohexenyl, cyclohexadienyl, cycloheptane, cyclohepttrienyl, cyclooctane, etc.; polycyclic carbocyclic rings may include spirocyclic, fused-ring, and bridged-ring carbocyclic rings. Alicyclic groups can be substituted or unsubstituted. In this invention, the term "carbocyclic group" generally refers to a residue derived by removing a hydrogen atom from a carbon atom of a carbide ring. The term "carbocyclic ring" generally refers to saturated or partially unsaturated monocyclic or polycyclic cyclic hydrocarbons containing 3 to 20 carbon atoms, 3 to 12 carbon atoms, 3 to 10 carbon atoms, or 3 to 8 carbon atoms. Non-limiting examples of monocyclic carbocyclic rings include cyclopropane, cyclobutane, cyclopentane, cyclopentene, cyclohexane, cyclohexene, cyclohexadiene, cycloheptane, cycloheptanetriene, cyclooctane, etc.; polycyclic carbocyclic rings can include spirocyclic, fused, and bridged rings. The carbocyclic group can be substituted or unsubstituted. In some cases, alicyclic and carbocyclic rings can be used interchangeably.

[0806] In this invention, the term "partially unsaturated" generally refers to a cyclic structure in which the cyclic molecules contain at least one double or triple bond. The term "partially unsaturated" encompasses cyclic structures with multiple unsaturations, but is not intended to include aromatic or heteroaromatic rings as defined in this invention. The term "unsaturated" indicates that a portion has one or more degrees of unsaturation.

[0807] In this invention, the term "alicyclic group" generally refers to a residue derived by removing two hydrogen atoms from a carbon atom of an alicyclic ring. For example, it can be cyclopropane, cyclobutane, cyclopentane, cyclopentenyl, cyclohexane, cyclohexenyl, cyclohexadienyl, cycloheptane, cycloheptanetrienyl, cyclooctyl, etc.; the polycyclic carbocyclic ring can include spirocyclic, fused-ring, and bridged-ring carbocyclic rings. The alicyclic group can be substituted or unsubstituted.

[0808] In this invention, the term "aliphatic heterocyclic group" generally refers to a stable, non-aromatic 3-7 member monocyclic carbon ring structure, a fused 7-10 member bicyclic heterocyclic structure, or a bridged 6-10 member bicyclic heterocyclic structure. These cyclic structures can be saturated or partially saturated. In addition to carbon atoms, these cyclic structures contain one or more heteroatoms, wherein the heteroatoms can be selected from the group consisting of oxygen, sulfur, and nitrogen. For example, it contains 1 to 4 heteroatoms as defined above. When used to refer to atoms in an aliphatic heterocyclic structure, the term "nitrogen" can include nitrogen that has undergone a substitution reaction. For example, an aliphatic heterocyclic group can include "heterocyclic alkyl group," which can refer to a stable, non-aromatic 3-7 member monocyclic alkyl structure, a fused 7-10 member bicyclic heterocyclic structure, or a bridged 6-10 member bicyclic heterocyclic structure. In addition to carbon atoms, these cyclic structures contain one or more heteroatoms, wherein the heteroatoms can be selected from the group consisting of oxygen, sulfur, and nitrogen. For example, it contains 1 to 4 heteroatoms as defined above. Heterocyclic alkyl groups can be substituted or unsubstituted. Alicyclic groups can be substituted or unsubstituted.

[0809] In this invention, the term "allicyclic group" generally refers to a residue derived from the removal of two hydrogen atoms from a carbon atom of an alicyclic ring. Allicyclic groups can be substituted or unsubstituted.

[0810] In this invention, the terms "optional" or "optionally" generally refer to events or circumstances described subsequently that may but do not necessarily occur, and this description includes situations in which the event or circumstance occurs or does not occur. For example, "optionally alkyl-substituted heterocyclic group" means that an alkyl group may but does not necessarily exist, and this description can include cases where the heterocyclic group is substituted with an alkyl group and cases where the heterocyclic group is not substituted with an alkyl group.

[0811] In this invention, the term "substituted" generally refers to one or more hydrogen atoms in a group, for example, up to five, or for example, one to three hydrogen atoms, independently substituted by the corresponding number of substituents. Substituents are only considered in their possible chemical positions, and those skilled in the art can determine (experimentally or theoretically) possible or impossible substitutions without much effort. For example, an amino or hydroxyl group with free hydrogen may be unstable when combined with a carbon atom having an unsaturated bond (such as an alkene).

[0812] In this invention, as those skilled in the art will know, terms such as "alkyl," "alkenyl," and "cycloalkyl" may be preceded by an identifier indicating the number of atoms present in the group under specific conditions, for example, C1-C4 alkyl, C3-C7 cycloalkoxy, C1-C4 alkylcarbonylamino, etc., with the subscript number following "C" indicating the number of carbon atoms present in the group. For example, C3 alkyl refers to an alkyl group having three carbon atoms (e.g., n-propyl, isopropyl); in C1-10, members of the group may have any number of carbon atoms falling within the range of 1-10. One or more hydrogen atoms in the group, for example, up to five, or for example, one to three hydrogen atoms, are independently substituted by the corresponding number of substituents. Substituents are only in their possible chemical positions, and those skilled in the art can determine (by experiment or theory) possible or impossible substitutions without much effort. For example, an amino or hydroxyl group with free hydrogen may be unstable when bonded to a carbon atom with an unsaturated bond (such as an alkene).

[0813] In this invention, the term "compound" generally refers to a substance having two or more different elements. For example, the compounds of this invention can be organic compounds, and can be compounds with a molecular weight of less than 500, less than 1000, more than 1000, or more than 10,000 or 100,000. In this invention, a compound can also refer to a compound linked by chemical bonds, for example, a compound in which one or more molecules with a molecular weight of less than 1000 are linked by chemical bonds to a biological macromolecule, such as a polysaccharide, protein, nucleic acid, polypeptide, etc. For example, the compounds of this invention can include compounds in which a protein is linked to one or more molecules with a molecular weight of less than 1000, compounds in which a protein is linked to one or more molecules with a molecular weight of less than 10,000, or compounds in which a protein is linked to one or more molecules with a molecular weight of less than 100,000.

[0814] In this invention, the term "comprising" generally means including the explicitly specified features, but does not exclude other elements. The terms "above" and "below" generally refer to situations that include the stated number.

[0815] In this invention, the term "about" generally refers to a variation within a range of 0.5% to 10% above or below a specified value, such as a variation within a range of 0.5%, 1%, 1.5%, 2%, 2.5%, 3%, 3.5%, 4%, 4.5%, 5%, 5.5%, 6%, 6.5%, 7%, 7.5%, 8%, 8.5%, 9%, 9.5%, or 10% above or below a specified value.

[0816] In this invention, the compounds comprise tautomers, meso compounds, racemates, enantiomers, and / or diastereomers of the compounds. In this invention, the term "diastereomer" generally refers to a stereoisomer having two or more chiral centers and whose molecules are not mirror images of each other. Diastereomers can have different physical properties, such as melting point, boiling point, spectral properties, and reactivity. In this invention, the terms "tautomer" or "tautomer form" are used interchangeably and generally refer to structural isomers of different energies that can be interconverted through a low energy barrier. For example, proton tautomers (also known as prototropic tautomers) include interconversions via proton migration, such as keto-enol isomerization and imine-enamine isomerization. Valence tautomers include interconversions via the rearrangement of some bonding electrons. In this invention, the term "meta-form" generally refers to a molecule containing asymmetric atoms but possessing symmetry factors that result in zero total optical rotation within the molecule. The terms "racemic form" or "racemic mixture" refer to a composition consisting of two enantiomers in equimolar amounts.

[0817] In this invention, certain atoms of the compounds may appear in more than one isotopic form. For example, hydrogen may be in the form of gas (H), deuterium (H), etc. 2 H) and tritium ( 3 Carbon exists in the form of H, and may naturally exist in three different isotopes (12C, 13C, and 14C). Examples of isotopes that can be incorporated into the compounds of the present invention include, but are not limited to, 18F, 32P, 33p, 129I, 13'I, 123I, 124I, 125I, or similar isotopes. Therefore, the compounds of the present invention can be enriched in one or more of these isotopes relative to their natural abundance. As those skilled in the art will know, such isotope-enriched compounds can be used for a variety of purposes. For example, with heavy isotopes such as deuterium (H) 2 H) substitution may offer certain therapeutic advantages, possibly due to greater metabolic stability. For example, deuterium (H) 2The natural abundance of H is approximately 0.015%. Therefore, there is approximately one deuterium atom for every 6500 hydrogen atoms in nature. Thus, the deuterium-containing compounds of the present invention have a deuterium abundance greater than 0.015% at one or more positions (as the case may be). Unless otherwise specified, the structures described in the present invention may also include compounds that differ only in the presence or absence of one or more isotopically enriched atoms. For example, compounds whose structures are otherwise identical to those of the present invention, except that hydrogen atoms are replaced by deuterium or tritium, or carbon atoms are replaced by carbon-13 or carbon-14, are within the scope of the present invention.

[0818] In this invention, the term "analyte" generally refers to a compound having the same or similar structure or function as the inhibitor, which is capable of inhibiting the activity of the enzyme by at least 50%. The analogue may be an isomer, isomer, derivative, metabolite, precursor, or resolution product of the inhibitor, or a compound obtained by adding, deleting, substituting, or altering one or more atoms, chemical bonds, functional groups, substituents, or stereoconfigurations in the molecular structure of the inhibitor. The analogue may have the same or different pharmacological properties as the inhibitor, such as solubility, stability, bioavailability, half-life, toxicity, or side effects.

[0819] In this invention, the term "pharmaceutical composition" generally refers to a mixture containing one or more of the compounds described in this invention or their physiologically / pharmacologically acceptable salts or prodrugs, along with other chemical components, such as physiologically / pharmacologically acceptable carriers and excipients. Pharmaceutical compositions can facilitate administration to an organism, promote the absorption of the active ingredient, and thereby exert its biological activity. The preparation of conventional pharmaceutical compositions can be found in techniques commonly used in the art.

[0820] In this invention, the term "pharmaceutically acceptable salt" or "medicinal salt" generally refers to a salt of the compound or ligand-drug conjugate of this invention, or a salt of the compound described in this invention, which may be safe and / or effective when used in mammals and may have the desired biological activity. The antibody-antibody-drug conjugate of this invention may form salts with acids. Non-limiting examples of pharmaceutically acceptable salts include: hydrochloride, hydrobromide, hydroiodide, sulfate, hydrogen sulfate, citrate, acetate, succinate, ascorbate, oxalate, nitrate, sorbate, hydrogen phosphate, dihydrogen phosphate, salicylate, hydrogen citrate, tartrate, maleate, fumarate, formate, benzoate, methanesulfonate, ethanesulfonate, benzenesulfonate, or p-toluenesulfonate.

[0821] In this invention, the term "coupled compound" generally refers to a compound prepared by one or more chemical reactions, or a compound connected to each other by one or more connecting structures such as a bridge, spacer, or connecting portion.

[0822] In this invention, the term "pharmaceutically acceptable carrier" generally refers to a carrier for administering therapeutic agents, such as antibodies or peptides, genes, and other therapeutic agents. This term refers to any pharmaceutical carrier that does not itself induce the production of antibodies harmful to the individual receiving the composition and can be administered without causing excessive toxicity. For example, a pharmaceutically acceptable carrier can be distinguished from a nucleic acid vector used in genetic engineering to contain a target gene. Suitable carriers can be large, slowly metabolized macromolecules, such as proteins, polysaccharides, polylactic acid, polyglycolic acid, polyamino acids, amino acid copolymers, lipid aggregates, and inactivated viral particles. These carriers are well known to those skilled in the art. Pharmaceutically acceptable carriers in therapeutic compositions may include liquids, such as water, saline, glycerol, and ethanol. These carriers may also contain excipients, such as wetting agents or emulsifiers, pH buffers, etc.

[0823] In this invention, the term "group capable of coupling with a thiol group" generally refers to compound A having a thiol group and compound B having a group capable of coupling with a thiol group. Compound B can achieve the connection between compound A and compound B by reacting the thiol group of compound A with the thiol group capable of coupling with a thiol group.

[0824] In this invention, the term "linker" generally refers to a chemical structure, fragment, or bond that is connected at one end to a group and at the other end to another group. It may also refer to a linker connected to other linkers before being linked to a drug and / or ligand. The direct or indirect ligand linker can refer to the group directly connecting to the ligand via a covalent bond, or it can refer to the ligand being connected via a linker. For example, the linker can be the structure shown in Q1 of this invention. For example, chemical structure fragments or bonds containing acid-labile linker structures (e.g., hydrazones), protease-sensitive (e.g., peptidase-sensitive) linker structures, light-labile linker structures, dimethyl linker structures, or disulfide-containing linker structures can be used as linkers.

[0825] In this invention, the term "linking group" generally refers to a group that has the ability to connect with another group. For example, a compound having a linking group can achieve the connection of the compound with another group through a coupling reaction between the linking group and another group. For example, a maleimide group can serve as a linking group.

[0826] In this invention, the term "pharmaceutical unit" generally refers to a chemical moiety that directly or indirectly conjugates an antibody or antigen-binding fragment to form an immunoconjugate. For example, a "pharmaceutical unit" includes, but is not limited to, compounds with antitumor activity described herein. For example, pharmaceutical units include topoisomerase inhibitors.

[0827] In this invention, the term "compound with antitumor activity" generally refers to a compound that has the ability to reduce the proliferation rate, viability, or metastatic activity of tumor cells. For example, antitumor activity may be demonstrated by a reduction in the growth rate of abnormal cells that appear during treatment, or by stabilization or shrinkage of tumor size, or by longer survival due to treatment compared to a control without treatment. Antitumor activity can be assessed using recognized in vitro or in vivo tumor models, such as xenograft models.

[0828] In some embodiments of the present invention, the bioactive molecule in the conjugate is a compound with specific antitumor activity, such as a radioactive isotope, for example, At. 211 I 131 I 125 Y 90 Re 186 Re 188 、Sm 153 Bi 212 P 32 Pb 212 Radioactive isotopes of Lu; metal complexes, such as platinum complexes (e.g., oxaliplatin) or gold complexes; glycopeptide antibiotics, such as bleomycin or bleomycin; topoisomerase inhibitors; drugs that interfere with DNA synthesis, such as methotrexate, 5-fluorouracil, cytarabine, gemcitabine, mercaptopurine, pentostatin, fludarabine, cladribine, or nerabine; drugs that act on structural proteins, such as microtubule inhibitors (e.g., vinblastine alkaloids, vincristine, paclitaxel, maytansine, auristatin, tubulysin B, or eribulin); tumor signaling pathway inhibitors, such as serine / threonine kinase inhibitors, tyrosine kinase inhibitors, aspartate kinase inhibitors, or histidine kinase inhibitors; proteasome inhibitors; epigenetic target inhibitors; tumor angiogenesis inhibitors; cyclin inhibitors;

[0829] In this invention, the term "topoisomerase inhibitor" or "drug targeting topoisomerase" generally refers to compounds or derivatives thereof that include topoisomerase I inhibitors and topoisomerase II inhibitors. Examples of topoisomerase I inhibitors include, but are not limited to, camptothecin and its analogues; topoisomerase II inhibitors (such as Voreloxin (CAS175414-77-4) or its derivatives, actinomycin D, doxorubicin, doxorubicin, docarmicin, daunorubicin, mitoxantrone, podophyllotoxin, or etoposide, etc.). A topoisomerase can be an enzyme that corrects the number of rings in DNA by cleaving phosphodiester bonds in one or both strands of DNA, then rewinding and sealing them.

[0830] In this invention, the term "camptothecin analogue" generally refers to compounds that are structurally similar to or derived from camptothecin. For example, camptothecin analogues may refer to ethatecan (Exatecan, CAS171335-80-1), DXd (CAS1599440-33-1), 7-ethyl-10-hydroxycamptothecin (SN38, CAS86639-52-3), belotecone (Belotecan, CAS213819-48-8), (4-NH2)-exatecan (AZD'0132, CAS2495742-21-5), 7-MAD-MDCPT (CAS 765871-81-6), 7-aminomethyl-10-methyl-11-fluorocamptothecin (CAS2378616-23-8), etc.

[0831] In this invention, the term "disease associated with the expression of a target" generally refers to a disease in which the occurrence and / or progression of the disease is correlated with the expression level of that target. For example, high expression means that the expression level of a target is increased in cells from a disease area, such as a specific tissue or organ of a patient, relative to the expression level in normal cells from the tissue or organ. Or, for example, low expression means that the expression level of a target is decreased in cells from a disease area, such as a specific tissue or organ of a patient, relative to the expression level in normal cells from the tissue or organ. Or, for example, positive expression means that cells from a disease area, such as a specific tissue or organ of a patient, express a target. Or, negative expression means that cells from a disease area, such as a specific tissue or organ of a patient, do not express a target. For example, the characteristics of target expression can be determined by standard assays known in the art.

[0832] In this invention, the term "effective amount" generally refers to the amount of a therapeutic agent that treats, alleviates, or prevents a target disease or condition, or the amount that exhibits a detectable therapeutic or preventative effect. The precise effective amount for a given subject depends on that subject's body size and health status, the nature and severity of the condition, and the chosen therapeutic agent and / or combination of therapeutic agents. Therefore, it is useless to pre-specify an accurate effective amount. However, for a given condition, the effective amount can be determined using routine experiments, and a clinician can judge it accordingly.

[0833] Unless otherwise specified, all compounds mentioned in this invention are intended to include all possible optical isomers, such as compounds with a single chirality, or mixtures of various chiral compounds (i.e., racemates). In all compounds of this invention, each chiral carbon atom may optionally be in the R configuration or the S configuration, or a mixture of the R and S configurations.

[0834] As used herein, the term "compound of the invention" refers to any compound provided by the present invention. The term also includes various crystal forms, pharmaceutically acceptable salts, hydrates, or solvates of the compounds of the invention.

[0835] When a trade name is used in this document, it is intended to include the product formulation, its generic counterpart, and the active pharmaceutical ingredient of the product.

[0836] As used herein, “antibody” is used in its broadest sense and specifically covers monoclonal antibodies, polyclonal antibodies, dimers, multimers, multispecific antibodies (e.g., bispecific antibodies), and antibody fragments, provided they exhibit the desired biological activity. Antibodies can be mouse, human, humanized, chimeric, or derived from other species. Antibodies are proteins produced by the immune system capable of recognizing and binding to specific antigens. Target antigens generally have numerous binding sites, also called epitopes, recognized by the CDRs of various antibodies. Antibodies that specifically bind to different epitopes have different structures. Therefore, an antigen can have more than one corresponding antibody. Antibodies include full-length immunoglobulin molecules or the immunoactive portion of full-length immunoglobulin molecules, i.e., molecules containing antigens or portions thereof that specifically bind to the target of interest, including, but not limited to, cancer cells or cells that produce autoantibodies associated with autoimmune diseases. The immunoglobulins described in this invention can have any type (e.g., IgG, IgE, IgM, IgD, and IgA), class (e.g., IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2), or subclass of immunoglobulin molecules. Immunoglobulins can be derived from any species. However, in one aspect, immunoglobulins are derived from humans, mice, or rabbits. An "antibody fragment" can comprise a portion of a full-length antibody, generally its antigen-binding region or variable region. Examples of antibody fragments include: Fab, Fab', F(ab')2, and Fv fragments; biantibodies; linear antibodies; minibody; fragments prepared from Fab expression libraries; anti-idiotypic (anti-Id) antibodies; CDR (complementarity-determining region); and any of the above epitope-binding fragments that bind to cancer cell antigens, viral antigens, or microbial antigens in an immune-specific manner; single-chain antibody molecules; and multispecific antibodies formed from antibody fragments. The aforementioned antibodies can also be modified using THIOMAB technology to modify natural amino acids, specifically modifying unpaired cysteine ​​residues to achieve more coupling sites and site-specific coupling. The antibodies constituting the antibody-drug conjugates of this invention can maintain their original wild-state antigen-binding ability. Therefore, the antibodies of this invention can, for example, specifically bind to antigens. The antigens involved include, for example, tumor-associated antigens (TAAs), cell surface receptor proteins and other cell surface molecules, cell survival regulators, cell proliferation regulators, molecules related to tissue growth and differentiation (such as those known or anticipated to be functional), lymphokines, cytokines, molecules involved in cell circulation regulation, molecules involved in angiogenesis, and molecules related to angiogenesis (such as those known to be functional). The antigens bound by the antibodies can be one or a subset of the above categories, while other subsets include other molecules / antigens with specific properties (compared to the target antigen). Antibodies used in antibody-drug conjugates include, but are not limited to, antibodies against cell surface receptors and tumor-associated antigens.Such tumor-associated antigens are well-known in the industry and can be prepared using well-known antibody preparation methods and information. These targets can be specifically expressed on the surface of one or more cancer cells, while being expressed sparingly or not at all on the surface of one or more non-cancer cells. Typically, such tumor-associated peptides can be overexpressed on the surface of cancer cells compared to non-cancer cells.

[0837] In this invention, the term "peptide residue" generally refers to a residue consisting of one or more amino acid residues linked together. For example, one or more amino acids in a peptide residue may be optionally substituted.

[0838] In this invention, the term "polyethylene glycol group" generally refers to a residue consisting of one or more ethylene glycol residues linked together. For example, a polyethylene glycol group may contain -(CH2CH2O)p-, where p is a number from 1 to 10. For example, the polyethylene glycol group in this invention may be optionally substituted.

[0839] In this invention, the term "glycol group" generally refers to a polyethylene glycol group. For example, the glycol group in this invention may be optionally substituted. For example, the number preceding the glycol group may indicate the number of ethylene glycol units in the glycol group; for example, a diethylene glycol group may refer to two ethylene glycol polymerized residues.

[0840] In this invention, the term "polysarcosine residue" generally refers to a residue comprising one or more sarcosine residues linked together. For example, a polysarcosine residue may contain -(COCH2N(CH3))q-, where q is a number at least 1. For example, the polysarcosine residue in this invention may be optionally substituted. For example, a structure comprising a polysarcosine residue may be, where n2 is a number from 4 to 18, and R is an alkyl group, or an alkyl group substituted with hydrophilic groups such as polyhydroxyl, sulfonic acid, phosphate, or carboxyl groups.

[0841] In this invention, the term "sodium dodecyl sulfate polyacrylamide gel electrophoresis" generally refers to a material analysis and characterization technique. For example, sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) can detect the molecular weight of a substance.

[0842] In this invention, the term "hydrophobic chromatography" generally refers to an analytical technique based on the differences in hydrophobicity between substances.

[0843] In this invention, the term "liquid chromatography-mass spectrometry" generally refers to an analytical method for identifying the components of a substance. For example, liquid chromatography-mass spectrometry can analyze the molecular weight of an analyte using liquid chromatography-mass spectrometry.

[0844] In this invention, the term "tumor" generally refers to any new pathological tissue proliferation. For the purposes of this invention, angiogenesis is part of the characteristics of a tumor. Tumors can be benign or malignant. The term "tumor" is generally used to refer to either benign or malignant tumors, while the term "cancer" is generally used to refer to malignant tumors, which can be metastatic or non-metastatic.

[0845] Unless otherwise stated, as used herein, the term “treating” means to reverse, alleviate, or inhibit the progression of a disease or condition to which such term applies, or one or more symptoms of such a disease or condition, or to prevent such a disease or condition, or one or more symptoms of such a disease or condition.

[0846] As used herein, “individual” includes both human and non-human animals. Exemplary human individuals include human individuals suffering from a disease (such as the disease described herein) (referred to as patients) or normal individuals. In this invention, “non-human animals” includes all vertebrates, such as non-mammals (e.g., birds, amphibians, reptiles) and mammals, such as non-human primates, livestock, and / or domesticated animals (e.g., sheep, dogs, cats, cows, pigs, etc.).

[0847] Brief description of the attached figures

[0848] Figure 1 shows the tumor growth curves of tumor-bearing mice in Experiment 1 (Example V) of Test 2.

[0849] Figure 2 shows the tumor growth curves of tumor-bearing mice in Experiment 2 (Example V) of Test 2. Example

[0850] The raw materials described in this invention are commercially available products, or are prepared by methods known in the art or according to the methods described herein.

[0851] The structure of the compound was confirmed by nuclear magnetic resonance spectroscopy (HNMR) or mass spectrometry (MS). The instrument used for HNMR spectroscopy was a Bruker 400MHz NMR spectrometer; the solvent used was hexadeuterated dimethyl sulfoxide (DMSO-d6); and the internal standard was tetramethylsilane (TMS).

[0852] The abbreviations in nuclear magnetic resonance spectroscopy have the following meanings: s: singlet; d: doublet; t: triplet; q: quartet; dd: double doublet; qd: quadruple doublet; ddd: double double doublet; ddt: double triplet; dddd: double double double doublet; m: multiplet; br: broad peak; / : coupling constant; Hz: Hertz.

[0853] Chemical shift (5) is given in parts per million (ppm).

[0854] The mass spectrometry (MS) instrument used was a SHIMADZU LCMS-2020.

[0855] Example I. Preparation of Toxin

[0856] Preparation of compound 1a

[0857] Step 1: Synthesis of intermediate 1a

[0858] (1S,9S)-1-amino-9-ethyl-5-fluoro-9-hydroxy-4-methyl-1,2,3,9,12,15-hexahydro-10H,13H-benzo[de]pyrano[3',4':6,7]indolazino[1,2-b]quinoline-10,13-dione methanesulfonate (500 mg, 0.94 mmol), 2-bromomethyl-1,1-difluorocyclopropane (322 mg, 1.88 mmol), and diisopropylethylamine (606 mg, 4.7 mmol) were dissolved in dimethyl sulfoxide (10 mL). The reaction was stirred at 100 °C for 16 hours. After the reaction, the solution was purified by HPLC (Waters Sunfire Prep C8 OBD 19*250 mm 10 μm, 0.1% FA aqueous solution-CH3CN, 254 nm / 214 nm, 20 mL / min).

[0859] Compound 1a was obtained (30 mg, yield: 6%). LCMS (ESI) m / z: 526.2 [M+H]+.

[0860] 1 HNMR(400MHz,DMSO-d6)δ7.74(d,J=10.8Hz,1H),7.31(s,1H),6.52(s,1H),5.44–5.38(m,4H),4.29(s,1H),3.24–3.18(m,1H),3. 04–3.00(m,1H),2.88–2.83(m,2H),2.38(s,3H),2.27–2.22(m,1H),2.04–1.83(m,5H),1.60–1.56(m,2H),0.87(t,J=7.2Hz,3H).

[0861] Preparation of compound 7a

[0862] Step 1: Synthesis of 3,3-difluorocyclobutane-1-carboxaldehyde

[0863] In a 25 mL single-necked flask, a solution of 3,3-difluorocyclobutane-1-methanol (1.5 g, 5.8 mmol, 1.0 equivalent) in dichloromethane (16 mL) was added to a mixture of pyridinium chlorochromate (2.82 g, 13.1 mmol, 1.6 equivalents). The reaction was stirred at room temperature for 1 hour. The reaction solution was diluted with ether (20 mL), filtered through a silica gel column, and the filtrate was concentrated under reduced pressure at low temperature to give crude 3,3-difluorocyclobutane-1-carboxaldehyde (700 mg). ¹H NMR (400 MHz, DMSO-d⁶) δ 9.69 (s, 1H), 4.14 (d, J = 6.0 Hz, 1H), 2.50–2.32 (m, 4H).

[0864] Step 2: Synthesize compound 7a

[0865] In a 25 mL single-necked flask, triethylamine (9.5 mg, 0.09 mmol, 1.0 equivalent) was added to a mixture of (9S)-1-amino-9-ethyl-5-fluoro-9-hydroxy-4-methyl-1,2,3,9,12,15-hexahydro-10H,13H-benzo[d]pyrano[3',4':6,7] indo[1,2-b]quinoline-10,13-dione methanesulfonate (50 mg, 0.09 mmol, 1.0 equivalent) and dimethyl sulfoxide (2 mL). After the reaction solution became clear, formic acid (22 mg, 0.47 mmol, 5.0 equivalent) and 3-fluorocyclobutane-1-carboxaldehyde (16 mg, 0.14 mmol, 1.5 equivalent) were added and the mixture was stirred for 10 minutes. Sodium cyanoborohydride (8 mg, 0.14 mmol, 1.5 equivalent) was then added to the reaction solution. The reaction was stirred at room temperature for 2 hours. The reaction solution was filtered, and the filtrate was purified by high-performance liquid chromatography (HPLC) (Waters Sunfire Prep C8 OBD 19*250mm 10um, 0.1% FA aqueous solution-CH3CN, 254nm / 214nm, 20mL / min) to obtain (9S)-9-ethyl-5-fluoro-1-((3-fluorocyclobutyl)methyl)amino)-9-hydroxy-4-methyl-1,2,3,9,12,15-hexahydro-10H,13H-benzo[d]pyrano[3',4':6,7] indo[1,2-b]quinoline-10,13-dione compound 7a (24 mg, 0.05 mmol, 49% yield), a white solid. LCMS (ESI) m / z: 540.3 [M+H]+;

[0866] 1H NMR (400MHz, DMSO-d6) δ7.79(d,J=10.8Hz,1H),7.38(s,1H),5.48–5.32(m,4H),4.91(s,1H),3.37(s,1H),3.29–3.12(m,2H),3. 09–3.01(m,1H),2.74–2.59(m,3H),2.54(s,1H),2.47–2.30(m,5H),2.24–2.13(m,1H),1.92–1.77(m,2H),0.84(t,J=7.3Hz,2H).

[0867] Preparation of compound 11a

[0868] Step 1: Synthesis of (3-fluorobicyclo[1.1.1]pentan-1-yl)methanol

[0869] Under ice bath conditions, a borane dimethyl sulfide complex (2.0 M, 38.5 mL, 77 mmol, 2.0 equivalent) was added to a tetrahydrofuran (50 mL) solution of 3-fluorobicyclo[1.1.1]pentane-1-carboxylic acid (5.0 g, 38.5 mmol, 1.0 equivalent). The reaction was stirred at room temperature for 16 hours. The reaction solution was quenched with methanol (100 mL), stirred at room temperature for 2 hours, and then concentrated under reduced pressure to obtain crude (3-fluorobicyclo[1.1.1]pentane-1-yl)methanol (4.0 g), which was used directly in the next step. 1 H NMR (400MHz, CDCl3) δ3.84 (s, 2H), 2.00 (s, 6H).

[0870] Step 2: Synthesis of (3-fluorobicyclo[1.1.1]pentan-1-yl)formaldehyde

[0871] (3-fluorobicyclo[1.1.1]pentan-1-yl)methanol (200 mg, 1.72 mmol, 1.0 equivalent) was dissolved in dichloromethane (5 mL), and Desmartin oxidant (1.1 g, 2.58 mmol, 1.5 equivalent) was added at 0°C. After the addition was complete, the reaction mixture was stirred at room temperature for 4 hours. The reaction mixture was filtered, and the filtrate was concentrated under reduced pressure to obtain (3-fluorobicyclo[1.1.1]pentan-1-yl)formaldehyde (100 mg), which was used directly in the next step. 1 H NMR (400MHz, CDCl3) δ9.69 (d, J = 6.0 Hz, 1H), 2.30 (d, J = 2.4 Hz, 6H).

[0872] Step 3: Synthesize compound 11a

[0873] (9S)-1-amino-9-ethyl-5-fluoro-9-hydroxy-4-methyl-1,2,3,9,12,15-hexahydro-10H,13H-benzo[d]pyrano[3',4':6,7] indo[1,2-b]quinoline-10,13-dione methanesulfonate (50 mg, 0.094 mmol, 1.0 equivalent) and triethylamine (10 mg, 0.094 mmol, 1.0 equivalent) were added to dimethyl sulfoxide (2 mL) and stirred at room temperature for 10 minutes. Then, 3-fluorobicyclo[1.1.1]pentane-1-carboxaldehyde (16 mg, 0.141 mmol, 1.5 equivalent) and formic acid (22 mg, 0.470 mmol, 5 equivalent) were added sequentially to the reaction mixture. After the addition was complete, the mixture was stirred at room temperature for 30 minutes. Sodium cyanoborohydride (9 mg, 0.141 mmol, 1.5 equivalents) was added to the reaction solution. The reaction solution was stirred at room temperature for 16 hours. The reaction solution was purified by preparative high performance liquid chromatography (Waters Sunfire Prep C8 OBD 19*250 mm 10 μm, 0.1% FA aqueous solution-CH3CN, 254 nm / 214 nm, 20 mL / min) to obtain the target compound 11a. 1 H NMR (400MHz, DMSO-d6) δ7.88(d,J=10.8Hz,1H),7.39(s,1H),5.54–5.39(m,4H),5.01(s,1H),3.52(d,J=12.8Hz,1H),3.28–3.11(m,2 H),3.09–3.01(m,1H),2.78–2.74(m,1H),2.56(s,2H),2.42(s,3H),2.12(d,J=2.4Hz,6H),1.94–1.85(m,2H),0.88(t,J=7.2Hz,3H).

[0874] Preparation of compound 15a

[0875] Step 1: Synthesis of compound 15a

[0876] Triethylamine (9.52 mg, 0.09 mmol, 1 equivalent) was added to a solution of (1S,9S)-1-amino-9-ethyl-5-fluoro-9-hydroxy-4-methyl-1,2,3,9,12,15-hexahydro-10H,13H-benzo[d]pyrano[3',4':6,7] indo[1,2-b]quinoline-10,13-dione methanesulfonate (50 mg, 0.09 mmol, 1 equivalent) in dimethyl sulfoxide (1 mL). The mixture was stirred at room temperature for 15 minutes. 4,4-Difluorocyclohexane-1-carboxaldehyde (16.72 mg, 0.112 mmol, 1.2 equivalent) and formic acid (21.65 mg, 0.047 mmol, 5 equivalent) were then added to the mixture. The reaction mixture was stirred at room temperature for 30 minutes under argon protection. Sodium cyanoborohydride (9 mg, 0.014 mmol, 1.5 equivalents) was added to the reaction solution. The reaction solution was stirred at room temperature for 2 hours under argon protection. The reaction solution was filtered and purified by preparative high-performance liquid chromatography (Waters Sunfire Prep C8 OBD 19*250mm 10µm, 0.1% FA aqueous solution-CH3CN, 254nm / 214nm, 20mL / min) to obtain the target compound 15a (26 mg, yield 48%), LCMS (ESI) m / z: 568.1 [M+H]. + ;1H NMR (400MHz, DMSO) δ7.88(s,1H),7.38(s,1H),5.54(d,J=19.4Hz,1H),5.46(s,2H),5.40(d,J=19.0Hz,1H),5.02(s,1H),3.17(d,J=42.2Hz, 4H),2.72(d,J=22.5Hz,1H),2.42(s,3H),2.18(s,1H),2.07–2.00(m,2H),1.94–1.75(m,7H),1.26(d,J=16.4Hz,4H),0.88(t,J=7.3Hz,3H).

[0877] Preparation of compound 17a

[0878] Step 1: Synthesis of N-(3-fluoro-7-(hydroxyimino)-4-methoxy-8-oxy-5,6,7,8-tetrahydronaphth-1-yl)acetamide

[0879] Potassium tert-butoxide (16.1 g, 143 mmol, 2 equivalents) was added to anhydrous tetrahydrofuran solution (400 mL) and cooled to 0 °C. Anhydrous tetrahydrofuran solution (18 g, 71.64 mmol, 1 equivalent) of N-(3-fluoro-4-methoxy-8-oxo-5,6,7,8-tetrahydronaphth-1-yl)acetamide (18 g, 71.64 mmol, 1 equivalent) was slowly added dropwise to the reaction mixture. The reaction was stirred at room temperature for 0.5 h. Tert-butyl nitrite (14.8 g, 143 mmol, 2 equivalents) was slowly added dropwise to the reaction mixture at 0 °C. The reaction was stirred at room temperature for 16 h. The reaction mixture was poured into water (1000 mL) and extracted with ethyl acetate (400 mL x 2). The organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The crude product was slurried with diethyl ether to yield the target compound N-(3-fluoro-7-(hydroxyimino)-4-methoxy-8-oxy-5,6,7,8-tetrahydronaphth-1-yl)acetamide (15 g, 53.52 mmol, yield 75%), as a brown solid. LCMS (ESI) m / z: 281.1 [M+H] + .

[0880] Step 2: Synthesis of N-(7-amino-3-fluoro-4-methoxy-8-oxo-5,6,7,8-tetrahydronaphth-1-yl)acetamide

[0881] (Z)-N-(3-fluoro-7-(hydroxyimino)-4-methoxy-8-oxy-5,6,7,8-tetrahydronaphth-1-yl)acetamide (6 g, 21.41 mmol, 1 equivalent) was dissolved in 150 mL of methanol, and 600 mg of 10% palladium on carbon and 15 mL of 3 M hydrochloric acid were added. The reaction was stirred at room temperature under hydrogen atmosphere for 2 hours. The reaction solution was filtered through diatomaceous earth, the filter cake was washed with methanol, and the filtrate was concentrated under reduced pressure to give the target compound N-(7-amino-3-fluoro-4-methoxy-8-oxy-5,6,7,8-tetrahydronaphth-1-yl)acetamide (5 g, 18.8 mmol, yield 88%), a black solid. LCMS (ESI) m / z: 267.1 [M+H] + .

[0882] Step 3: Synthesis of (9H-fluorene-9-yl)methyl(8-acetamido-6-fluoro-5-methoxy-1-oxo-1,2,3,4-tetrahydronaphth-2-yl)carbamate

[0883] N-(7-amino-3-fluoro-4-methoxy-8-oxo-5,6,7,8-tetrahydronaphth-1-yl)acetamide (5 g, 18.8 mmol, 1 equivalent) was dissolved in a mixture of 1,4-dioxane (200 mL) and water (50 mL). Sodium bicarbonate (6.31 g, 75.1 mmol, 4 equivalents) and 9-fluorenylmethyl-N-succinimidyl carbonate (7.6 g, 22.5 mmol, 1.2 equivalents) were slowly added to the reaction mixture at room temperature. The reaction mixture was stirred at room temperature for 2 hours. The reaction mixture was poured into water (500 mL), extracted with ethyl acetate (200 mL), and the organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The crude product was subjected to high-performance liquid chromatography (HPLC) (acetonitrile, trifluoroacetic acid aqueous solution system) to obtain the target compound (9H-fluorene-9-yl)methyl (8-acetamido-6-fluoro-5-methoxy-1-oxo-1,2,3,4-tetrahydronaphth-2-yl)carbamate (4.3 g, 8.86 mmol, yield 47%), a black solid. LCMS (ESI) m / z: 489.2 [M+H] +

[0884] Step 4: Synthesis of (9H-fluorene-9-yl)methyl(8-amino-6-fluoro-5-methoxy-1-oxo-1,2,3,4-tetrahydronaphth-2-yl)carbamate hydrochloride

[0885] (9H-fluorene-9-yl)methyl(8-acetamido-6-fluoro-5-methoxy-1-oxo-1,2,3,4-tetrahydronaphth-2-yl)carbamate (1 g, 3.24 mmol, 1 equivalent) was dissolved in anhydrous methanol (10 mL), and 4M hydrochloric acid in methanol (10 mL) was added to the reaction solution. The reaction was stirred at room temperature for 2 hours. The reaction solution was concentrated under reduced pressure to give the target compound (9H-fluorene-9-yl)methyl(8-amino-6-fluoro-5-methoxy-1-oxo-1,2,3,4-tetrahydronaphth-2-yl)carbamate hydrochloride (1 g, 3.33 mmol, yield 101%), a yellow solid. LCMS (ESI) m / z: 447.1 [M+H] + .

[0886] Step 5: Synthesis of (9H-fluorene-9-yl)methyl((9S)-9-ethyl-5-fluoro-9-hydroxy-4-methoxy-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,12H-benzo[d]pyrano[3',4':6,7] indo[1,2-b]quinoline-1-yl)carbamate

[0887] (9H-fluorene-9-yl)methyl(8-amino-6-fluoro-5-methoxy-1-oxo-1,2,3,4-tetrahydronaphth-2-yl)carbamate hydrochloride (1 g, 2.07 mmol, 1 equivalent) was dissolved in anhydrous toluene solution (100 mL). (S)-4-ethyl-4-hydroxy-7,8-dihydro-1H-pyran[3,4-f] nidene-3,6,10(4H)-trione (818 mg, 3.11 mmol, 1.5 equivalent) and p-toluenesulfonic acid (71 mg, 0.41 mmol, 0.2 equivalent) were added to the reaction solution. The reaction was stirred at 130 °C for 16 hours. The reaction solution was concentrated under reduced pressure, and the crude product was purified by rapid silica gel column chromatography (methanol:dichloromethane = 0-6%) to obtain the target compound (9H-fluorene-9-yl)methyl ((9S)-9-ethyl-5-fluoro-9-hydroxy-4-methoxy-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,12H-benzo[d]pyrano[3',4':6,7]indo[1,2-b]quinoline-1-yl)carbamate (740 mg, 1.1 mmol, yield 53%), a brown solid. LCMS (ESI) m / z: 674.2 [M+H] +

[0888] Step 6: Synthesis of (9S)-1-amino-9-ethyl-5-fluoro-9-hydroxy-4-methoxy-1,2,3,9,12,15-hexahydro-10H,13H-benzo[d]pyrano[3',4':6,7] indo[1,2-b]quinoline-10,13-dione

[0889] (9H-fluorene-9-yl)methyl ((9S)-9-ethyl-5-fluoro-9-hydroxy-4-methoxy-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,12H-benzo[d]pyrano[3',4':6,7] indo[1,2-b]quinoline-1-yl)carbamate (700 mg, 1.04 mmol, 1 equivalent) was dissolved in N,N-dimethylformamide (2 mL), and diethylamine (152 mg, 2.08 mmol, 2 equivalents) was added. The reaction was stirred at room temperature for 1 hour. The reaction solution was concentrated under reduced pressure, the crude product was pulped with ethyl acetate, filtered, and the filter cake was dried to obtain (9S)-1-amino-9-ethyl-5-fluoro-9-hydroxy-4-methoxy-1,2,3,9,12,15-hexahydro-10H,13H-benzo[d]pyrano[3',4':6,7] indo[1,2-b]quinoline-10,13-dione (380 mg, yield 81%), as a black solid.

[0890] Step 8: Synthesis of (1S)-9-ethyl-5-fluoro-1-(((3-fluorobicyclo[1.1.1]pent-1-yl)methyl)amino)-9-hydroxy-4-methoxy-1,2,3,9,12,15-hexahydro-10H,13H-benzo[de]pyrano[3',4':6,7] indo[1,2-b]quinoline-10,13-dione

[0891] Triethylamine (1.1 g, 11.1 mmol, 1.0 equivalent) was added to a dimethyl sulfoxide (4 mL) solution of (9S)-1-amino-9-ethyl-5-fluoro-9-hydroxy-4-methoxy-1,2,3,9,12,15-hexahydro-10H,13H-benzo[de]pyrano[3',4':6,7] indo[1,2-b]quinoline-10,13-dione (5.0 g, 0.4 mmol, 1.0 equivalent). After the reaction solution was clear, formic acid (2.5 g, 55.4 mmol, 5.0 equivalent) and 3-fluorobicyclo[1.1.1]pentane-1-carboxaldehyde (1.9 g, 16.6 mmol, 1.5 equivalent) were added. The reaction mixture was stirred at room temperature for 10 minutes, then sodium cyanoborohydride (1.0 g, 16.6 mmol, 1.5 equivalents) was added, and stirring continued at room temperature for 4 hours. The reaction mixture was filtered and purified by rapid silica gel column chromatography (dichloromethane:methanol = 50:1) to give the target compound 17 (1.6 g, 27% yield) as an off-white solid.

[0892] LCMS(ESI) m / z: 550.8 [M+H] + .

[0893] Compound 17a: 1 H NMR (400MHz, DMSO-d6) δ7.83(d,J=12.4Hz,1H),7.29(s,1H),6.50(s,1H),5.48–5.27(m,3H),4.22(s,1H),3.94(s,3H),3. 27–3.22(m,1H),3.17–3.10(m,1H),3.02–2.94(m,2H),2.16(s,2H),2.02(s,7H),1.93–1.82(m,2H),0.88(t,J=7.2Hz,3H).

[0894] The racemic mixture 17 was chirally resolved to yield target compounds 17a (retention time 1: 2.414 s) and 17b (retention time 2: 4.134 s);

[0895] In the corresponding preparation flow charts for 17a and 17b, 17-p1 (900 mg, 15% yield, brown solid) or 17-p2 (600 mg, 11% yield, brown solid) is used; that is, 17a corresponds to 17-p1 and 17b corresponds to 17-p2; or 17a corresponds to 17-p2 and 17b corresponds to 17-p1.

[0896] Other compounds listed in Table A can be prepared by methods similar to those described in the above examples (with appropriate modifications if necessary).

[0897] Example II. Toxin Test

[0898] Test Example 1: Cell Viability Test

[0899] The inhibitory activity of the drug compounds on the in vitro proliferation of SNU-5, MKN-45, SW480, LS1034, and AsPC-1 tumor cells was tested. After 6 days of culture, cell proliferation was detected using CGT reagent (CellTiter-Glo). The inhibitory activity was determined based on the IC50 value. 50 The in vitro activity of the compound was determined by measuring its value.

[0900] Note: DXd's sensitivity to killing tumor cells: SNU-5 (high), MKN-45 (medium), SW480 (medium), LS1034 (low) and AsPC-1 (low).

[0901] A. Materials and Equipment

[0902] 1. Reagents and consumables: SNU-5 (ATCC), MKN-45 (CTCC), SW480 (ATCC), LS1034 (ATCC), and AsPC-1 (ATCC); IMDM medium (Gibco), RPMI-1640 medium (Gibco), Leibovitz's L-15 medium (Gibco), trypsin (Gibco), fetal bovine serum (Vivacell), penicillin and streptomycin (Invitrogen), phenol blue (Biological Industries), DPBS (Biosera), DMSO (Sigma), Staurosporine 96 (Selleck), CellTiter-Glo (Promega), 96-well cell culture plates (Corning), 96-well V-plates (Corning)

[0903] 2. Instruments: Inverted microscope (OLYMPUS), CO2 incubator (ThermoFisher), centrifuge (Eppendorf), cell counter (Shanghai Meng Microbial Medical), multi-functional microplate reader (PerkinElmer).

[0904] B. Testing Methods

[0905] Experimental steps:

[0906] 1. Culture SNU-5, MKN-45, SW480, LS1034 and AsPC-1 in their respective cell cultures (see Table 1) until the confluence is about 70-90%.

[0907] 2. Passage the cells (cells should be passaged 2-15 after revival) and resuspend the cells in the corresponding complete culture medium (see Table 1). After cell counting (it is recommended that the cell viability be ≥90%), record the cell passage number and viability.

[0908] 3. Seed 90 μL of cells into each well of a 96-well plate and incubate overnight at 37°C.

[0909] 4. The following day, prepare the drug according to the preparation protocol in Table 3. Take out the 96-well plate and add 10 μL of 10x test drug, positive control staurosporine, or vehicle control to each well. The total system volume is 100 μL.

[0910] 5. After mixing, place the cell culture plate in a 37°C, 5% CO2 or 37°C, 0% CO2 (SW480 cells) incubator and continue incubation for 6 days.

[0911] 6. After incubation, remove the cell culture plate and allow it to equilibrate to room temperature.

[0912] 7. Add 50 μL of CellTiter Glo reagent to each well, lyse at room temperature for 2 minutes, and then equilibrate for 10 minutes.

[0913] 8. Use an Envision microplate reader to read the plate and detect the luminescence value.

[0914] 9. Data Analysis: Using the four-parameter fitting formula in GraphPad software, an S-shaped curve of cell survival was plotted, and the IC50 of the drug on cell killing was calculated. 50 .

[0915] Table 1. Cell lines

[0916] Table 2. Seed plate density of cell lines used

[0917] **Note: The cell seeding density is set based on the confluence of cells 7 days after seeding.

[0918] Table 3. Medication Dispensing Plan

[0919] The in vitro inhibitory activity against tumor cell proliferation was tested according to the above experimental steps, and the results are shown in Table 4.

[0920] Table 4

[0921] *Represents the Dxd cell killing IC in the same plate 50 value

[0922] Table 4 (continued)

[0923] *Is the cytotoxic IC50 of ethatecan in the same plate. 50 value

[0924] Experimental results showed that compounds 1a, 7a, 11a, and 15a exhibited superior cytotoxic activity against all five tumor cell lines compared to Dxd. Specifically, compounds 1a, 7a, 11a, and 15a showed significantly better activity against Dxd in both Dxd and low-sensitivity cell lines. In the Dxd-sensitive tumor cell lines LS1034 and AsPc-1, compounds 1a, 7a, 11a, and 15a were comparable to or superior to essanotecan.

[0925] Test Example 2: Caco-2 Cell Efflux Rate Assay

[0926] A. Materials and Equipment

[0927] Caco-2 cells (ATCC), Hanke balanced salt solution (HBSS), and non-essential amino acids (NEAA) were purchased from Thermo Fisher Scientific. HEPES, penicillin, streptomycin, and trypsin / EDTA were purchased from Solarbio. Fetal bovine serum (FBS) was purchased from AusGeneX. High-glucose DMEM medium was purchased from Hyclone. HTS-96-well Transwell plates and other sterile consumables were purchased from Corning. The Millicell electrical resistance measurement system was purchased from Millipore. Vision was purchased from Nexcelom Bioscience. The Infinite 200PRO microplate reader was purchased from Tecan. The MTS2 / 4orbital shaker was purchased from IKA Labortechnik.

[0928] B. Testing Methods

[0929] 1. Cell culture and seeding plates

[0930] 1) Use high-glucose DMEM medium containing L-glutamine, with 10% fetal bovine serum, 0.1 mg / mL streptomycin, 100 units of penicillin, and 1× non-essential amino acids added for cell culture.

[0931] 2) Caco-2 cells were cultured in cell culture flasks. The incubator was set to 37°C, 5% CO2, and 95% relative humidity. When the cell confluence reached 70-90%, the cells could be used for Transwell inoculation.

[0932] 3) Before cell seeding, add 50 μL of cell culture medium to each well in the upper chamber of the Transwell and 25 mL of cell culture medium to the lower culture plate. After incubating the culture plate in a 37°C, 5% CO2 incubator for 1 hour, it can be used for cell seeding.

[0933] 4) After cell digestion, aspirate the cell suspension and transfer it to a round-bottom centrifuge tube, then centrifuge at 120g for 5 minutes.

[0934] 5) Resuspend the cells in culture medium to a final concentration of 6.86 × 10⁻⁶. 5 Cells / mL. Add 50 μL of cell suspension to each well of a 96-well Transwell plate, resulting in a final seeding density of 2.4 × 10⁶ cells / mL. 5 cells / cm 2 .

[0935] 6) Change the medium 48 hours after inoculation and culture for 14-18 days, changing the medium every other day.

[0936] 7) The process of changing the culture medium is as follows: Separate the Transwell chamber from the receiving plate, discard the culture medium in the receiving plate first, then discard the culture medium in the Transwell chamber, and finally add 75 μL of fresh culture medium to each chamber and 25 mL of fresh culture medium to the receiving plate.

[0937] 2. Evaluation of cell monolayer membrane integrity

[0938] 1) After 14-18 days of culture, Caco-2 should have completely merged and differentiated. At this point, it can be used for the breakthrough test.

[0939] 2) Measure the resistance of the single-layer film using a resistance meter (Millipore, USA) and record the resistance of each pore.

[0940] 3) After the measurement is completed, put the Transwell culture plate back into the incubator.

[0941] 4) Calculation of resistance value: Measure resistance value (ohms) × film area (cm²) 2 ) = TEER value (ohm·cm) 2 ),

[0942] If the TEER value is <230 ohms·cm 2 If so, the hole cannot be used for a penetration test.

[0943] 3. Solution preparation

[0944] 1) Prepare 1L HBSS (10mM HEPES, pH 7.4): Weigh 2.38g HEPES and 0.35g sodium bicarbonate, add 900mL of pure water to dissolve them, then add 100mL of 10×HBSS and stir well. Adjust the pH to 7.4 and finally filter.

[0945] 2) Prepare a high-concentration DMSO stock solution of the test substance and dilute it to 1 mM with DMSO. Then, dilute it accordingly with HBSS (10 mM HEPES, pH 7.4) to obtain a test concentration of 5 μM.

[0946] 3) Prepare high-concentration DMSO stock solutions of the control drugs digoxin and metoprolol, and dilute them to 2 mM stock solution with DMSO. Then, dilute accordingly with HBSS (10 mM HEPES, pH 7.4) to obtain a test concentration of 10 μM.

[0947] 4. Drug penetration test

[0948] 1) Remove the Transwell culture plate from the incubator. Rinse the cell monolayer twice with HBSS (10mM HEPES, pH 7.4) buffer and incubate at 37°C for 30 minutes.

[0949] 2) Determine the transport rate of the compound from the top to the base. Add 125 μL of the drug delivery solution to each well in the upper chamber (top), then transfer 50 μL of the sample to 200 μL of acetonitrile containing the internal standard as the sample delivered to the top of the Transwell plate at 0 minutes for detection. Add 235 μL of the receiver solution to each well in the lower chamber (base).

[0950] 3) Determine the transport rate of the compound from the base to the top. Add 75 μL of receiving end solution to each well in the upper chamber (top) and 285 μL of dosing end solution to each well in the lower chamber (base). Then transfer 50 μL of sample to 200 μL of acetonitrile containing internal standard as the 0-minute dosing sample from the base of the Transwell plate for detection.

[0951] 4) After merging the upper and lower transfer devices, incubate at 37°C for 2 hours.

[0952] 5) Transfer 50 μL of sample from the working solution preparation plate and add it to 200 μL of acetonitrile containing the internal standard as the 0-minute dosing sample for detection.

[0953] 6) After incubation, take 50 μL of sample from each well of the upper and lower chambers of the Transwell culture plate and add it to a new sample tube. Add 200 μL of acetonitrile containing the internal standard to the sample tube, vortex for 10 minutes, and then centrifuge at 3220g for 30 minutes. Take 150 μL of the supernatant, dilute it with an equal volume of water, and then perform LC-MS / MS analysis. All samples are prepared in duplicate.

[0954] 7) Evaluate the integrity of the cell monolayer after 2 hours of incubation using fluorescein (LY) leakage. Dilute the fluorescein stock solution to a final concentration of 100 μM using HBSS (10 mM HEPES, pH 7.4). Add 100 μL of fluorescein solution to each well of the upper Transwell plate and 300 μL of HBSS (10 mM HEPES, pH 7.4) to each well of the lower receiving plate. After incubation at 37°C for 30 minutes, aspirate 80 μL of solution from both the upper and lower layers of each well into a new 96-well plate. Measure fluorescence using a microplate reader at an excitation wavelength of 485 nm and an emission wavelength of 530 nm.

[0955] 5. Data Analysis

[0956] All calculations were performed using Microsoft Excel. The apparent permeability coefficient (Papp, in cm / s) of the compound in Caco-2 cells was calculated using the following formula based on the specific concentrations at the receiving and administering ends:

[0957] in:

[0958] V A This refers to the volume of the solution at the receiving end (0.235 mL from the top to the base, and 0.075 mL from the base to the top).

[0959] Area is the area of ​​the Transwell-96-well plate membrane (0.143 cm²). 2 );

[0960] time is the incubation time (unit: seconds);

[0961] [drug] receiver The drug concentration at the receiving end;

[0962] [drug]initial,donor is the initial drug concentration at the dosing end.

[0963] The efflux ratio is calculated using the following formula:

[0964] in:

[0965] P app(B-A)The apparent permeability coefficient is measured from the base to the tip.

[0966] P app(A-B) The apparent permeability coefficient is measured from the top to the base.

[0967] Recovery rate (Recovery%) is calculated using the following formula:

[0968] in:

[0969] V A The volume of the solution at the receiving end (unit: mL);

[0970] V D The volume of the solution at the administration end (unit: mL);

[0971] [drug] receiver The drug concentration at the receiving end;

[0972] [drug]initial,donor is the initial drug concentration at the dosing end.

[0973] [drug] donor This represents the drug concentration at the dosing end.

[0974] The integrity of the Caco-2 cell monolayer membrane was calculated using the following formula:

[0975] in:

[0976] I receiver This refers to the fluorescence density of the receiving aperture (0.3 mL).

[0977] I donor This refers to the fluorescence density of the drug delivery well (0.1 mL).

[0978] Integrity is expressed as LY Leakage percentage (%LY Leakage).

[0979] %LY Leakage < 1.5% indicates an intact monolayer cell membrane. For individual cases where %LY Leakage > 1.5%, if P... app The values ​​are similar to those of other parallel holes, and based on scientific judgment, the final data can be adopted.

[0980] The potential absorption and efflux of the test substance were investigated by measuring its permeability in the Caco-2 cell model, as shown in Table 5.

[0981] Table 5

[0982] Note: Digoxin is a positive reference.

[0983] Experimental results show that the efflux rate of compound 1a is significantly lower than that of Dxd.

[0984] Test Example 3: Hepatocyte Stability of the Compound

[0985] The in vitro metabolic stability of the test compounds in hepatocytes of different species was investigated. The concentration of the parent drug in the incubation system was determined by LC / MS / MS, and the intrinsic clearance rate of the test compounds in the hepatocyte system was calculated to assess their stability.

[0986] The test concentrations for the test compound and the positive control compound were 1 μM.

[0987] 1. Materials and Reagents

[0988] Hepatocytes were preserved in liquid nitrogen; details are shown in Table 6 below. Information on other reagents will be included in the experimental report.

[0989] Table 6

[0990] 2. Experimental Design

[0991] 2.1 Preparation of the compound working solution

[0992] High-concentration stock solutions of the test substance and the control drug verapamil powder were prepared using DMSO, and then diluted with DMSO to a 100 μM working solution before use. The final concentration of the test substance and verapamil was 1 μM.

[0993] 2.2 Preparation of hepatocytes

[0994] 1) Specific preparation information for hepatocyte resuscitation solution is shown in Table 7 below. Mix 49.5 mL of Williams' E medium and 0.5 mL of glutaMAX as the incubation solution. Preheat the hepatocyte resuscitation solution and incubation solution in a 37°C water bath for at least 15 minutes before use.

[0995] Table 7

[0996] 2) Take a tube of cryopreserved hepatocytes, ensuring that the hepatocytes remain frozen before thawing. Quickly place the hepatocytes in a 37°C water bath and gently shake until all ice crystals are dispersed. Spray with 70% ethanol and transfer to a biosafety cabinet.

[0997] 3) Pour the contents of the hepatocyte tubules into a centrifuge tube containing 50 mL of resuscitation medium and centrifuge at 100 g for 10 minutes. After centrifugation, aspirate the resuscitation medium and add sufficient incubation medium to obtain a cell density of approximately 1.0 × 10⁻⁶ cells / mL. 6 Cell suspension of cells per mL.

[0998] 4) Use AO / PI staining to count cells and determine viable cell density. Hepatocyte viability must be greater than 75%. Dilute cells with culture medium to a working cell density of 0.5 × 10⁻⁶. 6 live cells / mL.

[0999] 2.3 Test Methods

[1000] 1) Transfer 247.5 μL of live cell suspension to a 96-well deep-well plate and preheat the plate in an incubator for 10 minutes on a vortex. Perform double parallel incubation.

[1001] 2) Add 2.5 μL of 100 μM test substance or verapamil to each well to initiate the reaction, and then place the deep well plate back onto the incubator vortex.

[1002] 3) Place the incubation plate in an incubator. At 0, 15, 30, 60, 90, and 120 minutes, take 25 μL of the suspension and add it to a new 96-well plate containing 12 times its volume (300 μL) of acetonitrile as an internal standard (100 nM alprazolam, 200 nM caffeine, and 100 nM tolbutamide) as a quencher to terminate the reaction. Vortex the plate for 5 minutes, then centrifuge at 3220 rpm and 4°C for 45 minutes to precipitate the protein. Transfer 100 μL of the supernatant to a sample plate, add 100 μL of pure water, mix well, and proceed with UPLC-MS / MS analysis. All incubations should be performed in duplicate.

[1003] 3. Data Analysis

[1004] All calculations were performed using Microsoft Excel software. Peak areas were detected by extracting ion spectra. The in vitro half-life (t) of the parent drug was determined by linearly fitting the natural logarithm of the elimination percentage of the parent drug to time. 1 / 2 ).

[1005] In vitro half-life (t) 1 / 2 ) Calculated by slope: In vitro t 1 / 2 = -0.693 / k.

[1006] In vitro clearance rate (unit: μL / min / 10) 6 (per cell) is calculated using the following formula: In vitro CL int =-kV / N

[1007] in:

[1008] V = Incubation volume per well (0.25 mL);

[1009] N = Number of cells per well (0.125 × 10⁻⁶) 6 (cells).

[1010] The in vitro scale-up clearance rate (mL / min / kg), predicted clearance rate (mL / min / kg), and liver extraction rate (ER) were calculated using the following formulas:

[1011] In vitro expanded clearance rate (unit: mL / min / kg):

[1012] In vitro expansion of CL int =(0.693 / t) 1 / 2 )×(1 / hepatocyte density(0.5×10 6 (cells / mL) × proportionality factor (Table 8).

[1013] Predicted Hepatic Clearance (unit: mL / min / kg):

[1014] Predicting liver CL H = (QH × extracorporeal expansion CL) int ×fub) / (QH+external expansion CL) int ×fub);

[1015] Liver extraction rate (ER) = In vitro expanded CL H / QH;

[1016] in:

[1017] QH is the hepatic blood flow rate (mL / min / kg) (Table 8).

[1018] fub represents the portion of the drug that is free in the plasma, assumed to be 1.

[1019] Table 8. Proportion factors for predicting clearance in vivo in humans, monkeys, mice, and rats.

[1020] a Proportion factor = (Hepatocyte density) × (Liver weight)

[1021] 4. Data Processing Rules

[1022] The data processing rules are summarized in Table 9.

[1023] Table 9. Data Processing Rules

[1024] Experimental results showed that the half-life of toxin 1a in human, monkey, rat, and mouse hepatocytes was less than Dxd. This suggests that compound 1a, as an ADC load, can function effectively while being less prone to accumulation.

[1025] Example III. Preparation of Linker-Toxin Linker

[1026] 1. Preparation of compound A1

[1027] Step 1: Synthesis of (9H-fluorene-9-yl)methyl tert-butyl ((6S,9S,40S)-1-amino-6-((4-(hydroxymethyl)phenyl)carbamoyl)-9-isopropyl-1,8,11,39-tetraoxo-14,17,20,23,26,29,32,35-octaoxa-2,7,10,38-tetraazatetracarbamo-40,44-diyl)dicarbamate

[1028] To a solution of (S)-10-(((9H-fluorene-9-yl)methoxy)carbonyl)amino)-2,2-dimethyl-4,11-dioxo-3,15,18,24,27,30,33,36-nonoxy-5,12-diazanontriane-39-acid (1.6 g, 1.8 mmol, 1.0 equivalent) in N,N-dimethylformamide (20 mL), HATU (1.02 g, 2.7 mmol, 1.5 equivalent), N,N-diisopropylethylamine (695 mg, 5.4 mmol, 3.0 equivalent), and (S)-2-((S)-2-amino-3-methylbutamido)-N-(4-(hydroxymethyl)phenyl)-5-ureidopentanamide (851 mg, 2.24 mmol, 1.25 equivalent) were added. The reaction was stirred at room temperature for 2 hours. The reaction solution was purified by reversed-phase silica gel column chromatography (0.5% formic acid, acetonitrile) to give the target compound (9H-fluorene-9-yl)methyl tert-butyl ((6S,9S,40S)-1-amino-6-((4-(hydroxymethyl)phenyl)carbamoyl)-9-isopropyl-1,8,11,39-tetraoxo-14,17,20,23,26,29,32,35-octaoxa-2,7,10,38-tetraazatetracarbon-40,44-diyl)dicarbamate (1.1 g, yield 49%), a white solid. LCMS (ESI) m / z: 1254.0 [M+H] + .

[1029] Step 2: Synthesis of (9H-fluorene-9-yl)methyl tert-butyl ((6S,9S,40S)-1-amino-9-isopropyl-6-((4-(((((4-nitrophenoxy)carbonyl)oxy)methyl)carbamoyl)-1,8,11,39-tetraoxo-14,17,20,23,26,29,32,35-octaoxa-2,7,10,38-tetraazatetracarbon-40,44-diyl)dicarbamate

[1030] To a solution of (9H-fluorene-9-yl)methyl tert-butyl ((6S,9S,40S)-1-amino-6-((4-(hydroxymethyl)phenyl)carbamoyl)-9-isopropyl-1,8,11,39-tetraoxo-14,17,20,23,26,29,32,35-octaoxa-2,7,10,38-tetraazatetracarbon-40,44-diyl)dicarbamate (1.1 g, 0.87 mmol, 1.0 equivalent) in dichloromethane (12 mL), N,N-dimethylformamide (6 mL), bis(4-nitrophenyl) carbonate (534 mg, 1.76 mmol, 2.0 equivalent), and N,N-diisopropylethylamine (227 mg, 1.76 mmol, 2.0 equivalent) were added. The reaction was stirred at room temperature for 16 hours. The reaction mixture was poured into water (10 mL) and extracted three times with dichloromethane (10 mL). The organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The resulting crude oil was slurried with diethyl ether (20 mL), filtered, and the solid was dried to give the target compound (9H-fluorene-9-yl)methyl tert-butyl ((6S,9S,40S)-1-amino-9-isopropyl-6-((4-(((((4-nitrophenoxy)carbonyl)oxy)methyl)carbamoyl)-1,8,11,39-tetraoxo-14,17,20,23,26,29,32,35-octaoxa-2,7,10,38-tetraazatetracarbon-40,44-diyl)dicarbamate (910 mg, 73% yield), a white solid. LCMS (ESI) m / z: 1418.3 [M+H] + .

[1031] Step 3: Synthesis of (9H-fluorene-9-yl)methyl tert-butyl ((6S,9S,40S)-1-amino-6-((4-(1S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,12H-benzopyran[3',4':6,7] indo[1,2-b]quinoline-1-yl)((3-fluorobicyclo[1.1.1]pent-1-yl)methyl)carbamoyl)oxymethyl)phenyl)carbamoyl)-9-isopropyl-1,8,11,39-tetraoxo-14,17,20,23,26,29,32,3) 5-Octoxy-2,7,10,38-tetraazatetracarbamate-40,44-diyl)dicarbamate

[1032] N,N- of ((9H-fluorene-9-yl)methyl tert-butyl((6S,9S,40S)-1-amino-9-isopropyl-6-((4-(((((4-nitrophenoxy)carbonyl)oxy)methyl)carbamoyl)-1,8,11,39-tetraoxo-14,17,20,23,26,29,32,35-octaoxa-2,7,10,38-tetraazatetracarbon-40,44-diyl)dicarbamate (900 mg, 0.63 mmol, 1.0 equivalent) Add (1S,9S)-9-ethyl-5-fluoro-1-(((3-fluorobicyclo[1.1.1]pent-1-yl)methyl)amino)-9-hydroxy-4-methyl-1,2,3,9,12,15-hexahydro-10H,13H-benzo[de]pyrano[3',4':6,7] indo[1,2-b]quinoline-10,13-dione (340 mg, 0.63 mmol, 1.0 equivalent) and 2,6-dimethylpyridine to a 10 mL solution of dimethylformamide. 2 mL) and 2-hydroxypyridine-N-oxide (78 mg, 0.70 mmol, 1.1 equivalents). The reaction mixture was stirred at room temperature for 48 hours. The reaction mixture was poured into a saturated sodium chloride aqueous solution (10 mL) and extracted three times with ethyl acetate (5 mL). The organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The crude product was purified by reversed-phase chromatography (0.1% trifluoroacetic acid, acetonitrile) to give the target compound (9H-fluorene-9-yl)methyl tert-butyl ((6S,9S,40S)-1-amino-6-((4-( 1S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,12H-benzopyran[3',4':6,7]indo[1,2-b]quinoline-1-yl)((3-fluorobicyclo[1.1.1]pent-1-yl)methyl)carbamoyl)oxymethyl)phenyl)carbamoyl)-9-isopropyl-1,8,11,39-tetraoxo-14,17,20,23,26,29,32,3 5-octyloxy-2,7,10,38-tetraazatetracarbon-40,44-diyl)dicarbamate (370 mg, yield 32%), white solid. LCMS (ESI) m / z: 1813.5 [M+H] + .

[1033] Step 4: Synthesis of 4-((10S,41S,44S)-10-amino-41-isopropyl-2,2-dimethyl-4,11,39,42-tetraoxo-44-(3-ureopropyl)-3,15,18,21,24,27,30,33,36-nonoxy-5,12,40,43-tetraazapentane-45-amido)benzyl((1S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,12H-benzopyrano[3',4':6,7] indo[1,2-b]quinoline-1-yl)((3-fluorobicyclo[1.1.1]pent-1-yl)methyl)carbamate

[1034] To (9H-fluorene-9-yl)methyl tert-butyl((6S,9S,40S)-1-amino-6-((4-(1S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,12H-benzopyran[3',4':6,7] in indo[1,2-b]quinoline-1-yl)((3-fluorobicyclo[1.1.1]pent-1-yl)methyl)carbamoyl)oxymethyl)phenyl)carbamoyl)-9-isopropyl-1,8,11,39-tetraoxo-14,17,20,23,26,29,32,3 Diethylamine (0.3 mL) was added to a 3 mL solution of 5-octyloxy-2,7,10,38-tetraazatetracarbamate-40,44-diyl)dicarbamate (370 mg, 0.2 mmol, 1.0 equivalent) in N,N-dimethylformamide. The reaction was stirred at room temperature for 2 hours. The reaction solution was concentrated under reduced pressure to remove the solvent. The crude product was slurried with diethyl ether, and the solid was collected and dried to give the target compound 4-((10S,41S,44S)-10-amino-41-isopropyl-2,2-dimethyl-4,11,39,42-tetraoxo-44-(3-ureopropyl)-3,15,18,21,24,27,30,33,36-nonoxy-5,12,40,43-tetraazapentane-45 (-Amide group)benzyl((1S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,12H-benzopyrano[3',4':6,7]indo[1,2-b]quinoline-1-yl)((3-fluorobicyclo[1.1.1]pent-1-yl)methyl)carbamate (260 mg, yield 80%), white solid.

[1035] LCMS(ESI) m / z: 1590.8 [M+H] + .

[1036] Step 5: Synthesis of 4-((10S,41S,44S)-41-isopropyl-2,2-dimethyl-10-(2-(methanesulfonyl)pyrimidin-5-carbamate)-4,11,39,42-tetraoxo-44-(3-ureopropyl)-3,15,18,21,24,27,30,33,36-nonoxy-5,12,40,43-tetraazapentane Alkyl-45-amino)benzyl((1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,12H-benzopyran[3',4':6,7] indene[1,2-b]quinoline-1-yl)((3-fluorobicyclo[1.1.1]pent-1-yl)methyl)carbamate

[1037] 4-((10S,41S,44S)-10-amino-41-isopropyl-2,2-dimethyl-4,11,39,42-tetraoxo-44-(3-ureopropyl)-3,15,18,21,24,27,30,33,36-nonoxy-5,12,40,43-tetraazapentane-45-amido)benzyl((1S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,12H-benzopyrano[ In a 4 mL solution of tetrahydrofuran containing indo[1,2-b]quinoline-1-yl)((3-fluorobicyclo[1.1.1]pent-1-yl)methyl)carbamate (180 mg, 0.11 mmol, 1.0 equivalent), 2-(methanesulfonyl)pyrimidine-5-carboxylic acid (32 mg, 0.16 mmol, 1.4 equivalent), HATU (65 mg, 0.17 mmol, 1.5 equivalent), and N,N-diisopropylethylamine (44 mg, 0.34 mmol, 3.0 equivalent) were added. The reaction was stirred at room temperature for 2 hours. The reaction solution was purified by reversed-phase column chromatography (0.5% trifluoroacetic acid, acetonitrile) to obtain the target compound 4-((10S,41S,44S)-41-isopropyl-2,2-dimethyl-10-(2-(methanesulfonyl)pyrimidin-5-carbamate)-4,11,39,42-tetraoxo-44-(3-ureopropyl)-3,15,18,21,24,27,30,33,36-nonoxy-5,12,40,43 -Tetraazapentane-45-amino)benzyl((1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,12H-benzopyran[3',4':6,7]indo[1,2-b]quinoline-1-yl)((3-fluorobicyclo[1.1.1]pent-1-yl)methyl)carbamate (97 mg, 48% yield), white solid. LCMS(ESI) m / z: 1774.9 [M+H] + .

[1038] Step 6: Synthesis of 4-((3S,34S,37S)-3-(4-aminobutyl)-34-isopropyl-1-(2-(methylsulfonyl)pyrimidin-5-yl)-1,4,32,35-tetraoxo-37-(3-ureopropyl)-8,11,14,17,20,23,26,29-octaoxa-2,5,33,36-tetraazaoctane- 38-Amamido)benzyl((1S,9R)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,12H-benzopyran[3',4':6,7] indene[1,2-b]quinoline-1-yl)((3-fluorobicyclo[1.1.1]pent-1-yl)methyl)carbamate

[1039] 4-((10S,41S,44S)-41-isopropyl-2,2-dimethyl-10-(2-(methanesulfonyl)pyrimidin-5-carbamate)-4,11,39,42-tetraoxo-44-(3-ureopropyl)-3,15,18,21,24,27,30,33,36-nonoxy-5,12,40,43-tetraazapentane-45-amino)benzyl((1S,9S)-9-ethyl-5- Trifluoroacetic acid (0.4 mL) was added to a solution of fluoro-9-hydroxy-4-methyl-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,12H-benzopyran[3',4':6,7] indo[1,2-b]quinoline-1-yl)((3-fluorobicyclo[1.1.1]pent-1-yl)methyl)carbamate (90 mg, 0.05 mmol, 1.0 equivalent) in dichloromethane (1 mL). The reaction was stirred in an ice bath for 2 hours. The reaction solution was concentrated under reduced pressure to obtain the target 4-((3S,34S,37S)-3-(4-aminobutyl)-34-isopropyl-1-(2-(methanesulfonyl)pyrimidin-5-yl)-1,4,32,35-tetraoxo-37-(3-ureopropyl)-8,11,14,17,20,23,26,29-octaoxa-2,5,33,36-tetraazaoctane-38-amido)benzyl Crude carbamate of ((1S,9R)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,12H-benzopyran[3',4':6,7] indo[1,2-b]quinoline-1-yl)((3-fluorobicyclo[1.1.1]pent-1-yl)methyl)carbamate (85 mg, 100% yield), colorless oil. LCMS (ESI) m / z: 1675.7 [M+H] + .

[1040] Step 7: Synthesis of 2,5-dioxopyrrolidone-1-yl-3,6,9,12,15,18,21,24,27,30-decamethyl-4,7,10,13,16,19,22,22,25,28,31-decaoxo-3,6,9,12,15,18,21,24,27,30-decaazatrioleate

[1041] To a solution of 3,6,9,12,15,18,21,24,27,30-decamethonium-4,7,10,13,16,19,22,25,28,31-decaoxy-3,6,9,12,25,18,21,24,24,27,30-decaazatricarbonenoic acid (85 mg, 0.11 mmol, 1.0 equivalent) in dichloromethane (2 mL), 1-hydroxypyrrolidine-2,5-dione (15 mg, 0.13 mmol, 1.2 equivalent) and dicyclohexylmethyldiimide (27 mg, 0.13 mmol, 1.2 equivalent) were added. The reaction was stirred at room temperature for 4 hours. The reaction solution was filtered to remove the solids, and the filtrate was concentrated under reduced pressure to obtain the target compound 2,5-dioxopyrrolidone-1-yl-3,6,9,12,15,18,21,24,27,30-decamethyl-4,7,10,13,16,19,22,22,25,28,31-decaoxo-3,6,9,12,15,18,21,24,27,30-decaazatrioleate crude product (95 mg, 100% yield), colorless oil.

[1042] LCMS(ESI) m / z: 868.6 [M+H] + .

[1043] Step 8: Synthesis of 4-((38S, 69S, 72S)-69-isopropyl-3,6,9,12,15,18,21,24,27,30-decamethyl-38-(2-(methanesulfonyl)pyrimidin-5-carbamate)-2,5,8,11,14,17,20,23,26,29,32,39,67,70-tetradecyloxy-72-(3-ureopropyl)-43,46,49,52,55,58,61,64-octaoxa-3,6,9,12, 15,18,21,24,27.30,33,40,68,71-Tetraazatriheptanone-73-amido)benzyl((1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,12H-benzo[de]pyrano[3',4':6,7]indo[1,2-b]quinoline-1-yl)((3-fluorobicyclo[1.1.1]pent-1-yl)methyl)carbamate (A1)

[1044] To 4-((3S,34S,37S)-3-(4-aminobutyl)-34-isopropyl-1-(2-(methanesulfonyl)pyrimidin-5-yl)-1,4,32,35-tetraoxo-37-(3-ureopropyl)-8,11,14,17,20,23,26,29-octaoxa-2,5,33,36-tetraazaoctane-38-amido)benzyl((1S,9R)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,12H-benzopyran[3',4':6,7] indene[1,2-b]quinoline 1-yl)((3- To a solution of fluorobicyclo[1.1.1]pent-1-yl)methyl)carbamate (85 mg, 0.05 mmol, 1.0 equivalent) in N,N-dimethylformamide (2 mL), 2,5-dioxopyrrolidone-1-yl-3,6,9,12,15,18,21,24,27,30-decamethyl-4,7,10,13,16,19,22,22,25,28,31-decaoxo-3,6,9,12,15,18,21,24,27,30-decaazatrioleate (66 mg, 0.07 mmol, 1.5 equivalent) and N,N-diisopropylethylamine (20 mg, 0.15 mmol, 3.0 equivalent) were added. The reaction was stirred at room temperature for 2 hours. The reaction solution was purified by high-performance preparative liquid chromatography (0.1% formic acid, acetonitrile) and lyophilized to obtain the target compound 4-((38S, 69S, 72S)-69-isopropyl-3,6,9,12,15,18,21,24,27,30-decamethyl-38-(2-(methylsulfonyl)pyrimidin-5-carbamate)-2,5,8,11,14,17,20,23,26,29,32,39,67,70-tetradecyloxy-72-(3-ureopropyl)-43,46,49,52,55,58,61,64-octaoxa-3,6 ,9,12,15,18,21,24,27.30,33,40,68,71-Tetradecazazatriheptanone-73-amido)benzyl((1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,12H-benzo[de]pyrano[3',4':6,7]indo[1,2-b]quinoline-1-yl)((3-fluorobicyclo[1.1.1]pent-1-yl)methyl)carbamate (A1; 25 mg, 20% yield), is a white solid.

[1045] LCMS(ESI) m / z: 1214.5 [M / 2+H] + .

[1046] 1 H NMR(400MHz,DMSO-d6)δ10.00(s,1H),9.41(s,1H),9.09(s,1H),8.13(s,2H),7.87(s,1H),7.79 (s,1H),7.64(s,1H),7.46(s,1H),7.31(d,J=4.4Hz,1H),6.5(s,0.5H),5.98(s,0.5H),5.44(s, 2H),5.11–5.03(m,3H),4.33–4.23(m,12H),4.04–3.91(m,12H),3.48(s,46H),3.22(s,4H),3.0 4(s,5H),2.92–2.76(m,32H),2.38–2.33(m,5H),2.15–1.54(m,17H),1.40(s,5H),0.86(s,9H).

[1047] 2. Preparation of compound A2

[1048] Step 1: Synthesis of (S)-10-((((9H-fluorene-9-yl(methoxy)carbonyl)amino-2,2-dimethyl-4,11-dioxy-3,15,18,21,24,27,30,33,36-nonoxy-5,12-diazatricontan-39-acid)

[1049] 1-Amino-3,6,9,12,15,18,21,24-octoxyheptaose-27-acid (1.72 g, 3.89 mmol, 1 equivalent) was dissolved in N,N-dimethylformamide (20 mL), followed by the addition of N,N-diisopropylethylamine (1.01 g, 7.78 mmol, 2 equivalents) and 2,5-dioxopyrrolidine-1-ylN2-((9H-fluorene-9-yl)methoxy)carbonyl)-n6-(tert-butylcarbonyl)-l-lysine (2.2 g, 3.89 mmol, 1 equivalent). The reaction was stirred at room temperature for 1 hour. The reaction solution was purified by high-performance liquid chromatography (acetonitrile and trifluoroacetic acid aqueous solution system) to obtain the target compound (S)-10-((((9H-fluorene-9-yl(methoxy)carbonyl)amino-2,2-dimethyl-4,11-dioxy-3,15,18,21,24,27,30,33,36-nonoxy-5,12-diazatricontan-39-acid) (3.2 g, 3.59 mmol, yield 92.23%), a colorless oil. LCMS (ESI) m / z: 892.4 [M+H] + .

[1050] Step 2: Synthesis of ((9H-fluorene-9-yl)methyl tert-butyl((2S,5S,36S)-1-((4-(hydroxymethyl)phenyl)amino)-5-isopropyl-2-methyl-1,4,7,35-tetraoxy-10,13,16,19,22,25,28,31-octaoxy-3,6,34-triazatetraconcanane-36,40-dicarbamate)

[1051] Dissolve (S)-10-((((9H-fluorene-9-yl(methoxy)carbonyl)amino-2,2-dimethyl-4,11-dioxy-3,15,18,21,24,27,30,33,36-nonoxy-5,12-diazatricontan-39-acid (1.2 g, 1.35 mmol, 1 equivalent) in anhydrous N,N-dimethylformamide solution (10 mL). (S)-2-amino-n-((S)-1-((4-(hydroxymethyl)phenyl)amino)-1-oxopropan-2-yl)-3-methylbutanamide (0.59 g, 2.02 mmol, 1.5 equivalents), 1H-benzotriazol-1-yloxotripyrrolidinyl hexafluorophosphate (1.05 g, 2.02 mmol, 1.5 equivalents), 1-hydroxybenzotriazole (0.272 g, 2.02 mmol, 1.5 equivalents). 0.2 mmol (1.5 equivalents) and N,N-diisopropylethylamine (0.35 g, 2.69 mmol, 2 equivalents) were added to the reaction solution. The reaction was stirred at room temperature for 16 hours. The reaction solution was purified by high performance liquid chromatography (acetonitrile, trifluoroacetic acid aqueous solution system) to give the target compound ((9H-fluorene-9-yl)methyl tert-butyl((2S,5S,36S)-1-((4-(hydroxymethyl)phenyl)amino)-5-isopropyl-2-methyl-1,4,7,35-tetraoxy-10,13,16,19,22,25,28,31-octaoxy-3,6,34-triazatetraconanone-36,40-dicarbamate) (1.1 g, 0.94 mmol, yield 70.05%), a brown solid. LCMS (ESI) m / z: 1167.5 [M+H] + .

[1052] Step 3: Synthesis of (9H-fluorene-9-yl)methyl tert-butyl((2S,5S,36S)-5-isopropyl-2-methyl-1-((4-(((((4-nitrophenoxy)carbonyl)oxy)methyl)phenyl)amino)-1,4,7,35-tetraoxy-10,13,16,19,22,25,28,31-octaoxy-3,6,34-triazatetraconcanane-36,40-diyl)dicarbamate

[1053] (9H-fluorene-9-yl)methyl-tert-butyl ((2S,5S,36S)-1-((4-(hydroxymethyl)phenyl)amino)-5-isopropyl-2-methyl-1,4,7,35-tetraoxy-10,13,16,19,22,25,28,31-octaoxy-3,6,34-triazatetraconcanane-36,40-dicarbamate (1.1 g, 0.94 mmol, 1 equivalent)) was dissolved in N,N-dimethylformamide (5 mL) and dichloromethane (40 mL), followed by the addition of di(p-nitrobenzene) carbonate (429 mg, 1.41 mmol, 1.5 equivalent) and N,N-diisopropylethylamine (244 mg, 1.88 mmol, 2 equivalent). The reaction was carried out at room temperature. Stir for 2 hours. The reaction mixture was concentrated under reduced pressure to remove the solvent. The crude product was purified by rapid silica gel column chromatography (methanol / dichloromethane = 0–10%) to give the target compound (9H-fluorene-9-yl)methyl-tert-butyl((2S,5S,36S)-5-isopropyl-2-methyl-1-((4-(((((4-nitrophenoxy)carbonyl)oxy)methyl)phenyl)amino)-1,4,7,35-tetraoxy-10,13,16,19,22,25,28,31-octaoxy-3,6,34-triazatetraconanone-36,40-diyl)dicarbamate (1 g, 0.75 mmol, 79.65% yield), a white solid. LCMS (ESI) m / z: 1332.5 [M+H] + .

[1054] Step 4: Synthesis of (9H-fluoro-9-yl)methyl tert-butyl((2S,5S,36S)-1-((4-(((((1S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxy-2,3,9,10,13,15-hexahydro-1h,12h-benzo[de]pyran[3',4':6,7]indoline-1,2-b-quinoline) -1-yl)((3-fluorobicyclo[1.1.1]pentan-1-yl)methyl)amino)(3-fluorobicyclo[1.1.1]methyl)amino)phenyl)amino)-5-isopropyl-2-methyl-1,4,7,35-tetraoxy-10,13,16,19,22,25,28,31-octaoxy-3,6,34-triazatetraconan-36,40-dicarbamate

[1055] (9H-fluorene-9-yl)methyl tert-butyl ((2S,5S,36S)-5-isopropyl-2-methyl-1-((4-(((((4-nitrophenoxy)carbonyl)oxy)methyl)phenyl)amino)-1,4,7,35-tetraoxy-10,13,16,19,22,25,28,31-octaoxy-3,6,34-triazatetraconcanane-36,40-diyl)dicarbamate (1 g, 0.75 mmol, 1.1 equivalents) was dissolved in anhydrous N,N-dimethylformamide solution (10 mL) and dimethylpyridine (2 In a 1 mL solution, 2-hydroxypyridine-N-oxide (83.38 mg, 0.75 mmol, 1.1 equivalents) and (1S,9S)-9-ethyl-5-fluoro-1-((3-fluorobicyclo[1.1.1]pentan-1-yl)methyl)amino)-9-hydroxy-4-methyl-1,2,3,9,12,15-hexahydro-10h,13h-benzo[de]pyran[3',4':6,7]indolquinone[1,2-b]quinoline-10,13-dione (364 mg, 0.68 mmol, 1 equivalent) were added. The reaction was stirred at room temperature for 48 hours. The reaction solution was purified by high performance liquid chromatography (acetonitrile, trifluoroacetic acid aqueous solution system) to obtain the target compound (9H-fluoro-9-yl)methyl tert-butyl ((2S,5S,36S)-1-((4-(((((1S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxy-2,3,9,10,13,15-hexahydro-1h,12h-benzo[de]pyran[3',4':6,7]indoline-1,2-b-quinoline-1-yl)((3-fluorobicyclo[1 [1.1.1]Pentane-1-yl)methyl)amino)(3-fluorobicyclo[1.1.1]methyl)amino)phenyl)amino)-5-isopropyl-2-methyl-1,4,7,35-tetraoxy-10,13,16,19,22,25,28,31-octaoxy-3,6,34-triazatetraconcanane-36,40-dicarbamate) (500 mg, 0.29 mmol, yield 42.44%), brown oil. LCMS (ESI) m / z: 1727.8 [M+H] + .

[1056] Step 5: Synthesis of 4-((10S,41S,44S)-10-amino-41-isopropyl-2,2,44-trimethyl-4,11,39,42-tetraoxo-3,15,18,21,24,27,30,33,36-nonoxa-5,12,40,43-tetraazapentacosane-45-amide)benzyl((1S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,12H-benzo[de]pyrano[3',4':6,7]indolazino[1,2-b]quinoline-1-yl)((3-fluorobicyclo[1.1.1]pentan-1-yl)methyl)carbamate

[1057] (9H-fluoro-9-yl)methyl tert-butyl((2S,5S,36S)-1-((4-(((((1S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxy-2,3,9,10,13,15-hexahydro-1h,12h-benzo[de]pyran[3',4':6,7]indoline-1,2-b-quinoline-1-yl)((3-fluorobicyclo[1.1.1]pentane) -1-yl)methyl)amino)(3-fluorobicyclo[1.1.1]methyl)amino)phenyl)amino)-5-isopropyl-2-methyl-1,4,7,35-tetraoxy-10,13,16,19,22,25,28,31-octaoxy-3,6,34-triazatetraconanone-36,40-dicarbamate) (400 mg, 0.23 mmol, 1 equivalent) soluble in N,N-dimethylformamide (8 mg) The solution was added to a container (L), and then diethylamine (0.8 mL) was added. The reaction was carried out at room temperature for 1 hour. The reaction solution was concentrated under reduced pressure to give the target compound 4-((10S,41S,44S)-10-amino-41-isopropyl-2,2,44-trimethyl-4,11,39,42-tetraoxo-3,15,18,21,24,27,30,33,36-nonoxa-5,12,40,43-tetraazapentacosane- 4,5-Amide)benzyl((1S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,12H-benzo[de]pyrano[3',4':6,7]indolazino[1,2-b]quinoline-1-yl)((3-fluorobicyclo[1.1.1]pentan-1-yl)methyl)carbamate (400 mg crude), brown solid.

[1058] LCMS(ESI) m / z: 1505.6 [M+H] + .

[1059] Step 6: Synthesis of 4-((10S,41S,44S)-41-isopropyl-2,2,44-trimethyl-10-(2-(methylsulfonyl)pyrimidin-5-carbamate)-4,11,39,42-tetraoxo-3,15,18,21,24,27,30,33,36-nonoxa-5,12,40,43-tetraazapentacosane-45 -amido)benzyl((1S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,12H-benzo[de]pyrano[3',4':6,7]indolo[1,2-b]quinoline-1-yl)((3-fluorobicyclo[1.1.1]pent-1-yl)methyl)carbamate

[1060] 4-((10S,41S,44S)-10-amino-41-isopropyl-2,2,44-trimethyl-4,11,39,42-tetraoxo-3,15,18,21,24,27,30,33,36-nonoxa-5,12,40,43-tetraazapentacosane-45-amide)benzyl((1S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,12H-benzo[de]pyrano[3',4':6,7]in Dolino[1,2-b]quinoline-1-yl)((3-fluorobicyclo[1.1.1]pentan-1-yl)methyl)carbamate (295 mg, 0.20 mmol, 1 equivalent) was dissolved in anhydrous tetrahydrofuran solution (6 mL). 2-(methylsulfonyl)pyrimidine-5-carboxylic acid (59.46 mg, 0.29 mmol, 1.5 equivalent), N,N'-diisopropylcarbodiimide (37 mg, 0.29 mmol, 1.5 equivalent), and ethyl 2-oxime cyanoacetate (42 mg, 0.29 mmol, 1.5 equivalent) were added to the reaction solution. The reaction was stirred at room temperature for 2 hours. The reaction solution was purified by high-performance liquid chromatography (acetonitrile, trifluoroacetic acid aqueous solution system) to obtain the target compound 4-((10S,41S,44S)-41-isopropyl-2,2,44-trimethyl-10-(2-(methanesulfonyl)pyrimidin-5-carbamate)-4,11,39,42-tetraoxo-3,15,18,21,24,27,30,33,36-nonoxa-5,12,40,43-tetraazapentacosane-45 (-Amamido)benzyl((1S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,12H-benzo[de]pyrano[3',4':6,7]indolo[1,2-b]quinoline-1-yl)((3-fluorobicyclo[1.1.1]pent-1-yl)methyl)carbamate (0.37 g, 0.21 mmol, yield 105%), brown solid. LCMS(ESI) m / z: 1688.7 [M+H] + .

[1061] Step 7: Synthesis of 4-((3S,34S,37S)-3-(4-aminobutyl)-34-isopropyl-37-methyl-1-(2-(methanesulfonyl)pyrimidin-5-yl)-1,4,32,35-tetraoxo-8,11,14,17,20,23,26,29-octaoxa-2,5,33,36-tetraazaoctadecane-38-amide)benzyl((1S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,12H-benzo[de]pyrano[3',4':6,7]indolazino[1,2-b]quinoline-1-yl)((3-fluorobicyclo[1.1.1]pentane-1-yl)methyl)carbamate

[1062] Add 0.2 mL of trifluoroacetic acid to 4-((10S,41S,44S)-41-isopropyl-2,2,44-trimethyl-10-(2-(methanesulfonyl)pyrimidin-5-carbamate)-4,11,39,42-tetraoxo-3,15,18,21,24,27,30,33,36-nonoxa-5,12,40,43-tetraazapentacosane-45-amido)benzyl((1S)-9- Ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,12H-benzo[de]pyrano[3',4':6,7]indolo[1,2-b]quinoline-1-yl)((3-fluorobicyclo[1.1.1]pent-1-yl)methyl)carbamate (100 mg, 0.059 mmol, 1.0 equivalent) was reacted in a 2 mL solution of dichloromethane. The reaction mixture was stirred at 0 °C for 1 hour. The reaction solution was concentrated under reduced pressure to give the target compound 4-((3S,34S,37S)-3-(4-aminobutyl)-34-isopropyl-37-methyl-1-(2-(methanesulfonyl)pyrimidin-5-yl)-1,4,32,35-tetraoxo-8,11,14,17,20,23,26,29-octaoxa-2,5,33,36-tetraazaoctadecane-38-amide)benzyl( (1S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,12H-benzo[de]pyrano[3',4':6,7]indolazino[1,2-b]quinoline-1-yl)((3-fluorobicyclo[1.1.1]pentan-1-yl)methyl)carbamate (100 mg, crude), yellow oil.

[1063] LCMS(ESI) m / z: 1589.1 [M+H] + .

[1064] Step 8: Synthesis of 4-((38S,69S,72S)-69-isopropyl-3,6,9,12,15,18,21,24,27,30,72-undecyl-38-(2-(methanesulfonyl)pyrimidin-5-carbamate)-2,5,8,11,14,17,20,23,26,29,32,39,67,70-tetradecoxo-43,46,49,52,55,58,61,64-octaoxa-3,6,9,12,15, 18,21,24,27,30,33,40,68,71-Tetraazahepta-73-amido)benzyl((1S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,12H-benzo[de]pyrano[3',4':6,7]indolo[1,2-b]quinoline-1-yl)((3-fluorobicyclo[1.1.1]pent-1-yl)methyl)carbamate (A2)

[1065] 4-((3S,34S,37S)-3-(4-aminobutyl)-34-isopropyl-37-methyl-1-(2-(methanesulfonyl)pyrimidin-5-yl)-1,4,32,35-tetraoxo-8,11,14,17,20,23,26,29-octaoxa-2,5,33,36-tetraazaoctadecane-38-amide)benzyl((1S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,12H-benzo[de]pyrano[3',4':6,7]indolazino[1,2-b]quinoline-1-yl)((3-fluorobicyclo[1 [1.1] Pentane-1-yl)methyl)carbamate (100 mg, 0.063 mmol, 1 equivalent) was dissolved in anhydrous N,N-dimethylformamide (2 mL), followed by the addition of N,N-diisopropylethylamine (48.81 mg, 0.38 mmol, 6 equivalents) and 2,5-dioxopyrrolidone-1-yl3,6,9,12,15,18,21,24,27,30-decamethyl-4,7,10,13,16,19,22,25,28,31-decaoxo-3,6,9,12,15,18,21,24,27,30-decaazahexadecanoate (71 mg, 0.082 mmol, 1.5 equivalents). The reaction was carried out at room temperature for 1 hour. The reaction solution was diluted with water (10 mL) and extracted with dichloromethane (5 mL x 2). The organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to remove the solvent. The crude product was purified by preparative high-performance liquid chromatography (0.1% formic acid, acetonitrile), lyophilized, and the target compound 4-((38S,69S,72S)-69-isopropyl-3,6,9,12,15,18,21,24,27,30,72-undecyl-38-(2-(methanesulfonyl)pyrimidin-5-carbamate)-2,5,8,11,14,17,20,23,26,29,32,39,67,70-tetradecoxo-43,46,49,52,55,58,61,64-octaoxa-3,6,9,12,15, 18,21,24,27,30,33,40,68,71-Tetraazahepta-73-amido)benzyl((1S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,12H-benzo[de]pyrano[3',4':6,7]indolo[1,2-b]quinoline-1-yl)((3-fluorobicyclo[1.1.1]pent-1-yl)methyl)carbamate (28.92 mg, 0.012 mmol, yield 19.62%), white solid. LCMS(ESI) m / z: 1171.4 [M+H] +. .1H NMR (400MHz, DMSO) δ9.97(s,1H),9.41(s,2H),9.10–9.08(m,1H),8.16–8.12(m,2H),7.88(d,J=8.0Hz,1H),7.77(d,J=8.0Hz,1H),7 .63(s,1H),7.47(s,1H),7.31(s,1H),6.51(s,1H),5.45(s,2H),5.12–5.04(m,3H),4.29–4.27(m,6H),4.26–4.24(m,6H),4.23–3.2 7(m,11H),3.57–3.53(m,2H),3.51–3.47(m,28H),3.42–3.37(m,2H),3.26–3.23(m,3H),3.15–3.02(m,3H),3.00–2.61(m,35H),2.4 8–2.46(m,1H),2.41–2.27(m,6H),1.93–1.82(m,10H),1.79–1.74(m,2H),1.72–1.69(m,1H),1.43–1.30(m,8H),0.89–0.83(m,9H).

[1066] 3. Preparation of compound A7

[1067] Step 1: Synthesis of (2S,3R,4S,5S,6S)-2-(4-formyl-2-nitrophenoxy)-6-(methoxycarbonyl)tetrahydro-2H-pyran-3,4,5-triacyltriacetate

[1068] To a solution of (2R,3R,4S,5S,6S)-2-bromo-6-(methoxycarbonyl)tetrahydro-2H-pyran-3,4,5-triacyltriacetate (20.0 g, 57.9 mmol, 1.0 equivalent) in acetonitrile (700 mL), 4-hydroxy-3-nitrobenzaldehyde (19.3 g, 115.8 mmol, 2.0 equivalent) and silver oxide (67.1 g, 289.6 mmol, 5.0 equivalent) were added. The reaction mixture was stirred at room temperature in the dark for 16 hours. The reaction solution was diluted with ethyl acetate (600 mL), the solid was removed by filtration, and the filtrate was concentrated under reduced pressure. The crude product was purified by rapid silica gel column chromatography (petroleum ether: ethyl acetate = 2:1) to give the target compound (2S,3R,4S,5S,6S)-2-(4-formyl-2-nitrophenoxy)-6-(methoxycarbonyl)tetrahydro-2H-pyran-3,4,5-triacyltriacetate (20 g, 71% yield), a pale yellow solid.

[1069] 1H NMR(400MHz, DMSO-d6)δ9.98(s,1H),8.45(d,J=2.0Hz,1H),8.24–8.21(m,1H),7.64(d,J=8.4Hz,1H),5.94(d, J=7.6Hz,1H),5.47(t,J=9.6Hz,1H),5.21–5.09(m,2H),4.80(d,J=9.6Hz,1H),3.64(s,3H),2.07–2.00(m,9H).

[1070] Step 2: Synthesis of (2S,3R,4S,5S,6S)-2-(2-amino-4-(hydroxymethyl)phenoxy)-6-(methoxycarbonyl)tetrahydro-2H-pyran-3,4,5-triacyltriacetate

[1071] To a solution of 2S,3R,4S,5S,6S)-2-(4-formyl-2-nitrophenoxy)-6-(methoxycarbonyl)tetrahydro-2H-pyran-3,4,5-triacyltriacetate (1.5 g, 4.1 mmol, 1.0 equivalent) in ethyl acetate (40 mL), N,N-diisopropylethylamine (1.1 mL) and 10% palladium on carbon (200 mg, 10% w / w) were added. The reaction was carried out under hydrogen pressure and stirred at room temperature for 16 hours. The reaction mixture was filtered through diatomaceous earth, the filter cake was washed with ethyl acetate, and the filtrates were combined and concentrated under reduced pressure to give the target compound (2S,3R,4S,5S,6S)-2-(2-amino-4-(hydroxymethyl)phenoxy)-6-(methoxycarbonyl)tetrahydro-2H-pyran-3,4,5-triacyltriacetate (1.2 g, 85% yield), a pale yellow solid.

[1072] 1H NMR (400MHz, DMSO-d6) δ6.80(d,J=8.0Hz,1H),6.66(d,J=2.0Hz,1H),6.47–6.44(m,2.0Hz,1H),5.48(t,J=9.6Hz,1H),5.39(d,J=8.0Hz,1H),5. 13–5.02(m,2H),4.97(t,J=6.4Hz,1H),4.66(d,J=9.6Hz,1H),4.59(s,2 H),4.31(d,J=5.6Hz,2H),3.65(s,3H),2.04(s,3H),2.02–1.99(m,6H).

[1073] Step 3: Synthesis of (2S,3R,4S,5S,6S)-2-(2-(1-(9H-fluorene-9-yl)-3-oxo-2,7,10,13,16,19,22-heptoxy-4-azapentane-25-amido)-4-(hydroxymethyl)phenoxy)-6-(methoxycarbonyl)tetrahydro-2H-pyran-3,4,5-triacyltriacetate)

[1074] To a solution of (2S,3R,4S,5S,6S)-2-(2-amino-4-(hydroxymethyl)phenoxy)-6-(methoxycarbonyl)tetrahydro-2H-pyran-3,4,5-triacyltriacetate (5.0 g, 10.98 mmol, 1 equivalent) in dichloromethane (50 mL), 1-(9H-fluorene-9-yl)-3-oxo-2,7,10,13,16,19,22-heptoxy-4-azapentacarbon-25-acid (6.32 g, 10.98 mmol, 1 equivalent) and 2-ethoxy-1-ethoxycarbonyl-1,2-dihydroquinoline (5.42 g, 21.98 mmol, 2 equivalent) were added. The reaction was carried out under nitrogen atmosphere and stirred at room temperature for 16 hours. The reaction solution was concentrated under reduced pressure, and the crude product was purified by rapid silica gel column chromatography (dichloromethane:methanol = 30:1) to give the target compound (2S,3R,4S,5S,6S)-2-(2-(1-(9H-fluorene-9-yl)-3-oxo-2,7,10,13,16,19,22-heptoxy-4-azapentane-25-amido)-4-(hydroxymethyl)phenoxy)-6-(methoxycarbonyl)tetrahydro-2H-pyran-3,4,5-triacyltriacetate (7 g, 6.91 mmol, 62.9% yield), a white solid.

[1075] LCMS(ESI) m / z: 1013.1 [M+H] + .

[1076] Step 4: Synthesis of (2S,3R,4S,5S,6S)-2-(2-(1-(9H-fluorene-9-yl)-3-oxo-2,7,10,13,16,19,22-heptoxy-4-azapentane-25-amido)-4-(((4-nitrophenoxy)carbonyl)oxy)methyl)phenoxy)-6-(methoxycarbonyl)tetrahydro-2H-pyran-3,4,5-triacyltriacetate)

[1077] To a solution of (2S,3R,4S,5S,6S)-2-(2-(1-(9H-fluorene-9-yl)-3-oxo-2,7,10,13,16,19,22-heptoxy-4-azapentane-25-amido)-4-(hydroxymethyl)phenoxy)-6-(methoxycarbonyl)tetrahydro-2H-pyran-3,4,5-triacyltriacetate (5 g, 4.94 mmol, 1.0 equivalent) in N,N-dimethylformamide (50 mL), N,N-diisopropylethylamine (1.27 g, 9.88 mmol, 2 equivalent), 4-dimethylaminopyridine (0.06 g, 0.494 mmol, 0.1 equivalent) and bis(4-nitrophenyl) carbonate (3.0 g, 9.88 mmol, 2 equivalent) were added. The reaction was stirred at room temperature for 16 hours under nitrogen protection. The reaction solution was quenched with water and extracted with ethyl acetate. The combined organic phases were washed with saturated sodium chloride aqueous solution, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The crude product was purified by rapid silica gel column chromatography (methanol:dichloromethane = 0-5%) to give the target compound (2S,3R,4S,5S,6S)-2-(2-(1-(9H-fluorene-9-yl)-3-oxo-2,7,10,13,16,19,22-heptoxy-4-azapentaane-25-amido)-4-(((4-nitrophenoxy)carbonyl)oxy)methyl)phenoxy)-6-(methoxycarbonyl)tetrahydro-2H-pyran-3,4,5-triacyltriacetate) (3.1 g, 2.63 mmol, 53.3% yield), a white solid. LCMS(ESI) m / z: 1178.3 [M+H] + .

[1078] Step 5: Synthesis of (2S,3R,4S,5S,6S)-2-(2-(1-(9H-fluoren-9-yl)-3-oxo-2,7,10,13,16,19,22-heptoxy-4-azapentane-25-amido)-4-(1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,12H-benzopyrano[3',4':6,7] indo[1,2-b]quinoline-1-yl)((3-fluorobicyclo[1.1.1]pent-1-yl)methyl)carbamoyl)oxy)methyl)phenoxy)-6-(methoxycarbonyl)tetrahydro-2H-pyran-3,4,5-triacyltriacetate)

[1079] Add 2,6- to a solution of (2S,3R,4S,5S,6S)-2-(2-(1-(9H-fluorene-9-yl)-3-oxo-2,7,10,13,16,19,22-heptoxy-4-azapentane-25-amido)-4-(((4-nitrophenoxy)carbonyl)oxy)methyl)phenoxy)-6-(methoxycarbonyl)tetrahydro-2H-pyran-3,4,5-triacyltriacetate (500 mg, 0.425 mmol, 1.0 equivalent) in N,N-dimethylformamide (8 mL) Dimethylpyridine (2 mL), 2-pyridine-1-oxide (52 mg, 0.468 mmol, 1.1 equivalents), and (1S)-9-ethyl-5-fluoro-1-(((3-fluorobicyclo[1.1.1]pent-1-yl)methyl)amino)-9-hydroxy-4-methyl-1,2,3,9,12,15-hexahydro-10H,13H-benzo[de]pyrano[3',4':6,7]indo[1,2-b]quinoline-10,13-dione (226 mg, 0.425 mmol, 1 equivalent) were prepared. The reaction was stirred at room temperature for 16 hours. The reaction solution was purified by high-performance liquid chromatography (acetonitrile and trifluoroacetic acid aqueous solution system), and lyophilized to obtain (2S,3R,4S,5S,6S)-2-(2-(1-(9H-fluoren-9-yl)-3-oxo-2,7,10,13,16,19,22-heptoxy-4-azapentane-25-amido)-4-(1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-di Oxo-2,3,9,10,13,15-hexahydro-1H,12H-benzopyrano[3',4':6,7]indo[1,2-b]quinoline-1-yl)((3-fluorobicyclo[1.1.1]pentan-1-yl)methyl)carbamoyl)oxy)methyl)phenoxy)-6-(methoxycarbonyl)tetrahydro-2H-pyran-3,4,5-triacyltriacetate (80 mg, 12% yield), white solid. LCMS (ESI) m / z: 1572.1 [M+H] + .

[1080] Step 6: Synthesis of (2S,3S,4S,5R,6S)-6-(2-(1-amino-3,6,9,12,15,18-hexaoxane-21-amido)-4-(1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,12H-benzopyrano[3',4':6,7]indo[1,2-b]quinoline-1-yl)((3-fluorobicyclo[1.1.1]pent-1-yl)methyl)carbamoyl)oxy)methylphenoxy)-3,4,5-trihydroxytetrahydro-2H-pyran-n-2-carboxylic acid

[1081] To (2S,3R,4S,5S,6S)-2-(2-(1-(9H-fluorene-9-yl)-3-oxo-2,7,10,13,16,19,22-heptoxy-4-azapentane-25-amido)-4-(1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,12H-benzopyrano[3',4':6,7] indene[1 A methanol (4 mL) solution of 500 mg (0.32 mmol, 1.0 equivalent) of [2-b]quinoline-1-yl)((3-fluorobicyclo[1.1.1]pent-1-yl)methyl)carbamoyl)oxy)methyl)phenoxy)-6-(methoxycarbonyl)tetrahydro-2H-pyran-3,4,5-triacyltriacetate) was added to a solution of dichloromethane (0.5 mL) and lithium hydroxide (23.0 mg, 0.96 mmol, 3.0 equivalent) in water (2 mL). The reaction was stirred at room temperature for 2 hours. 2N hydrochloric acid was added to the reaction solution to bring the pH to 5–6, and the solution was concentrated under reduced pressure. The crude product was purified by high performance liquid chromatography (acetonitrile / 0.1% formic acid aqueous solution = 0-33%), lyophilized, and the target compound (2S, 3S, 4S, 5R, 6S)-6-(2-(1-amino-3,6,9,12,15,18-hexaoxane-21-amido)-4-(1S, 9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxo-2 3,9,10,13,15-Hexahydro-1H,12H-Benzopyrano[3',4':6,7]indo[1,2-b]quinoline-1-yl)((3-fluorobicyclo[1.1.1]pent-1-yl)methyl)carbamoyl)oxy)methylphenoxy)-3,4,5-trihydroxytetrahydro-2H-pyran-n-2-carboxylic acid (250 mg, 64.9% yield), white solid.

[1082] LCMS(ESI) m / z: 1210.6 [M+H] + .

[1083] Step 7: Synthesis of (2S,3S,4S,5R,6S)-6-(4-(1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,12H-benzo[de]pyran[3',4':6,7] indene[1,2-b]quinoline-1-yl)(3-fluorobicyclo[1.1.1]pent-1-yl)methyl)carbamoyl)oxy)methyl-2-(1-(2-(methanesulfonyl)pyrimidin-5-yl)-1-oxo-5,8,11,14,17,20-hexaoxa-2-azatoritriane-23-amido)phenoxy)-3,4,5-trihydroxytetrahydro-2H-pyran-2-carboxylic acid (A7)

[1084] To (2S,3S,4S,5R,6S)-6-(2-(1-amino-3,6,9,12,15,18-hexaoxane-21-amido)-4-(1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,12H-benzopyrano[3',4':6,7] indene[1,2-b]quinoline-1-yl)((3-fluorobicyclo[1.1.1]pent-1-yl)methyl)carbamoyl To a solution of (50 mg, 0.041 mmol, 1.0 equivalent) of methylphenoxy-3,4,5-trihydroxytetrahydro-2H-pyran-n-2-carboxylic acid in N,N-dimethylformamide (0.5 mL), 2-(methanesulfonyl)pyrimidine-5-carboxylic acid (12 mg, 0.062 mmol, 1.5 equivalent), ethyl 2-oxime cyanoacetate (9 mg, 0.062 mmol, 1.5 equivalent), and N,N'-diisopropylcarbodiimide (8 mg, 0.062 mmol, 1.5 equivalent) were added. The reaction was stirred at room temperature for 1 hour. The reaction solution was immediately purified by high-performance liquid chromatography (acetonitrile, trifluoroacetic acid aqueous solution system), lyophilized, and then purified by preparative high-performance liquid chromatography (acetonitrile, formic acid aqueous solution system), lyophilized, to obtain the target compound ((2S,3S,4S,5R,6S)-6-(4-(1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,12H-benzo[de]pyran[3',4'] [6,7] Indo[1,2-b]quinoline-1-yl)(3-fluorobicyclo[1.1.1]pent-1-yl)methyl)carbamoyl)oxy)methyl-2-(1-(2-(methanesulfonyl)pyrimidin-5-yl)-1-oxo-5,8,11,14,17,20-hexaoxa-2-azatoridecane-23-amido)phenoxy)-3,4,5-trihydroxytetrahydro-2H-pyran-2-carboxylic acid (A7; 2 mg, 12% yield), white solid. LCMS (ESI) m / z: 1394.8 [M+H] + .

[1085] 4. Preparation of compound A18

[1086] Step 1: Synthesis of 2,5-dioxopyrrolidine-1-yl-1-(9H-fluorene-9-yl)-3-oxo-2,7,10,13,16,19,22,22,25-28-nonoxy-4-azatriacontane-31-ester

[1087] At room temperature, N-hydroxysuccinimide (191 mg, 1.66 mmol, 1.1 equivalents) and N,N'-dicyclohexylcarbodiimide (342 mg, 1.66 mmol, 1.1 equivalents) were added to a 10 mL solution of 1-(9H-fluorene-9-yl)-3-oxo-2,7,10,13,16,19,22,22,25-28-nonoxy-4-azatriacontane-31-acid (1.0 g, 1.51 mmol, 1 equivalent) in dichloromethane. The reaction was stirred at room temperature for 2 hours. A solid precipitated from the reaction solution, which was filtered, and the filter cake was washed with dichloromethane. The filtrates were combined and concentrated under reduced pressure to obtain the target compound 2,5-dioxopyrrolidine-1-yl-1-(9H-fluorene-9-yl)-3-oxo-2,7,10,13,16,19,22,22,25-28-nonoxy-4-azatriacontane-31-ester (1.3 g, crude product), a colorless oil.

[1088] Step 2: Synthesis of (9H-fluorene-9-yl)methyl((6S,9S)-1-amino-6-((4-(hydroxymethyl)phenyl)carbamoyl)-9-isopropyl-1,8,11-trioxo-14,17,20,23,26,29,32,35-octaoxa-2,7,10-triazaheptane-37-yl)carbamate

[1089] VCPAB (630 mg, 1.66 mmol, 1.1 equivalents) and N'N-diisopropylethylamine (293 mg, 2.27 mmol, 1.5 equivalents) were added to 15 mL of N,N-dimethylformamide in 2,5-dioxopyrrolidone-1-yl-1-(9H-fluorene-9-yl)-3-oxo-2,7,10,13,16,19,22,22,25-28-nonoxy-4-azatriacontane-31-ester (1.3 g, 1.51 mmol, 1 equivalent). The reaction was stirred at room temperature for 2 hours. The reaction solution was purified by preparative high-performance liquid chromatography (0.1% formic acid aqueous solution, acetonitrile), and lyophilized to obtain the target compound (9H-fluorene-9-yl)methyl((6S,9S)-1-amino-6-((4-(hydroxymethyl)phenyl)carbamoyl)-9-isopropyl-1,8,11-trioxo-14,17,20,23,26,29,32,35-octaoxa-2,7,10-triazaheptane-37-yl)carbamate (1.4 g, 1.37 mmol, yield 91%), a white solid. LCMS (ESI) m / z: 1025.3 [M+H] + .

[1090] Step 3: Synthesis of (9H-fluorene-9-yl)methyl((6S,9S)-1-amino-9-isopropyl-6-((4-(((((4-nitrophenoxy)carbonyl)oxy)methyl)carbamoyl)-1,8,11-trioxo-14,17,20,23,26,29,32,35-octoxy-2,7,10-triazaheptane-37-yl)carbamate

[1091] At room temperature, di(p-nitrobenzene) carbonate (100 mg, 0.098 mmol, 1 equivalent) and N,N-diisopropylethylamine (38 mg, 0.294 mmol, 3 equivalents) were added to a mixture of (9H-fluorene-9-yl)methyl ((6S,9S)-1-amino-6-((4-(hydroxymethyl)phenyl)carbamoyl)-9-isopropyl-1,8,11-trioxo-14,17,20,23,26,29,32,35-octaoxa-2,7,10-triazaheptane-37-yl)carbamate (100 mg, 0.098 mmol, 1 equivalent) in dichloromethane (1.6 mL) and N,N-dimethylformamide (0.2 mL). The reaction was stirred at room temperature for 16 hours. The reaction solution was purified by preparative high-performance liquid chromatography (0.1% formic acid aqueous solution, acetonitrile), and lyophilized to obtain the target compound (9H-fluorene-9-yl)methyl((6S,9S)-1-amino-9-isopropyl-6-((4-(((((4-nitrophenoxy)carbonyl)oxy)methyl)carbamoyl)-1,8,11-trioxo-14,17,20,23,26,29,32,35-octoxy-2,7,10-triazaheptane-37-yl)carbamate (100 mg, 0.084 mmol, yield 86%), a yellow solid. LCMS (ESI) m / z: 1190.4 [M+H] + .

[1092] Step 4: Synthesis of 4-((33S,36S)-1-(9H-fluorene-9-yl)-33-isopropyl-3,31,34-trioxo-36-(3-ureopropyl)-2,7,10,13,16,19,22,25,28-nonoxy-4,32,35-triazaheptane-37-amido)benzyl((1S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,12H-benzopyrano[3',4':6,7]indo[1,2-b]quinoline-1-yl)((3-fluorobicyclo[1.1.1]pent-1-yl)methyl)carbamate

[1093] At room temperature, (9H-fluorene-9-yl)methyl((6S,9S)-1-amino-9-isopropyl-6-((4-(((((4-nitrophenoxy)carbonyl)oxy)methyl)carbamoyl)-1,8,11-trioxo-14,17,20,23,26,29,32,35-octyloxy-2,7,10-triazaheptane-37-yl)carbamate (236 mg, 0.198 mmol, 1.5 equivalents) and 2-hydroxypyridine-N-oxide (22 mg, 0.1... 98 mmol (1.5 equivalents), 2,6-dimethylpyridine (0.11 mL) was added to (1S,9S)-9-ethyl-5-fluoro-1-(((3-fluorobicyclo[1.1.1]pent-1-yl)methyl)amino)-9-hydroxy-4-methyl-1,2,3,9,12,15-hexahydro-10H,13H-benzo[de]pyrano[3',4':6,7] indo[1,2-b]quinoline-10,13-dione (70 mg, 0.132 mmol, 1 equivalent) The reaction mixture was added to a solution of N,N-dimethylformamide (0.6 mL). The reaction mixture was stirred at 30 °C for 16 hours. The reaction mixture was analyzed by preparative high performance liquid chromatography (0.1% formic acid aqueous solution, acetonitrile) to obtain the target compound 4-((33S,36S)-1-(9H-fluorene-9-yl)-33-isopropyl-3,31,34-trioxo-36-(3-ureopropyl)-2,7,10,13,16,19,22,25,28-nonoxy-4,32,35-triazaheptane-37-amido) Benzyl ((1S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,12H-benzopyrano[3',4':6,7]indo[1,2-b]quinoline-1-yl)((3-fluorobicyclo[1.1.1]pent-1-yl)methyl)carbamate (108 mg, 0.068 mmol, 52% yield), off-white solid. LCMS (ESI) m / z: 1585.4 [M+H] + .

[1094] Step 5: Synthesis of 4-((29S,32S)-1-amino-29-isopropyl-27,30-dioxo-32-(3-ureopropyl)-3,6,9,12,15,18,21,24-octaoxa-28,31-diazatricarbon-3-amido)benzyl((1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,12H-benzopyran[3',4':6,7] indo[1,2-b]quinoline-1-yl)((3-fluorobicyclo[1.1.1]pent-1-yl)methyl)carbamate

[1095] Piperidine (0.5 mL) was added at room temperature to 4-((33S,36S)-1-(9H-fluorene-9-yl)-33-isopropyl-3,31,34-trioxo-36-(3-ureopropyl)-2,7,10,13,16,19,22,25,28-nonoxy-4,32,35-triazaheptane-37-amido)benzyl((1S)-9-ethyl-5-fluoro-9-hydroxy) -4-methyl-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,12H-benzopyrano[3',4':6,7] indo[1,2-b]quinoline-1-yl)((3-fluorobicyclo[1.1.1]pent-1-yl)methyl)carbamate (108 mg, 0.068 mmol, 1 equivalent) in N,N-dimethylformamide solution (1 mL). The reaction was stirred at room temperature for 1 hour. The reaction solution was concentrated under reduced pressure to remove the solvent. The crude product was pulped with diethyl ether, filtered, and the filter cake was washed with diethyl ether. The filter cake was dissolved in dichloromethane and concentrated under reduced pressure to obtain the target compound 4-((29S,32S)-1-amino-29-isopropyl-27,30-dioxo-32-(3-ureopropyl)-3,6,9,12,15,18,21,24-octaoxa-28,31-diazatricarbon-3-amido)benzyl((1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,12H-benzopyran[3',4':6,7] indo[1,2-b]quinoline-1-yl)((3-fluorobicyclo[1.1.1]pent-1-yl)methyl)carbamate (90 mg, crude product), a reddish-brown solid. LCMS(ESI) m / z: 1362.4 [M+H] + .

[1096] Step 6: Synthesis of 4-((5S,36S,39S)-5-(4-(bis((2S,3R,4R,5R)-2,3,4,5,6-pentahydroxyhexyl)amino)butyl)-1-(9H-fluorene-9-yl)-36-isopropyl-3,6,34,37-tetraoxo-39-(3-ureopropyl)-2,10,13,16,19,22,22,25,28,31-oxa-4,7, 35,38-Tetraazatetracarbamoyl-40-amido)benzyl((1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,12Hbenzo[de]pyrano[3',4':6,7]indo[1,2-b]quinoline-1-yl)((3-fluorobicyclo[1.1.1]pent-1-yl)methyl)carbamate

[1097] At room temperature, 4-((29S,32S)-1-amino-29-isopropyl-27,30-dioxo-32-(3-ureopropyl)-3,6,9,12,15,18,21,24-octaoxa-28,31-diazatricarbon-3-amido)benzyl((1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,12H-benzopyran[3',4':6,7] indene[1,2-b]quinoline-1-yl) ((3-fluorobicyclo[1.1.1]pent-1-yl)methyl)carbamate (20 mg, 0.015 mmol, 1 equivalent) and N,N-diisopropylethylamine (12 mg, 0.094 mmol, 6 equivalents) were added to 2,5-dioxopyrrolidone-1-ylN2-((9H-fluorene-9-yl)methoxy)carbonyl)-N6,N6bis((2S,3R,4R,5R)-2,3,4-5,6-pentahydroxyhexyl)-L-lysine (approximately 0.029 mmol, 2 equivalents) in N,N-dimethylformamide (1 mL). The reaction was stirred at room temperature for 2 hours. The reaction solution was purified by preparative high-performance liquid chromatography (0.1% formic acid aqueous solution, acetonitrile) and lyophilized to obtain the target compound 4-((5S, 36S, 39S)-5-(4-(bis((2S, 3R, 4R, 5R)-2,3,4,5,6-pentahydroxyhexyl)amino)butyl)-1-(9H-fluorene-9-yl)-36-isopropyl-3,6,34,37-tetraoxo-39-(3-ureopropyl)-2,10,13,16,19,22,22,25,28,31-oxa-4, 7,35,38-Tetraazatetracarbamoyl-40-amido)benzyl((1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,12Hbenzo[de]pyrano[3',4':6,7]indo[1,2-b]quinoline-1-yl)((3-fluorobicyclo[1.1.1]pent-1-yl)methyl)carbamate (14 mg, 0.007 mmol, yield 46%), off-white solid. LCMS (ESI) m / z: 1021.2 [M / 2+H] + .

[1098] Step 7: Synthesize 4-((2S,5S,36S,43S,44R,45R,46R)-36-amino-43,44,45,46,47-pentahydroxy-5-isopropyl-4,7,35-trioxo-41-(2S,3R,4R,5R)-2,3,4,5,6-pentahydroxyhexyl)-2-(3-ureopropyl)-10,13,16,19,22,22,25,28,31- Octoxa-3,6,34,41-tetraazaheptyl)benzyl((1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,12H-benzo[de]pyran[3',4':6,7] indene[1,2-b]quinoline-1-yl)((3-fluorobicyclo[1.1.1]pent-1-yl)methyl)carbamate

[1099] At room temperature, piperidine (0.5 mL) was added to 4-((5S,36S,39S)-5-(4-(bis((2S,3R,4R,5R)-2,3,4,5,6-pentahydroxyhexyl)amino)butyl)-1-(9H-fluorene-9-yl)-36-isopropyl-3,6,34,37-tetraoxo-39-(3-ureopropyl)-2,10,13,16,19,22,22,25,28,31-oxa-4,7,35,38-tetraazatetracarbon-40- The reaction mixture was prepared in 1 mL of N,N-dimethylformamide in a solution of (1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,12H-benzo[de]pyrano[3',4':6,7] indo[1,2-b]quinoline-1-yl)((3-fluorobicyclo[1.1.1]pent-1-yl)methyl)carbamate (14 mg, 0.007 mmol, 1 equivalent). The reaction mixture was stirred at room temperature for 1 hour. The solvent was removed by concentration under reduced pressure. The crude product was pulped with diethyl ether, filtered, and the filter cake was washed with diethyl ether. The filter cake was dissolved in dichloromethane and concentrated under reduced pressure to obtain the target compound 4-((2S,5S,36S,43S,44R,45R,46R)-36-amino-43,44,45,46,47-pentahydroxy-5-isopropyl-4,7,35-trioxo-41-(2S,3R,4R,5R)-2,3,4,5,6-pentahydroxyhexyl)-2-(3-ureopropyl)-10,13,16,19,22,22,25,28,31- Octoxa-3,6,34,41-tetraazaheptyl)benzyl((1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,12H-benzo[de]pyran[3',4':6,7]indo[1,2-b]quinoline-1-yl)((3-fluorobicyclo[1.1.1]pent-1-yl)methyl)carbamate (12 mg, crude), reddish-brown solid. LCMS(ESI) m / z: 1819.7 [M+H] + .

[1100] Step 8: Synthesize 4-((2S,5S,36S,43S,44R,45R,46R)-43,44,45,46,47-pentahydroxy-5-isopropyl-36-(2-(methanesulfonyl)pyrimidin-5-carbamate)-4,7,35-trioxo-41-((2S,3R,4R,5R)-2,3,4,5,6-pentahydroxyhexyl)-2-(3-ureopropyl)-10,13,16,19,22,22,25, 28,31-octaoxa-3,6,34,41-tetraazaheptantetraoxy)benzyl((1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,12H-benzo[de]pyrano[3',4':6,7]indo[1,2-b]quinoline-1-yl)((3-fluorobicyclo[1.1.1]pent-1-yl)methyl)carbamate (A18)

[1101] 2-(methanesulfonyl)pyrimidine-5-carboxylic acid (3 mg, 0.016 mmol, 1 equivalent), HATU (9 mg, 0.024 mmol, 1.5 equivalent), and N,N-diisopropylethylamine (6 mg, 0.048 mmol, 3 equivalent) were dissolved in N,N-dimethylformamide (0.5 mL) at room temperature. The mixture was stirred at room temperature for 5 minutes. 4-((2S,5S,36S,43S,44R,45R,46R)-36-amino-43,44,45,46,47-pentahydroxy-5-isopropyl-4,7,35-trioxo-41-(2S,3R,4R,5R)-2,3,4,5,6-pentahydroxyhexyl)-2-(3-ureopropyl)-10,13,16,19,22,22,25,28,31-octaoxa-3,6,34,41-tetraaza Heptylbenzyl((1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,12H-benzo[de]pyran[3',4':6,7] indo[1,2-b]quinoline-1-yl)((3-fluorobicyclo[1.1.1]pent-1-yl)methyl)carbamate (30 mg, 0.016 mmol, 1 equivalent) was added to the above mixture. The reaction was stirred at room temperature for 2 hours. The reaction solution was purified by preparative high-performance liquid chromatography (0.1% formic acid aqueous solution, acetonitrile) and lyophilized to obtain the target compound 4-((2S,5S,36S,43S,44R,45R,46R)-43,44,45,46,47-pentahydroxy-5-isopropyl-36-(2-(methanesulfonyl)pyrimidin-5-carboxamido)-4,7,35-trioxo-41-((2S,3R,4R,5R)-2,3,4,5,6-pentahydroxyhexyl)-2-(3-ureopropyl)-10,13,16,19,22,22, 25,28,31-Octazo-3,6,34,41-tetraazaheptantetraoxy)benzyl((1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,12H-benzo[de]pyrano[3',4':6,7]indo[1,2-b]quinoline-1-yl)((3-fluorobicyclo[1.1.1]pent-1-yl)methyl)carbamate (A18; 1.17 mg, 0.001 mmol, 7% yield), white solid. LCMS (ESI) m / z: 1002.7 [M+H] + .

[1102] 5. Preparation of compound A3

[1103] Step 1: Synthesis of 4-(S)-2-(S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-methylbutamido)propamido)benzyl((1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,12H-benzopyrano[3',4':6,7]indo[1,2-b]quinoline-1-yl)((3-fluorobicyclo[1.1.1]pent-1-yl)methyl)carbamate

[1104] At room temperature, Fmoc-Val-Ala-pAB-PNP (575 mg, 0.845 mmol, 1.5 equivalents), 2-hydroxypyridine-N-oxide (94 mg, 0.845 mmol, 1.5 equivalents), and 2,6-dimethylpyridine (0.5 mL) were added to a solution of (1S,9S)-9-ethyl-5-fluoro-1-(((3-fluorobicyclo[1.1.1]pent-1-yl)methyl)amino)-9-hydroxy-4-methyl-1,2,3,9,12,15-hexahydro-10H,13H-benzo[de]pyrano[3',4':6,7] indo[1,2-b]quinoline-10,13-dione (300 mg, 0.563 mmol, 1 equivalent) in N,N-dimethylformamide (2.4 mL). The reaction solution was stirred at 30°C for 16 hours. The reaction solution was subjected to preparative high performance liquid chromatography (0.1% formic acid aqueous solution, acetonitrile) to obtain the target compound 4-(S)-2-(S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-methylbutamido)propamido)benzyl((1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,12H-benzopyrano[3',4':6,7]indo[1,2-b]quinoline-1-yl)((3-fluorobicyclo[1.1.1]pent-1-yl)methyl)carbamate (394 mg, 0.367 mmol, yield 65%), an off-white solid. LCMS(ESI) m / z: 1075.4 [M+H] + .

[1105] Step 2: Synthesis of 4-(S)-2-((S)-2-amino-3-methylbutamido)propamido)benzyl((1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,12H-benzo[de]pyrano[3',4':6,7]indo[1,2-b]quinoline-1-yl)((3-fluorobicyclo[1.1.1]pent-1-yl)methyl)carbamate

[1106] Piperidine (0.5 mL) was added at room temperature to a 1 mL solution of 4-(S)-2-(S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-methylbutamido)propamido)benzyl((1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,12H-benzopyrano[3',4':6,7] indo[1,2-b]quinoline-1-yl)((3-fluorobicyclo[1.1.1]pent-1-yl)methyl)carbamate (300 mg, 0.279 mmol, 1 equivalent) in N,N-dimethylformamide. The reaction was stirred at room temperature for 1 hour. The reaction solution was concentrated under reduced pressure to remove the solvent. The crude product was pulped with diethyl ether, filtered, and the filter cake was washed with diethyl ether. The filter cake was dissolved in dichloromethane and concentrated under reduced pressure to obtain the target compound 4-(S)-2-((S)-2-amino-3-methylbutamido)propamido)benzyl((1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,12H-benzo[de]pyrano[3',4':6,7]indo[1,2-b]quinoline-1-yl)((3-fluorobicyclo[1.1.1]pent-1-yl)methyl)carbamate (284 mg, crude product), a reddish-brown solid. LCMS(ESI) m / z: 853.2 [M+H] + .

[1107] Step 3: Synthesis of 4-((33S,36S)-1-(9H-fluorene-9-yl)-33-isopropyl-36-methyl-3,31,34-trioxo-2,7,10,13,16,19,22,25,28-nonoxy-4,32,35-triazaheptane-37-amino)benzyl((1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,12H-benzopyrano[3',4':6,7]indo[1,2-b]quinoline-1-yl)((3-fluorobicyclo[1.1.1]pent-1-yl)methyl)carbamate

[1108] At room temperature, 1-(9H-fluorene-9-yl)-3-oxo-2,7,10,13,16,19,22,22,25-28-nonoxy-4-azatriacontane-31-acid (221 mg, 0.333 mmol, 1 equivalent), HATU (190 mg, 0.500 mmol, 1.5 equivalent), and N,N-diisopropylethylamine (174 mg, 0.999 mmol, 3 equivalent) were dissolved in N,N-dimethylformamide (3 mL). The mixture was stirred at room temperature for 5 minutes. 4-(S)-2-((S)-2-amino-3-methylbutamido)propamido)benzyl((1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,12H-benzo[de]pyrano[3',4':6,7] indo[1,2-b]quinoline-1-yl)((3-fluorobicyclo[1.1.1]pent-1-yl)methyl)carbamate (284 mg, 0.333 mmol, 1 equivalent) was added to the above mixture. The reaction was stirred at room temperature for 2 hours. The reaction solution was purified by preparative high-performance liquid chromatography (0.1% formic acid aqueous solution, acetonitrile) and lyophilized to obtain the target compound 4-((33S, 36S)-1-(9H-fluorene-9-yl)-33-isopropyl-36-methyl-3,31,34-trioxo-2,7,10,13,16,19,22,25,28-nonoxy-4,32,35-triazaheptane-37-amino)benzyl((1S, 9S) 9-Ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,12H-benzopyrano[3',4':6,7]indo[1,2-b]quinoline-1-yl)((3-fluorobicyclo[1.1.1]pent-1-yl)methyl)carbamate (210 mg, 0.140 mmol, 42% yield), pale brown solid. LCMS (ESI) m / z: 1499.4 [M+H] + .

[1109] Step 4: Synthesis of 4-((29S,32S)-1-amino-29-isopropyl-32-methyl-27,30-dioxo-3,6,9,12,15,18,21,24-octaoxa-28,31-diazatricarbon-3-amido)benzyl((1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,12H-benzopyrano[3',4':6,7] indo[1,2-b]quinoline-1-yl)((3-fluorobicyclo[1.1.1]pent-1-yl)methyl)carbamate

[1110] At room temperature, piperidine (0.5 mL) was added to 4-((33S,36S)-1-(9H-fluoren-9-yl)-33-isopropyl-36-methyl-3,31,34-trioxo-2,7,10,13,16,19,22,25,28-nonoxy-4,32,35-triazaheptane-37-amino)benzyl((1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4) The reaction mixture was prepared in 1 mL of N,N-dimethylformamide solution containing methyl-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,12H-benzopyrano[3',4':6,7]-indo[1,2-b]quinoline-1-yl)((3-fluorobicyclo[1.1.1]pent-1-yl)methyl)carbamate (100 mg, 0.067 mmol, 1 equivalent). The reaction mixture was stirred at room temperature for 1 hour. The solvent was removed by concentration under reduced pressure. The crude product was pulped with diethyl ether, filtered, and the filter cake was washed with diethyl ether. The filter cake was dissolved in dichloromethane and concentrated under reduced pressure to obtain the target compound 4-((29S,32S)-1-amino-29-isopropyl-32-methyl-27,30-dioxo-3,6,9,12,15,18,21,24-octaoxa-28,31-diazatricarbon-3-amido)benzyl((1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,12H-benzopyrano[3',4':6,7]indo[1,2-b]quinoline-1-yl)((3-fluorobicyclo[1.1.1]pent-1-yl)methyl)carbamate (80 mg, crude product), a reddish-brown solid. LCMS(ESI) m / z: 1276.5 [M+H] + .

[1111] Step 5: Synthesis of N2-((9H-fluorene-9-yl)methoxy)carbonyl)-N6,N6bis((2S,3R,4R,5R)-2,3,4-5,6-pentahydroxyhexyl)-L-lysine

[1112] Under ice-water bath conditions, ((9H-fluorene-9-yl)methoxy)carbonyl)-L-lysine (3 g, 8.14 mmol, 1 equivalent) and (2R,3S,4R,5R)-2,3,4-5,6-pentahydroxyhexanal (14.67 g, 81.43 mmol, 10 equivalents) were added to a 10% acetic acid-methanol solution (60 mL). After stirring for 2 hours, sodium cyanoborohydride (2.60 g, 40.17 mmol, 5 equivalents) was added. The reaction was stirred at 40°C for 48 hours. The target compound N2-((9H-fluorene-9-yl)methoxy)carbonyl)-N6,N6bis((2S,3R,4R,5R)-2,3,4-5,6-pentahydroxyhexyl)-L-lysine (2.6 g, 3.73 mmol, yield 46%) was obtained by reversed-phase rapid column chromatography (0.5% formic acid aqueous solution, acetonitrile, 27%) as a white solid.

[1113] Step 6: Synthesis of 2,5-dioxopyrrolidine-1-ylN2-((9H-fluorene-9-yl)methoxy)carbonyl)-N6,N6bis((2S,3R,4R,5R)-2,3,4-5,6-pentahydroxyhexyl)-L-lysine

[1114] At room temperature, N-hydroxysuccinimide (22 mg, 0.190 mmol, 1.2 equivalents) and N,N'-dicyclohexylcarbodiimide (39 mg, 0.190 mmol, 1.2 equivalents) were added to a 1 mL solution of N2-((9H-fluorene-9-yl)methoxy)carbonyl)-N6,N6bis((2S,3R,4R,5R)-2,3,4-5,6-pentahydroxyhexyl)-L-lysine (110 mg, 0.158 mmol, 1 equivalent). The reaction was stirred at room temperature for 2 hours. A solid precipitated from the reaction mixture; the solid was filtered, and the filter cake was washed with DMF. The combined filtrates were used directly in the next step of the reaction. LCMS (ESI) m / z: 794.3 [M+H] + .

[1115] Step 7: Synthesis of 4-((5S,36S,39S)-5-(4-(bis((2S,3R,4R,5R)-2,3,4,5,6-pentahydroxyhexyl)amino)butyl)-1-(9H-fluorene-9-yl)-36-isopropyl-39-methyl-3,6,34,37-tetraoxo-2,10,13,16,19,22,25,28,31-nonoxy-4,7,35 ,38-Tetraazatetradecane-40amido)benzyl((1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,12H-benzopyrano[3',4':6,7]indo[1,2-b]quinoline-1-yl)((3-fluorobicyclo[1.1.1]pent-1-yl)methyl)carbamate

[1116] At room temperature, 4-((29S,32S)-1-amino-29-isopropyl-32-methyl-27,30-dioxo-3,6,9,12,15,18,21,24-octaoxa-28,31-diazatricarbon-3-amido)benzyl((1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,12H-benzopyrano[3',4':6,7] indene[1,2-b]quinoline-1-yl)((3- Fluorobionic bicyclo[1.1.1]pent-1-yl)methyl)carbamate (80 mg, 0.063 mmol, 1 equivalent) and N,N-diisopropylethylamine (12 mg, 0.094 mmol, 1.5 equivalent) were added to 2,5-dioxopyrrolidone-1-ylN2-((9H-fluorene-9-yl)methoxy)carbonyl)-N6,N6bis((2S,3R,4R,5R)-2,3,4-5,6-pentahydroxyhexyl)-L-lysine (approximately 0.158 mmol, 1 equivalent) in N,N-dimethylformamide (2 mL). The reaction was stirred at room temperature for 2 hours. The reaction solution was purified by preparative high-performance liquid chromatography (0.1% formic acid aqueous solution, acetonitrile) and lyophilized to obtain the target compound 4-((5S,36S,39S)-5-(4-(bis((2S,3R,4R,5R)-2,3,4,5,6-pentahydroxyhexyl)amino)butyl)-1-(9H-fluorene-9-yl)-36-isopropyl-39-methyl-3,6,34,37-tetraoxo-2,10,13,16,19,22,25,28,31-nonoxy-4,7, 35,38-Tetraazatetradecane-40amido)benzyl((1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,12H-benzopyrano[3',4':6,7]indo[1,2-b]quinoline-1-yl)((3-fluorobicyclo[1.1.1]pent-1-yl)methyl)carbamate (40 mg, 0.020 mmol, yield 32%), off-white solid. LCMS (ESI) m / z: 978.3 [M / 2+H] + .

[1117] Step 8: Synthesis of 4-((2S,5S,36S,43S,44R,45R,46R)-36-amino-43,44,45,46,47-pentahydroxy-5-isopropyl-2-methyl-4,7,35-trioxo-41-(2S,3R,4R,5R)-2,3,4,5,6-pentahydroxyhexyl)-10,13,16,19,22,25,28,31-octaoxa -3,6,34,41-Tetraazaheptane-amino)benzyl((1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,12H-benzopyran[3',4':6,7]indo[1,2-b]quinoline-1-yl)((3-fluorobicyclo[1.1.1]pent-1-yl)methyl)carbamate

[1118] Piperidine (0.5 mL) was added to 4-((5S,36S,39S)-5-(4-(bis((2S,3R,4R,5R)-2,3,4,5,6-pentahydroxyhexyl)amino)butyl)-1-(9H-fluorene-9-yl)-36-isopropyl-39-methyl-3,6,34,37-tetraoxo-2,10,13,16,19,22,25,28,31-nonoxy-4,7,35,38-tetraazatetradecane-40amido group at room temperature. The reaction mixture was prepared in 1 mL of N,N-dimethylformamide solution of benzyl((1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,12H-benzopyrano[3',4':6,7] indo[1,2-b]quinoline-1-yl)((3-fluorobicyclo[1.1.1]pent-1-yl)methyl)carbamate (40 mg, 0.020 mmol, 1 equivalent). The reaction mixture was stirred at room temperature for 1 hour. The solvent was removed by concentration under reduced pressure. The crude product was pulped with diethyl ether, filtered, and the filter cake was washed with diethyl ether. The filter cake was dissolved in dichloromethane and concentrated under reduced pressure to obtain the target compound 4-((2S,5S,36S,43S,44R,45R,46R)-36-amino-43,44,45,46,47-pentahydroxy-5-isopropyl-2-methyl-4,7,35-trioxo-41-(2S,3R,4R,5R)-2,3,4,5,6-pentahydroxyhexyl)-10,13,16,19,22,25,28,31-octaoxa -3,6,34,41-Tetraazaheptaneamino)benzyl((1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,12H-benzopyran[3',4':6,7]indo[1,2-b]quinoline-1-yl)((3-fluorobicyclo[1.1.1]pent-1-yl)methyl)carbamate (25 mg, crude), reddish-brown solid. LCMS(ESI) m / z: 1732.7 [M+H] + .

[1119] Step 9: Synthesis of 4-((2S,5S,36S,43S,44R,45R,46R)-43,44,45,45,46,47-pentahydroxy-5-isopropyl-2-methyl-36-(2-(methanesulfonyl)pyrimidin-5-carbamate)-4,7,35-trioxo-41-(2S,3R,4R,5R)-2,3,4,5,6-pentahydroxyhexyl)-10,13,16,19,22,25,28,3 1-Octaoxa-3,6,34,41-tetraazaheptantetraalkylamido)benzyl((1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,12H-benzo[de]pyrano[3',4':6,7]indo[1,2-b]quinoline-1-yl)((3-fluorobicyclo[1.1.1]pent-1-yl)methyl)carbamate (A3)

[1120] 2-(methanesulfonyl)pyrimidine-5-carboxylic acid (3 mg, 0.014 mmol, 1 equivalent), HATU (8 mg, 0.022 mmol, 1.5 equivalent), and N,N-diisopropylethylamine (10 mg, 0.084 mmol, 6 equivalent) were dissolved in N,N-dimethylformamide (0.5 mL) at room temperature. The mixture was stirred at room temperature for 5 minutes. 4-((2S,5S,36S,43S,44R,45R,46R)-36-amino-43,44,45,46,47-pentahydroxy-5-isopropyl-2-methyl-4,7,35-trioxo-41-(2S,3R,4R,5R)-2,3,4,5,6-pentahydroxyhexyl)-10,13,16,19,22,25,28,31-octaoxa-3,6,34,41-tetraazaheptane Aminobenzyl((1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,12H-benzopyran[3',4':6,7] indo[1,2-b]quinoline-1-yl)((3-fluorobicyclo[1.1.1]pent-1-yl)methyl)carbamate (25 mg, 0.014 mmol, 1 equivalent) was added to the above mixture. The reaction was stirred at room temperature for 2 hours. The reaction solution was purified by preparative high-performance liquid chromatography (0.1% formic acid aqueous solution, acetonitrile) and lyophilized to obtain the target compound 4-((2S,5S,36S,43S,44R,45R,46R)-43,44,45,45,46,47-pentahydroxy-5-isopropyl-2-methyl-36-(2-(methanesulfonyl)pyrimidin-5-carbamate)-4,7,35-trioxo-41-(2S,3R,4R,5R)-2,3,4,5,6-pentahydroxyhexyl)-10,13,16,19,22,25, 28,31-Octazo-3,6,34,41-Tetraazaheptantetraalkylamido)benzyl((1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,12H-benzo[de]pyrano[3',4':6,7]indo[1,2-b]quinoline-1-yl)((3-fluorobicyclo[1.1.1]pent-1-yl)methyl)carbamate (A3; 2 mg, 0.001 mmol, 7% yield), white solid. LCMS (ESI) m / z: 1917.7 [M+H] + .

[1121] 6. Preparation of compound A6

[1122] Step 1: Synthesis of (9H-fluorene-9-yl)methyl tert-butyl((6S,9S,40S)-1-amino-6-((4-ethyl-5-fluoro-9-hydroxy-4-methoxy-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,12H-benzo[de]pyran[3',4':6,7] indene[1,2-b]quinoline-1-yl)(3-fluorobicyclo[1.1.1]pent-1-yl)methyl)carbamoyl)oxy)methyl)phenyl)carbamoyl)-9-isopropyl-1,8,11,39-tetraoxo-14,17,20,23,26,26) 9,32,35-octaoxa-2,7,10,38-tetraazatetracarbamate-40,44-diyl)dicarbamate

[1123] Anhydrous N,N-dimethylformamide (N,N-dimethylformamide) of (1S,9S)-9-ethyl-5-fluoro-1-(((3-fluorobicyclo[1.1.1]pent-1-yl)methyl)amino)-9-hydroxy-4-methoxy-1,2,3,9,12,15-hexahydro-10H,13H-benzo[de]pyrano[3',4':6,7] indo[1,2-b]quinoline-10,13-dione (250 mg, 0.455 mmol, 1.0 equivalent) in indo[1,2-b]quinoline-10,13-dione (1,N-dimethylformamide) Add 968 mg of (9H-fluorene-9-yl)methyl tert-butyl ((6S,9S,40S)-1-amino-9-isopropyl-6-((4-(((((4-nitrophenoxy)carbonyl)oxy)methyl)carbamoyl)-1,8,11,39-tetraoxo-14,17,20,23,26,29,32,35-octaoxa-2,7,10,38-tetraazatetracarbon-40,44-diyl)dicarbamate to a 2 mL solution. 0.683 mmol (1.5 equivalents), 2-pyridine-1-oxide (76 mg, 0.683 mmol, 1.5 equivalents), and 2,6-dimethylpyridine (0.39 mL). The reaction was stirred at room temperature for 16 hours. The reaction solution was purified by high performance liquid chromatography (acetonitrile, 0.1% trifluoroacetic acid aqueous solution), lyophilized, to give the target compound (9H-fluorene-9-yl)methyl tert-butyl ((6S,9S,40S)-1-amino-6-((4-ethyl-5-) Fluoro-9-hydroxy-4-methoxy-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,12H-benzo[de]pyran[3',4':6,7]indene[1,2-b]quinoline-1-yl)(3-fluorobicyclo[1.1.1]pent-1-yl)methyl)carbamoyl)oxy)methyl)phenyl)carbamoyl)-9-isopropyl-1,8,11,39-tetraoxo-14,17,20,23,26,269,32,35-octaoxa-2,7,10,38-tetraazatetracarbamo-40,44-diyl)dicarbamate (280 mg, 34% yield), white solid. LCMS(ESI) m / z: 1829.9 [M+H] + .

[1124] Step 2: Synthesis of 4-((10S,41S,44S)-10-amino-41-isopropyl-2,2-dimethyl-4,11,39,42-tetraoxo-44-(3-ureopropyl)-3,15,18,21,24,27,30,33,36-nonoxy-5,12,40,43-tetraazapentane-45-amido)benzyl((1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methoxy-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,12H-benzo[de]pyran[3',4':6,7] indo[1,2-b]quinoline-1-yl)((3-fluorobicyclo[1.1.1]pentane-1-yl)methyl)carbamate

[1125] To (9H-fluorene-9-yl)methyl tert-butyl ((6S,9S,40S)-1-amino-6-((4-ethyl-5-fluoro-9-hydroxy-4-methoxy-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,12H-benzo[de]pyran[3',4':6,7] indene[1,2-b]quinoline-1-yl)(3-fluorobicyclo[1.1.1]pent-1-yl)methyl)carbamoyl)oxy)methyl)phenyl)carbamoyl)-9-isopropyl-1,8,11,39-tetraoxo-14,17,20,23,26,26 Diethylamine (0.3 mL) was added to a 3 mL solution of 9,32,35-octaoxa-2,7,10,38-tetraazatetracarbamate-40,44-diyl)dicarbamate (280 mg, 0.15 mmol, 1.0 equivalent) in N,N-dimethylformamide. The reaction mixture was stirred at room temperature for 1 hour. The reaction solution was concentrated under reduced pressure, and the resulting oil was slurried in 20 mL of diethyl ether and filtered. The solid was dried to give the target compound 4-((10S,41S,44S)-10-amino-41-isopropyl-2,2-dimethyl-4,11,39,42-tetraoxo-44-(3-ureopropyl)-3,15,18,21,24,27,30,33,36-nonoxy-5,12,40,43-tetraazapentane-45-amido)benzyl((1S,9S)-9- Ethyl-5-fluoro-9-hydroxy-4-methoxy-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,12H-benzo[de]pyran[3',4':6,7] indo[1,2-b]quinoline-1-yl)((3-fluorobicyclo[1.1.1]pentane-1-yl)methyl)carbamate (245 mg, 0.15 mmol, 100% yield), white solid. It is used directly in the next reaction. LCMS (ESI) m / z: 1606.7 [M+H] + .

[1126] Step 3: Synthesis of 4-((10S,41S,44S)-41-isopropyl-2,2-dimethyl-10-(2-(methanesulfonyl)pyrimidin-5-carbamate)-4,11,39,42-tetraoxo-44-(3-ureopropyl)-3,15,18,21,24,27,30,33,36-nonoxy-5,12,40,43-tetraazapentane Alkyl-45-amino)benzyl((1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methoxy-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,12H-benzopyran[3',4':6,7] indene[1,2-b]quinoline-1-yl)((3-fluorobicyclo[1.1.1]pent-1-yl)methyl)carbamate

[1127] Add N,N,N',N'-tetramethyl-O-(7-azabenzotriazol-1-yl)hexafluorophosphate urea (122 mg, 0.32 mmol, 2.1 equivalents) and N,N-diisopropylethylamine (79 mg, 0.61 mmol, 4.0 equivalents) to a solution of 2-(methylsulfonyl)pyrimidin-5-carboxylic acid (62 mg, 0.3 mmol, 2.0 equivalents) in N,N-dimethylformamide (3 mL). The reaction mixture was stirred for 10 minutes, and then 4-((10S,41S,44S)-10-amino-41-isopropyl-2,2-dimethyl-4,11,39,42-tetraoxo-44-(3-ureopropyl)-3,15,18,21,24,27,30,33,36-nonoxy-5,12,40,43-tetraazapentane-45-amido)benzyl((1S,9S)- 9-Ethyl-5-fluoro-9-hydroxy-4-methoxy-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,12H-benzo[de]pyran[3',4':6,7] indo[1,2-b]quinoline-1-yl)((3-fluorobicyclo[1.1.1]pentane-1-yl)methyl)carbamate (245 mg, 0.15 mmol, 1.0 equivalent). The reaction was stirred at room temperature for 2 hours. The reaction solution was purified by high performance liquid chromatography (acetonitrile, 0.1% formic acid aqueous solution) and lyophilized to obtain the target compound 4-((10S,41S,44S)-41-isopropyl-2,2-dimethyl-10-(2-(methanesulfonyl)pyrimidin-5-carbamate)-4,11,39,42-tetraoxo-44-(3-ureopropyl)-3,15,18,21,24,27,30,33,36-nonoxy-5,12,40,4 3-Tetraazapentane-45-amino)benzyl((1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methoxy-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,12H-benzopyran[3',4':6,7]indo[1,2-b]quinoline-1-yl)((3-fluorobicyclo[1.1.1]pent-1-yl)methyl)carbamate (130 mg, 50% yield), white solid. LCMS (ESI) m / z: 1788.5 [M+H] + .

[1128] Step 4: Synthesis of 4-((3S,34S,37S)-3-(4-aminobutyl)-34-isopropyl-1-(2-(methylsulfonyl)pyrimidin-5-yl)-1,4,32,35-tetraoxo-37-(3-ureopropyl)-8,11,14,17,20,23,26,29-octaoxa-2,5,33,36-tetraazaoctane- 38-Amamido)benzyl((1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methoxy-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,12H-benzopyran[3',4':6,7]-aza[1,2-b]quinoline-1-yl)((3-fluorobicyclo[1.1.1]pent-1-yl)methyl)carbamate

[1129] 4-((10S,41S,44S)-41-isopropyl-2,2-dimethyl-10-(2-(methanesulfonyl)pyrimidin-5-carbamate)-4,11,39,42-tetraoxo-44-(3-ureopropyl)-3,15,18,21,24,27,30,33,36-nonoxy-5,12,40,43-tetraazapentane-45-amino)benzyl((1S,9S)-9-ethyl-5-fluoro) A solution of 9-hydroxy-4-methoxy-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,12H-benzopyran[3',4':6,7] indo[1,2-b]quinoline-1-yl)((3-fluorobicyclo[1.1.1]pent-1-yl)methyl)carbamate (50 mg, 0.03 mmol, 1.00 equivalent) in dichloromethane (1 mL) was reacted with 0.3 mL of trifluoroacetic acid. The reaction mixture was stirred at room temperature for 1 hour. The reaction mixture was concentrated under reduced pressure, slurried with diethyl ether, and filtered. The solid was dried to give the target compound 4-((3S,34S,37S)-3-(4-aminobutyl)-34-isopropyl-1-(2-(methanesulfonyl)pyrimidin-5-yl)-1,4,32,35-tetraoxo-37-(3-ureopropyl)-8,11,14,17,20,23,26,29-octaoxa-2,5,33,36-tetraazaoctane-38-amido) Benzyl ((1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methoxy-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,12H-benzopyran[3',4':6,7]-aza[1,2-b]quinoline-1-yl)((3-fluorobicyclo[1.1.1]pent-1-yl)methyl)carbamate (46 mg, 99% yield), white solid. LCMS (ESI) m / z: 1690.7 [M+H] + .

[1130] Step 5: Synthesis of 4-((38S, 69S, 72S)-69-isopropyl-3,6,9,12,15,18,21,24,27,30-decamethyl-38-(2-(methanesulfonyl)pyrimidin-5-carbamate)-2,5,8,11,14,17,20,23,26,29,32,39,67,70-tetradecyloxy-72-(3-ureopropyl)-43,46,49,52,55,58,61,64-octaoxa-3,6,9,12,1 5,18,21,24,27.30,33,40,68,71-Tetraazatriheptanone-73-amido)benzyl((1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methoxy-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,12H-benzo[de]pyrano[3',4':6,7]indo[1,2-b]quinoline-1-yl)((3-fluorobicyclo[1.1.1]pent-1-yl)methyl)carbamate (A6)

[1131] To 4-((3S,34S,37S)-3-(4-aminobutyl)-34-isopropyl-1-(2-(methylsulfonyl)pyrimidin-5-yl)-1,4,32,35-tetraoxo-37-(3-ureopropyl)-8,11,14,17,20,23,26,29-octaoxa-2,5,33,36-tetraazaoctane-38-amido)benzyl((1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methoxy-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,12H-benzopyran[3',4':6,7] in aza[1,2-b]quinoline-1-yl)((3- To a solution (1 mL) of fluorobicyclo[1.1.1]pent-1-yl)methyl)carbamate (40 mg, 0.02 mmol, 1.00 equivalent) in N,N-dimethylformamide, 2,5-dioxopyrrolidone-1-yl-3,6,9,12,15,18,21,24,27,30-decamethyl-4,7,10,13,16,19,22,22,25,28,31-decaoxo-3,6,9,12,15,18,21,24,27,30-decaazatrioleate (31 mg, 0.03 mmol, 1.5 equivalent) and N,N-diisopropylethylamine (9 mg, 0.07 mmol, 3.0 equivalent) were added. The reaction mixture was stirred at room temperature for 2 hours. The reaction solution was purified by preparative high-performance liquid chromatography (acetonitrile, 0.1% formic acid aqueous solution), and lyophilized to obtain the target compound 4-((38S, 69S, 72S)-69-isopropyl-3,6,9,12,15,18,21,24,27,30-decamethyl-38-(2-(methanesulfonyl)pyrimidin-5-carbamate)-2,5,8,11,14,17,20,23,26,29,32,39,67,70-tetradecyloxy-72-(3-ureopropyl)-43,46,49,52,55,58,61,64-octaoxa-3, 6,9,12,15,18,21,24,27.30,33,40,68,71-Tetraazatriheptanone-73-amido)benzyl((1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methoxy-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,12H-benzo[de]pyrano[3',4':6,7]indo[1,2-b]quinoline-1-yl)((3-fluorobicyclo[1.1.1]pent-1-yl)methyl)carbamate (A6; 20 mg, 35% yield), white solid. LCMS(ESI) m / z: 1222.5 [M / 2+H] + .

[1132] 7. Preparation of A9

[1133] Step 1: Synthesis of N2-((9H-fluorene-9-yl)methoxy)carbonyl)-N6-(tert-butoxycarbonyl)-L-lysine benzyl ester

[1134] N2-((9H-fluorene-9-yl)methoxy)carbonyl)-N6-(tert-butoxycarbonyl)-L-lysine (20 g, 42.7 mmol, 1 equivalent) was dissolved in N,N-dimethylformamide (100 mL), and sodium bicarbonate (18 g, 213 mmol, 5 equivalents) was added. Benzyl bromide (14.6 g, 85.4 mmol, 2 equivalents) was slowly added dropwise to the reaction solution under ice bath conditions. The reaction was stirred at room temperature for 16 hours. The reaction solution was quenched with water (200 mL) and extracted with dichloromethane (200 mL x 2). The combined organic phases were washed with saturated sodium chloride aqueous solution (300 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The crude product was purified by rapid silica gel column chromatography (ethyl acetate: petroleum ether = 0%–50%) to obtain the target compound N2-((9H-fluorene-9-yl)methoxy)carbonyl)-N6-(tert-butoxycarbonyl)-L-lysine benzyl ester (24 g, yield 100%), a white solid.

[1135] Step 2: Synthesis of ((9H-fluorene-9-yl)methoxy)carbonyl)-L-lysine benzyl ester

[1136] N2-((9H-fluorene-9-yl)methoxy)carbonyl)-N6-(tert-butoxycarbonyl)-L-lysine benzyl ester (5 g, 8.95 mmol, 1 equivalent) was dissolved in dichloromethane (25 mL), and trifluoroacetic acid (25 mL) was slowly added. The reaction was stirred at room temperature for 2 hours. The reaction solution was concentrated under reduced pressure to give the target compound ((9H-fluorene-9-yl)methoxy)carbonyl)-L-lysine benzyl ester trifluoroacetate salt (4.5 g, 88% yield), a white solid. The compound was used directly in the next reaction.

[1137] Step 3: Synthesis of benzyl(S)-38-(((9H-fluorene-9-yl)methoxy)carbonyl)amino)-3,6,9,12,15,18,21,24,27,30-decamethyl-2,5,8,11,14,17,20,23,26,29,32-undecoxy-3,6,9,12,15,18,21,24,24,27,30,33-undecaza-nonanetriane-39-ester

[1138] To a solution of 3,6,9,12,15,18,21,24,27,30-decamethonium-4,7,10,13,16,19,22,25,28,31-decaoxy-3,6,9,12,25,18,21,24,24,27,30-decaazatricarbonenoic acid (538 mg, 0.7 mmol, 1.0 equivalent) in N,N-dimethylformamide (6 mL), HATU (278 mg, 0.73 mmol, 1.05 equivalent), ((9H-fluorene-9-yl)methoxy)carbonyl)-L-lysine benzyl ester trifluoroacetate (400 mg, 0.7 mmol, 1.0 equivalent), and N,N-diisopropylethylamine (180 mg, 1.4 mmol, 2.0 equivalent) were added. The reaction was stirred at room temperature for 2 hours. The reaction solution was purified by high performance liquid chromatography (acetonitrile, 0.1% formic acid aqueous solution), lyophilized, and the target compound benzyl(S)-38-(((9H-fluorene-9-yl)methoxy)carbonyl)amino)-3,6,9,12,15,18,21,24,27,30-decamethyl-2,5,8,11,14,17,20,23,26,29,32-undecoxy-3,6,9,12,15,18,21,24,24,27,30,33-undecazatriane-39-ester (680 mg, 80.3% yield) was obtained as a white solid.

[1139] LCMS(ESI) m / z: 1211.7 [M+H] + .

[1140] Step 4: Synthesis of (S)-38-((((9H-fluorene-9-yl)methoxy)carbonyl)amino)-3,6,9,12,15,18,21,24,27,30-decamethyl-2,5,8,11,14,17,20,23,26,29,32-undecoxy-3,6,9,12,15,18,21,24,27,30,33-undecazatriane-39-acid

[1141] To a mixture of tetrahydrofuran (6 mL) and methanol (6 mL) of benzyl(S)-38-(((9H-fluorene-9-yl)methoxy)carbonyl)amino)-3,6,9,12,15,18,21,24,27,30-decamethyl-2,5,8,11,14,17,20,23,26,29,32-undecoxy-3,6,9,12,15,18,21,24,24,27,30,33-undecazavinonoritriane-39-ester (680 mg, 0.56 mmol, 1.0 equivalent), 10% palladium on carbon (70 mg, 10% w / w) was added. The reaction was stirred at room temperature under hydrogen pressure for 24 hours. The reaction solution was filtered through diatomaceous earth, the filter cake was washed with methanol, and the filtrate was concentrated under reduced pressure to give the target compound (S)-38-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3,6,9,12,15,18,21,24,27,30-decamethyl-2,5,8,11,14,17,20,23,26,29,32-undecoxy-3,6,9,12,15,18,21,24,27,30,33-undecazatriane-39-acid (620 mg, 98.5% yield), a pale yellow solid. The crude product was used directly in the next reaction step.

[1142] LCMS(ESI) m / z: 1121.6 [M+H] + .

[1143] Step 5: Synthesis of 4-((38S, 41S, 44S)-38-(((9H-fluorene-9-yl)methoxy)carbonyl)amino)-41-isopropyl-3,6,9,12,15,18,21,24,30,44-undecyldimethyl-2,5,8,11,14,17,20,23,29,32,39,42-tetraceneoxy-3,6,9,12,15,18,21,24,27,30, 33,40,43-Tetrazazapentacarbamate-45-amido)benzyl((1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxy-2,3,9,10,13,15-hexahydro-1H,12H-benzo[de]pyrano[3',4':6,7]indo[1,2-b]quinoline-1-yl)((3-fluorobicyclo[1.1.1]pent-1-yl)methyl)carbamate

[1144] Add HATU (67 mg, 0.17 mmol, 1.5 equivalent) and 4-dimethylformamide (2 mL) to a solution of (S)-38-((((9H-fluorene-9-yl)methoxy)carbonyl)amino)-3,6,9,12,15,18,21,24,27,30-decamethyl-2,5,8,11,14,17,20,23,26,29,32-undecoxy-3,6,9,12,15,18,21,24,27,30,33-undecazapyronatriane-39-acid (131 mg, 0.12 mmol, 1.0 equivalent) and 4- (S)-2-((S)-2-amino-3-methylbutamido)propamido)benzyl((1R,9R)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,12H-benzo[de]pyrano[3',4':6,7]indo[1,2-b]quinoline-1-yl)((3-fluorobicyclo[1.1.1]pent-1-yl)methyl)carbamate (100 mg, 0.12 mmol, 1.0 equivalent) and N,N-diisopropylethylamine (45 mg, 0.35 mmol, 3.0 equivalent). The reaction was stirred at room temperature for 2 hours. The reaction solution was purified by high-performance liquid chromatography (acetonitrile, 0.1% trifluoroacetic acid aqueous solution), and lyophilized to obtain the target compound 4-((38S,41S,44S)-38-(((9H-fluorene-9-yl)methoxy)carbonyl)amino)-41-isopropyl-3,6,9,12,15,18,21,24,30,44-undecanodimethyl-2,5,8,11,14,17,20,23,29,32,39,42-tetraceneoxy-3,6,9,12,15,18,21,24 27,30,33,40,43-Tetrazazapentacarbamate-45-amido)benzyl((1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxy-2,3,9,10,13,15-hexahydro-1H,12H-benzo[de]pyrano[3',4':6,7]indo[1,2-b]quinoline-1-yl)((3-fluorobicyclo[1.1.1]pent-1-yl)methyl)carbamate (85 mg, 37.1% yield), white solid. LCMS(ESI) m / z: 1957.2 [M+H] + .

[1145] Step 6: Synthesis of 4-((38S, 41S, 44S)-38-amino-41-isopropyl-3,6,9,12,15,18,21,24,27,30,44-undecyl-2,5,8,11,14,17,20,23,26,29,32,39,42-tetrazoloxy-3,6,9,12,15,18,21,24,27,30,33,40- Tridecapentane-45-amido)benzyl((1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,12H-benzo[de]pyrano[3',4':6,7]indo[1,2-b]]quinoline-1-yl)((3-fluorobicyclo[1.1.1]pent-1-yl)methyl)carbamate

[1146] 4-((38S, 41S, 44S)-38-(((9H-fluorene-9-yl)methoxy)carbonyl)amino)-41-isopropyl-3,6,9,12,15,18,21,24,30,44-undecanodimethyl-2,5,8,11,14,17,20,23,29,32,39,42-tetrazooxy-3,6,9,12,15,18,21,24,27,30,33,40,43-tetrazolapentacartetraenoic acid-45-amido)benzyl((1 In a solution of N,N-dimethylformamide (0.5 mL), diethylamine (0.05 mL) was added to (S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxy-2,3,9,10,13,15-hexahydro-1H,12H-benzo[de]pyrano[3',4':6,7] indo[1,2-b]quinoline-1-yl)((3-fluorobicyclo[1.1.1]pent-1-yl)methyl)carbamate (30 mg, 0.015 mol, 1.0 equivalent). The reaction was stirred at room temperature for 2 hours. The reaction solution was concentrated under reduced pressure to remove the solvent. The crude product was slurried with 10 mL of diethyl ether, filtered as a solid, and dried to obtain the target compound 4-((38S,41S,44S)-38-amino-41-isopropyl-3,6,9,12,15,18,21,24,27,30,44-undecyl-2,5,8,11,14,17,20,23,26,29,32,39,42-tetrazoloxy-3,6,9,12,15,18,21,24,27,30. ,33,40-Tetrazopentane-45-amido)benzyl((1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,12H-benzo[de]pyrano[3',4':6,7]indo[1,2-b]]quinoline-1-yl)((3-fluorobicyclo[1.1.1]pent-1-yl)methyl)carbamate (26.0 mg, 98% yield), white solid. The crude product was used directly in the next reaction. LCMS (ESI) m / z: 1735.1 [M+H] + .

[1147] Step 7: Synthesis of 4-((38S, 41S, 44S)-38-(1-(9H-fluorene-9-yl)-3-oxo-2,7,10,13,16,19,22,22,25,28-nonoxy-4-azatritane-31-amido)-41-isopropyl-3,6,9,12,15,18,27,30,44-undecyl-2,5,8,11,14,17,20,23,26,29,32,39,42-tetrazopentoxy-3,6,9,12,15,18,21,24,27,30,33,40,43-tetrazopentane-45-amido)benzyl((1S, 9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10 1,3-Dioxo-2,3,9,10,13,15-hexahydro-1H,12H-benzo[de]pyrano[3',4':6,7]indo[1,2-b]quinoline-1-yl)((3-fluorobicyclo[1.1.1]pent-1-yl)methyl)carbamate

[1148] To a solution of 1-(9H-fluorene-9-yl)-3-oxo-2,7,10,13,16,19,22,22,25-28-nonoxy-4-azatriacontriacontria-31-acid (10 mg, 0.15 mmol, 1.0 equivalent) in N,N-dimethylformamide (0.5 mL), HATU (8.5 mg, 0.02 mmol, 1.5 equivalent), 1-(9H-fluorene-9-yl)-3-oxo-2,7,10,13,16,19,22,22,25-28-nonoxy-4-azatriacontriacontria-31-acid (26 mg, 0.15 mmol, 1.0 equivalent), and N,N-diisopropylethylamine (6 mg, 0.05 mmol, 3.0 equivalent) were added sequentially. The reaction was stirred at room temperature for 2 hours. The reaction solution was purified by high-performance liquid chromatography (acetonitrile, 0.1% trifluoroacetic acid aqueous solution), and lyophilized to obtain the target compound 4-((38S, 41S, 44S)-38-(1-(9H-fluorene-9-yl)-3-oxo-2,7,10,13,16,19,22,22,25,28-nonoxy-4-azatriacontane-31-amido)-41-isopropyl-3,6,9,12,1 5,18,27,30,44-Undecyl-2,5,8,11,14,17,20,23,26,29,32,39,42-Trigetaxoxy-3,6,9,12,15,18,21,24,27,30,33,40,43-Trigazapentadecan-45-amido)benzyl((1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10 1,3-Dioxo-2,3,9,10,13,15-hexahydro-1H,12H-benzo[de]pyrano[3',4':6,7]indo[1,2-b]quinoline-1-yl)((3-fluorobicyclo[1.1.1]pent-1-yl)methyl)carbamate (17 mg, 50% yield), white solid. LCMS (ESI) m / z: 1190.8 [M / 2+H] + .

[1149] Step 8: Synthesis of 4-((38S, 41S, 44S)-38-(1-amino-3,6,9,12,15,18,21,24-octaoxetane-27-amido)-41-isopropyl-3,6,9,12,15,18,21,21,24,27,30,44-undecylmethyl-2,5,8,11,14,17,20,23,26,29,32,39,42-tetracooxy-3,6,9,12, 25,18,24,27,30,33,40-Tetrazopentane-45-amido)benzyl((1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxy-2,3,9,10,13,15-hexahydro-1H,12Hbenzo[de]pyrano[3',4':6,7]indo[1,2-b]quinoline-1-yl)((3-fluorobicyclo[1.1.1]pent-1-yl)methyl)carbamate

[1150] 4-((38S,41S,44S)-38-(1-(9H-fluoren-9-yl)-3-oxo-2,7,10,13,16,19,22,22,25,28-nonoxy-4-azatriatracan-31-amido)-41-isopropyl-3,6,9,12,15,18,27,30,44-undecyl-2,5,8,11,14,17,20,23,26,29,32,39,42-tetrazoladecyloxy-3,6,9,12,15,18,21,24,27,30,33,40,43-tetrazoladecyl-45-amido)benzyl((1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10 Diethylamine (0.05 mL) was added to a solution of 1,3-dioxo-2,3,9,10,13,15-hexahydro-1H,12H-benzo[de]pyrano[3',4':6,7] indo[1,2-b]quinoline-1-yl)((3-fluorobicyclo[1.1.1]pent-1-yl)methyl)carbamate (17 mg, 0.007 mol, 1.0 equivalent) in N,N-dimethylformamide (0.5 mL). The reaction was stirred at room temperature for 1 hour. The reaction solution was concentrated under reduced pressure to remove the solvent. The crude product was slurried with 10 mL of diethyl ether, filtered as a solid, and dried to obtain the target compound 4-((38S, 41S, 44S)-38-(1-amino-3,6,9,12,15,18,21,24-octaoxetane-27-amido)-41-isopropyl-3,6,9,12,15,18,21,21,24,27,30,44-undecylmethyl-2,5,8,11,14,17,20,23,26,29,32,39,42-tetracooxy-3 6,9,12,25,18,24,27,30,33,40-Tetrazopentane-45-amido)benzyl((1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxy-2,3,9,10,13,15-hexahydro-1H,12Hbenzo[de]pyrano[3',4':6,7]indo[1,2-b]quinoline-1-yl)((3-fluorobicyclo[1.1.1]pent-1-yl)methyl)carbamate (13.4 mg, 86% yield), white solid. LCMS(ESI) m / z: 1179.4 [M / 2+H] + .

[1151] Step 9: Synthesize compound 11

[1152] To (S)-38-((((9H-fluorene-9-yl)methoxy)carbonyl)amino)-3,6,9,12,15,18,21,24,27,30-decamethyl-2,5,8,11,14,17,20,23,26,29,32-undecoxy-3,6,9,12,15,18,21,24,27.30,33-undecaza-nonanetriacon ... Add HATU (3.5 mg, 0.009 mmol, 1.5 equivalent) to a solution of N,N-dimethylformamide (0.5 mL) at a concentration of 0.006 mmol (1.0 equivalent). Also add 4-((38S, 41S, 44S)-38-(1-amino-3,6,9,12,15,18,21,24-octaoxetane-27-amido)-41-isopropyl-3,6,9,12,15,18,21,2 ... 1,24,27,30,44-Undecylmethyl-2,5,8,11,14,17,20,23,26,29,32,39,42-Tetrazolane-3,6,9,12,25,18,24,27,30,33,40-Tetrazolane-45-amido)benzyl((1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxy-2,3,9, 10,13,15-hexahydro-1H,12H-benzo[de]pyrano[3',4':6,7]indo[1,2-b]quinoline-1-yl)((3-fluorobicyclo[1.1.1]pent-1-yl)methyl)carbamate (13.4 mg, 0.006 mmol, 1.0 equivalent) and N,N-diisopropylethylamine (2.4 mg, 0.02 mmol, 3.0 equivalent) were reacted at room temperature with stirring for 2 hours. The reaction mixture was purified by high performance liquid chromatography (acetonitrile, 0.1% formic acid aqueous solution), lyophilized, to give target compound 11 (10 mg, 50% yield), a white solid. LCMS (ESI) m / z: 1631.3 [M / 2+H] + .

[1153] Step 10: Synthesize compound 12

[1154] Diethylamine (0.05 mL) was added to a solution of compound 7 (10 mg, 0.003 mol, 1.0 equivalent) in N,N-dimethylformamide (0.5 mL). The reaction mixture was stirred at room temperature for 2 hours. The solvent was removed by concentration under reduced pressure. The crude product was slurried in diethyl ether (10 mL), filtered as a solid, and dried to give compound 12 (9.0 mg, 96% yield) as a white solid. LCMS (ESI) m / z: 1152.2 [M / 2+H] + .

[1155] Step 11: Synthesize A9

[1156] To a solution of 2-(methylsulfonyl)pyrimidine-5-carboxylic acid (1 mg, 0.004 mol, 1.5 equivalents) in N,N-dimethylformamide (0.5 mL), ethyl 2-oxime cyanoacetate (1 mg, 0.004 mol, 1.5 equivalents), compound 8 (9.0 mg, 0.003 mol, 1.0 equivalents), and N,N'-diisopropylcarbodiimide (0.6 mg, 0.004 mol, 1.5 equivalents) were added. The reaction mixture was stirred at room temperature for 1 hour. The reaction solution was purified by preparative high-performance liquid chromatography (acetonitrile, 0.1% formic acid aqueous solution), lyophilized, and the target compound A9 (2.1 mg, 21% yield) was given as a white solid.

[1157] LCMS(ESI) m / z: 1612.4 [M / 2+H] + .

[1158] 1 H NMR(400MHz,DMSO-d6)δ9.41(s,1H),8.15(s,2H),8.03(s,1H),7.86–7.77(m,2H),7.66–7.62(m,2H),7.46(s,1H),7 .31(s,1H),6.53(d,J=6.4Hz,1H),5.75(s,1H),5.45(s,2H),5.11(s,2H),5.03(d,J=18.8Hz,2H),4.33–4.20(m,25H) ,4.08–3.87(m,32H),3.59(s,53H),3.04(s,6H),2.98–2.80(m,30H),2.79–2.67(m,20H),2.36(d,J=20.4Hz,6H),2.0 0(d,J=5.2Hz,3H),1.88(s,3H),1.84(s,2H),1.81–1.74(m,2H),1.66(s,2H),1.54–1.22(m,11H),0.90–0.83(m,6H).

[1159] 8. Preparation of A10

[1160] Step 1: Synthesis of 1-(9H-fluorene-9-yl)-3-oxo-2,7,10,13,16,19,22,25,28-nonoxy-4-azatriheptane-31-acid benzyl ester

[1161] 1-(9H-fluorene-9-yl)-3-oxo-2,7,10,13,16,19,22,22,25-28-nonoxy-4-azatriacontane-31-acid (0.5 g, 0.753 mmol, 1 equivalent) was dissolved in N,N-dimethylformamide (10 mL), and sodium bicarbonate (316 mg, 3.77 mmol, 5 equivalents) was added. Benzyl bromide (258 mg, 1.51 mmol, 2 equivalents) was slowly added dropwise to the reaction mixture under ice bath conditions. The reaction mixture was stirred at room temperature for 16 hours. The reaction mixture was poured into water (20 mL) and extracted with dichloromethane (20 mL x 2). The combined organic phases were washed with saturated sodium chloride aqueous solution (30 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The crude product was purified by rapid silica gel column chromatography (petroleum ether: ethyl acetate = 3:1) to give the target compound 1-(9H-fluorene-9-yl)-3-oxo-2,7,10,13,16,19,22,25,28-nonoxy-4-azatriheptane-31-acid benzyl ester (400 mg, yield 70.4%), a white solid. LCMS (ESI) m / z: 754.3 [M+H] + .

[1162] Step 2: Synthesis of 1-amino-3,6,9,12,15,18,21,24-octaoxetane-27-benzyl ester

[1163] 1-(9H-fluorene-9-yl)-3-oxo-2,7,10,13,16,19,22,25,28-nonoxy-4-azatriheptane-31-acid benzyl ester (400 mg, 0.568 mmol, 1.00 equivalent) was dissolved in N,N-dimethylformamide (8 mL), and diethylamine (0.8 mL) was added. The reaction was stirred at room temperature for 2 hours. The reaction solution was concentrated under reduced pressure to give the target compound 1-amino-3,6,9,12,15,18,21,24-octaoxetane-27-acid benzyl ester (280 mg, crude product), a white oil. The crude product was used directly in the next reaction step.

[1164] LCMS(ESI) m / z: 532.7 [M+H] + .

[1165] Step 3: Synthesis of benzyl 3,6,9,12,15,18,21,24,27,30-decamethyl-2,5,8,11,14,17,20,23,26,29,32,32-undecoxy-36,39,42,45,48,51,54,57-octaoxa-3,6,9,12,24,27,30,33-undecazahexadecane-60-carboxylic acid ester

[1166] 1-Amino-3,6,9,12,15,18,21,24-octaoxetane-27-acid benzyl ester (280 mg, 0.527 mmol, 1.0 equivalent) was dissolved in N,N-dimethylformamide (2 mL), and then 3,6,9,12,15,18,21,24,27,30-decamethyl-4,7,10,13,16,19,22,25,28,31-decaoxy-3,6,9,12,2...

Claims

A compound or a pharmaceutically acceptable salt, ester, stereoisomer, polymorph, solvate, N-oxide, isotopically labeled compound, metabolite, or prodrug thereof, wherein the compound has the structure of formula (I): in: Q is a functional group that can couple with cysteine, lysine, non-natural amino acids, or glycosyl groups of antibody molecules. D represents the drug unit; B1, B2, and B3 are each independently selected from bonded or branched segments; C1 is an independent spacer group; S2, S3, S4, and S5 are each independently a hydrophilic group or a group selected from various hydrophilic groups; F1 is selected from the direct bond or the group consisting of: optionally substituted alkylene, optionally substituted polyethylene glycol, optionally substituted alkenyl, optionally substituted ynylene, optionally substituted alicyclic, optionally substituted alicyclic, optionally substituted aryl, and optionally substituted heteroaryl; when substituted, the substituent is selected from halogen, hydroxyl, amino, carboxyl, carbonyl, sulfonic acid, sulfone, phosphate, and alkoxy. L1 is selected from either a direct bond or an extended unit; the condition is that F1 and L1 are not both direct bonds at the same time. a, b, c, and d are each independently 0, 1, 2, or 3, provided that a, b, c, and d are not all 0 at the same time; The functional groups conjugated to the cysteine, lysine, non-natural amino acids, or glycosyl groups of the antibody molecule are selected from those with optional substitutions. The drug structural unit is selected from the compounds shown in formula (A): in: X is CH2 or S; Ring A is independently selected from C 3-6 cycloalkyl or 3-6 membered heterocycloalkyl; R 1 and R 2 Each is independently selected from halogens, -NH2, -OH, and C. 1-3 Alkyl or C 1-3 Alkoxy; Or, R 1 R 2 Composition with adjacent carbon R is independently selected from halogen, hydroxyl, amino, or thiol groups; n is selected from 0, 1, 2, or 3; m is selected from 1, 2, 3, or 4; "---"for Or a mixture containing it. The compound according to claim 1, characterized in that, The compound of formula (I) has any of the following structures: (1) The compound has the structure of formula (Ia): in: Q is the functional group that can couple with cysteine, lysine, non-natural amino acids or glycosyl groups of antibody molecules. D represents the drug unit; C1 is the spacer group independently; S3 is independently the hydrophilic group or selected from the group consisting of each of the hydrophilic groups; F1 is selected from the direct bond or the group consisting of: optionally substituted alkylene, optionally substituted polyethylene glycol, optionally substituted alkenyl, optionally substituted ynylene, optionally substituted alicyclic, optionally substituted alicyclic, optionally substituted aryl, and optionally substituted heteroaryl; when substituted, the substituent is selected from halogen, hydroxyl, amino, carboxyl, carbonyl, sulfonic acid, sulfone, phosphate, and alkoxy. L1 is selected from either a direct key or the extended unit; the condition is that F1 and L1 are not both direct keys at the same time. a can be 1, 2, or 3 independently; Preferably, L1 is a direct bond; and / or a is 1; (2) The compound has the structure of formula (Ib): in: Q is the functional group that can couple with cysteine, lysine, non-natural amino acids or glycosyl groups of antibody molecules. D represents the drug unit; B1 is selected from the branched segment; C1 is either a direct bond or the spacer group; S2 is independently the hydrophilic group or selected from the group consisting of each of the hydrophilic groups; F1 is selected from the direct bond or the group consisting of: optionally substituted alkylene, optionally substituted polyethylene glycol, optionally substituted alkenyl, optionally substituted ynylene, optionally substituted alicyclic, optionally substituted alicyclic, optionally substituted aryl, and optionally substituted heteroaryl; when substituted, the substituent is selected from halogen, hydroxyl, amino, carboxyl, carbonyl, sulfonic acid, sulfone, phosphate, and alkoxy. L1 is the extension unit; b can be 1, 2, or 3 independently; Preferably, b is 1; (3) The compound has the structure of formula (Ic): in: Q is the functional group that can couple with cysteine, lysine, non-natural amino acids or glycosyl groups of antibody molecules. D represents the drug unit; B1 and B2 are independently selected from the branched segments; C1 is the spacer group independently; S3, S4 and S2 are independently the hydrophilic groups or selected from the group consisting of the hydrophilic groups; F1 is selected from the direct bond or the group consisting of: optionally substituted alkylene, optionally substituted polyethylene glycol, optionally substituted alkenyl, optionally substituted ynylene, optionally substituted alicyclic, optionally substituted alicyclic, optionally substituted aryl, and optionally substituted heteroaryl; when substituted, the substituent is selected from halogen, hydroxyl, amino, carboxyl, carbonyl, sulfonic acid, sulfone, phosphate, and alkoxy. L1 is selected from either a direct key or the extended unit; the condition is that F1 and L1 are not both direct keys at the same time. b and c can each be 1, 2, or 3 independently; a can be 0, 1, 2, or 3 independently; Preferably, wherein: F1 and L1 are not direct keys; and / or a is 0, or a is 1; and / or b is 1; and / or c is 1; (4) The compound has the structure of formula (Id): in: Q is the functional group that can couple with cysteine, lysine, non-natural amino acids or glycosyl groups of antibody molecules. D represents the drug unit; B2 is independently selected from the branched segment; C1 is the spacer group independently; S3 and S4 are independently the hydrophilic groups or selected from the group consisting of the hydrophilic groups; F1 is selected from the direct bond or the group consisting of: optionally substituted alkylene, optionally substituted polyethylene glycol, optionally substituted alkenyl, optionally substituted ynylene, optionally substituted alicyclic, optionally substituted alicyclic, optionally substituted aryl, and optionally substituted heteroaryl; when substituted, the substituent is selected from halogen, hydroxyl, amino, carboxyl, carbonyl, sulfonic acid, sulfone, phosphate, and alkoxy. L1 is selected from either a direct key or the extended unit; the condition is that F1 and L1 are not both direct keys at the same time. c can be 1, 2, or 3 independently; a can be 0, 1, 2, or 3 independently; Preferably, wherein: F1 and L1 are not direct keys; and / or a is 0, or a is 1; and / or c is 1; (5) The compound has the structure of formula (Ie): in: Q is the functional group that can couple with cysteine, lysine, non-natural amino acids or glycosyl groups of antibody molecules. D represents the drug unit; B3 is independently selected from the branched segment; C1 is the spacer group independently; S3 and S5 are independently the hydrophilic groups or selected from the group consisting of the hydrophilic groups; F1 is selected from the direct bond or the group consisting of: optionally substituted alkylene, optionally substituted polyethylene glycol, optionally substituted alkenyl, optionally substituted ynylene, optionally substituted alicyclic, optionally substituted alicyclic, optionally substituted aryl, and optionally substituted heteroaryl; when substituted, the substituent is selected from halogen, hydroxyl, amino, carboxyl, carbonyl, sulfonic acid, sulfone, phosphate, and alkoxy. L1 is selected from either a direct key or the extended unit; the condition is that F1 and L1 are not both direct keys at the same time. d can be 1, 2, or 3 independently; a can be 0, 1, 2, or 3 independently; Preferably, wherein: F1 and L1 are not direct keys; and / or a is 0, or a is 1; and / or d is 1; (6) Wherein, in the compound of formula (I), Q is the functional group that can couple with cysteine, lysine, non-natural amino acids or glycosyl groups of antibody molecules. D represents the drug unit; B1 is selected from the branched segment; C1 is either a direct bond or the spacer group; S2 and S3 are each independently the hydrophilic group or selected from the group consisting of each of the hydrophilic groups; F1 is selected from the direct bond or the group consisting of: optionally substituted alkylene, optionally substituted polyethylene glycol, optionally substituted alkenyl, optionally substituted ynylene, optionally substituted alicyclic, optionally substituted alicyclic, optionally substituted aryl, and optionally substituted heteroaryl; when substituted, the substituent is selected from halogen, hydroxyl, amino, carboxyl, carbonyl, sulfonic acid, sulfone, phosphate, and alkoxy. L1 is selected from either a direct key or the extended unit; the condition is that F1 and L1 are not both direct keys at the same time. a and b are independently 1, 2, or 3; Preferably, the compound has the structure of formula (If): The compound as claimed in claim 1 or 2, characterized in that, The compound contains any of the following characteristics: (1) B1, B2 and B3, when they exist, are each keys; (2) B1, B2, and B3, when they exist, are each... in: Connection point 3 This indicates that B1, B2, or B3 are connected to S2, S4, or S5 respectively; R 8 Selected from H or R 8 It is a hydrophilic group, and R 8 The hydrophilic groups in S2, S4 or S5 are each selected from: optionally substituted polysarcosine residues, polyglycerols, polyols, glycosyl groups, cyclodextrins, substituted glycol fragments, substituted glycosylated polyethylene glycol fragments, substituted glycosylated polyglycerols, substituted cyclodextrin polyethylene glycols or combinations thereof. Preferably, wherein: The optionally substituted polysarcosine residues are Wherein n2 is an integer between 4 and 20, 4 and 16, or 8 and 12, preferably 10; R0 is selected from C1-C6 alkyl, C1-C6 cycloalkyl, and C1-C6 alkoxy, preferably methyl; preferably, the optionally substituted polysarcosine residue is And / or, the substituted glycosylated polyglycerol fragment is Where n4 is an integer between 4 and 12, or between 4 and 10; And / or, the substituted polyethylene glycol fragment is Where n5 is an integer between 4 and 24, between 7 and 20, or between 8 and 18, preferably, the substituted polyethylene glycol fragment is... And / or, the substituted glycosylated polyethylene glycol fragment is Where n3 is an integer between 4 and 18, or between 4 and 12; preferably, the substituted glycosylated polyethylene glycol fragment is And / or, the hydrophilic group is selected from the group consisting of optionally substituted polyethylene glycol fragments and substituted polysarcosine fragments, preferably. Wherein n7 is an integer between 4 and 20, 4 and 16, or 8 and 12, preferably 10; R0 is selected from C1-C6 alkyl, C1-C6 cycloalkyl, and C1-C6 alkoxy, preferably methyl; n5 is an integer between 4 and 24, 7 and 20, or 8 and 18; more preferably, the hydrophilic group is: And / or, the polyol is Preferred And / or, the glycosyl group is More preferably, B1, B2, or B, when present, -B1-[S2] b -B2-[S4] c 、or -B3-[S2] a Each part is independently selected from: (3) L1 is an optional substituted amino acid when it is present; Preferably, the optionally substituted amino acid is selected from: phenylalanine, isoleucine, leucine, tryptophan, valine, methionine, tyrosine, alanine, threonine, histidine, serine, glutamine, arginine, lysine, asparagine, glutamic acid, proline, citrulline, aspartic acid, and glycine, preferably valine, more preferably valine. Further improvements (4) L1 is an optional substituted polypeptide residue when it is present; Preferably, L1, when present, independently comprises polypeptide residues consisting of optionally substituted amino acids selected from the group consisting of: phenylalanine, isoleucine, leucine, tryptophan, valine, methionine, tyrosine, alanine, threonine, histidine, serine, glutamine, arginine, lysine, asparagine, glutamic acid, proline, citrulline, aspartic acid, and glycine. More preferably, L1, when present, independently comprises optional substituted polypeptide residues consisting of amino acids selected from the group consisting of glycine, phenylalanine, valine, alanine, arginine, citrulline, aspartic acid, asparagine, and lysine. More preferably, L1, when present, independently comprises optionally substituted polypeptide residues selected from the group consisting of: phenylalanine-lysine (Phe-Lys), valine-alanine (Val-Ala), valine-citrulline (Val-Cit), glutamic acid-valine-alanine (Glu-Val-Ala), glutamic acid-valine-citrulline (Glu-Val-Cit), valine-lysine (Val-Lys), alanine-alanine (Ala-Ala), alanine-alanine-alanine (Ala-Ala-Ala), alanine-alanine-asparagine (Ala-Ala-Asn), alanine-leucine (Ala-Leu), leucine-leucine (Leu-Leu), phenylalanine-arginine (Phe-Arg), and phenylalanine-lysine (Phe-Lys). Glycine-glycine-phenylalanine-glycine (Gly-Gly-Phe-Gly), glycine-proline (Gly-Pro); More preferably, L1, when present, is independently phenylalanine-lysine (Phe-Lys), valine-alanine (Val-Ala), valine-citrulline (Val-Cit), alanine-alanine (Ala-Ala), and glycine-glycine-phenylalanine-glycine (Gly-Gly-Phe-Gly). More preferably, L1, when present, is independently valine-alanine (Val-Ala), valine-citrulline (Val-Cit), or alanine-alanine (Ala-Ala), preferably. More (5) Each C1 is independent as follows: Preferred More Where: Connection point 1 Connect to B3 or L1, and connect point 2. Connected to the drug unit D; And / or, when a is present and not zero, each S3 is independently the glycosyl or cyclodextrin, preferably the glycosyl, more preferably the glycosyl. Further improvements Preferably, -C1-[S3] a Part of (6) When F1 exists, each is an independent direct bond; (7) F1, when present, is independently selected from direct bonds or optionally substituted polyethylene glycol groups; Preferably, the optionally substituted polyethylene glycol group is Where n6 is an integer between 1 and 18, between 1 and 12, or between 1 and 10, preferably n6 is 1, 3 or 7; More preferably, F1 exists independently as Where n6 is 1, 3, or 7, or F1 exists independently as Where n6 is 1, 3, or 7; (8) The C in the drug unit D 3~6 The cycloalkyl group can be monocyclic, spirocyclic, fused, or bridged; preferably C10. 3~6 cycloalkyl groups are selected from C 3~6 Monocyclic cycloalkyl or C 5~6 Bridged cycloalkyl; Preferably, the C 3~6 The cycloalkyl group is selected from cyclopropane, cyclobutane, cyclopentane, cyclohexane, Preferred materials include cyclopropane, cyclobutane, cyclohexane, or... And / or, the 3-6 membered heterocyclic alkyl group in the pharmaceutical unit D may be ethylene oxide, aziridinyl, aziridine, oxadiazinyl, tetrahydrofuranyl, dioxadiazinyl, pyrrolidone, imidazoalkyl, pyrazolyl, pyrrolinyl, tetrahydropyranyl, piperidinyl, morpholinyl, dithiaalkyl, thiomorpholinyl, piperazine, or trithiaalkyl; (9) The R in the drug unit D 1 Selected from halogens, -NH2, -OH, C 1-3 Alkyl or C 1-3 Alkoxy; Preferably, the R in the drug unit D 1 The components are selected from F, Cl, Br, I, -NH2, -OH, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, or propoxy, preferably methyl, methoxy, Cl, -OH, or -NH2, and more preferably methyl or methoxy. (10) The R in the drug unit D 2 Selected from halogens, -NH2, -OH, C 1-3 Alkyl or C 1-3 Alkoxy; Preferably, the R in the drug unit D 2 Selected from F, Cl, Br, I, -NH2, -OH, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, or propoxy, more preferably F; (11) The R in the drug unit D is selected from F, Cl, Br or I, preferably F; (12) The n in the drug unit D is selected from 1 or 2, preferably 1; (13) The m in the drug unit D is selected from 1 or 2, preferably 1. The compound according to any one of claims 1-3, characterized in that, The compounds of formula (A) are selected from those represented by formula (A-1): in: Ring A can be cyclopropane, cyclobutane, cyclopentane, or cyclohexane. The R 2 F is preferred; The R 1 Preferably methyl or methoxy; Preferably, the compound of formula (A) is a compound of formula (A-1-1): in: R 1 Selected from methyl, Cl, -OH or -NH2, methoxy; R 2 selected from F; Or, R 1 R 2 Composition with adjacent carbon R is selected from F; and n is selected from 1; Preferably, it is a compound of formula (AA) Alternatively, the compound of formula (A) is a compound of formula (A-1-2): in: R 1 Selected from methyl, Cl, -OH or -NH2, methoxy; R 2 Selected from F; Or, R 1 R 2 Composition with adjacent carbon R is selected from F; and n is selected from 1 Alternatively, the compound of formula (A) is a compound of formula (A-1-3): in: R 1 Selected from methyl, Cl, -OH or -NH2, methoxy; R 2 Selected from F; Or, R 1 R 2 Composition with adjacent carbon R is selected from F; and n is selected from 1; Alternatively, the compound of formula (A) is a compound of formula (A-1-4): in: R 1 Selected from methyl, Cl, -OH or -NH2, methoxy; R 2 Selected from F; and n is selected from 0. The compound according to any one of claims 1-4, characterized in that, The compounds of formula (A) are selected from the following structures: The compound according to any one of claims 1-5, characterized in that, The compound is selected from compounds of formulas A1-A18: A linker or a pharmaceutically acceptable salt, ester, stereoisomer, polymorph, solvate, N-oxide, isotopically labeled compound, metabolite, or prodrug thereof, wherein said compound has the structure of formula (II): in: Q1 is a functional group that can couple with cysteine, lysine, non-natural amino acids or glycosyl groups of antibody molecules. D represents the drug unit; B1, B2, and B3 are independently selected from bonded or branched segments; C1 is an independent spacer group; S2, S3, S4 and S5 are each independently a hydrophilic group or selected from the group consisting of each of the aforementioned hydrophilic groups; F1 is selected from the direct bond or the group consisting of: optionally substituted alkylene, optionally substituted polyethylene glycol, optionally substituted alkenyl, optionally substituted ynylene, optionally substituted alicyclic, optionally substituted alicyclic, optionally substituted aryl, and optionally substituted heteroaryl; when substituted, the substituent is selected from halogen, hydroxyl, amino, carboxyl, carbonyl, sulfonic acid, sulfone, phosphate, and alkoxy. L1 is selected from either a direct bond or an extended unit; the condition is that F1 and L1 are not both direct bonds at the same time. a, b, c, and d are each independently 0, 1, 2, or 3, provided that a, b, c, and d are not all 0 at the same time; The functional groups conjugated to the cysteine, lysine, non-natural amino acids, or glycosyl groups of the antibody molecule are selected from those with optional substitutions. The drug structural unit is selected from the compounds shown in formula (A): in: X is CH2 or S; Ring A is independently selected from C 3-6 cycloalkyl or 3-6 membered heterocycloalkyl; R 1 and R 2 Each is independently selected from halogens, -NH2, -OH, and C. 1-3 Alkyl or C 1-3 Alkoxy; Or, R 1 R 2 Composition with adjacent carbon R is independently selected from halogen, hydroxyl, amino, or thiol groups; n is selected from 0, 1, 2, or 3; m is selected from 1, 2, 3, or 4; "---"for Or a mixture containing it. The connector as described in claim 7, characterized in that, The connector has any of the following structures: (1) The compound has the structure of formula (II-a): in: Q1 is the functional group that can couple with cysteine, lysine, non-natural amino acids or glycosyl groups of antibody molecules. D represents the drug unit; C1 is the spacer group independently; S3 is independently the hydrophilic group or selected from the group consisting of each of the hydrophilic groups; F1 is selected from the direct bond or the group consisting of: optionally substituted alkylene, optionally substituted polyethylene glycol, optionally substituted alkenyl, optionally substituted ynylene, optionally substituted alicyclic, optionally substituted alicyclic, optionally substituted aryl, and optionally substituted heteroaryl; when substituted, the substituent is selected from halogen, hydroxyl, amino, carboxyl, carbonyl, sulfonic acid, sulfone, phosphate, and alkoxy. L1 is selected from either a direct key or the extended unit; the condition is that F1 and L1 are not both direct keys at the same time. a can be 1, 2, or 3 independently; Preferably, L1 is a direct bond; and / or a is 1; (2) The compound has the structure of formula (II-b): in: Q1 is the functional group that can couple with cysteine, lysine, non-natural amino acids or glycosyl groups of antibody molecules. D represents the drug unit; B1 is selected from the branched segment; C1 is either a direct bond or the spacer group; S2 is independently the hydrophilic group or selected from the group consisting of each of the hydrophilic groups; F1 is selected from the direct bond or the group consisting of: optionally substituted alkylene, optionally substituted polyethylene glycol, optionally substituted alkenyl, optionally substituted ynylene, optionally substituted alicyclic, optionally substituted alicyclic, optionally substituted aryl, and optionally substituted heteroaryl; when substituted, the substituent is selected from halogen, hydroxyl, amino, carboxyl, carbonyl, sulfonic acid, sulfone, phosphate, and alkoxy. L1 is the extension unit; b can be 1, 2, or 3 independently; Preferably, b is 1; (3) The compound has the structure of formula (II-c): in: Q1 is the functional group that can couple with cysteine, lysine, non-natural amino acids or glycosyl groups of antibody molecules. D represents the drug unit; B1 and B2 are independently selected from the branched segments; C1 is the spacer group independently; S3, S4 and S2 are independently the hydrophilic groups or selected from the group consisting of the hydrophilic groups; F1 is selected from the direct bond or the group consisting of: optionally substituted alkylene, optionally substituted polyethylene glycol, optionally substituted alkenyl, optionally substituted ynylene, optionally substituted alicyclic, optionally substituted alicyclic, optionally substituted aryl, and optionally substituted heteroaryl; when substituted, the substituent is selected from halogen, hydroxyl, amino, carboxyl, carbonyl, sulfonic acid, sulfone, phosphate, and alkoxy. L1 is selected from either a direct key or the extended unit; the condition is that F1 and L1 are not both direct keys at the same time. b and c can each be 1, 2, or 3 independently; a can be 0, 1, 2, or 3 independently; Preferably, wherein: F1 and L1 are not direct keys; and / or a is 0, or a is 1; and / or b is 1; and / or c is 1; (4) The compound has the structure of formula (II-d): in: Q1 is the functional group that can couple with cysteine, lysine, non-natural amino acids or glycosyl groups of antibody molecules. D represents the drug unit; B2 is independently selected from the branched segment; C1 is the spacer group independently; S3 and S4 are independently the hydrophilic groups or selected from the group consisting of the hydrophilic groups; F1 is selected from the direct bond or the group consisting of: optionally substituted alkylene, optionally substituted polyethylene glycol, optionally substituted alkenyl, optionally substituted ynylene, optionally substituted alicyclic, optionally substituted alicyclic, optionally substituted aryl, and optionally substituted heteroaryl; when substituted, the substituent is selected from halogen, hydroxyl, amino, carboxyl, carbonyl, sulfonic acid, sulfone, phosphate, and alkoxy. L1 is selected from either a direct key or the extended unit; the condition is that F1 and L1 are not both direct keys at the same time. c can be 1, 2, or 3 independently; a can be 0, 1, 2, or 3 independently; Preferably, wherein: F1 and L1 are not direct keys; and / or a is 0, or a is 1; and / or c is 1; (5) The compound has the structure of formula (II-e): in: Q1 is the functional group that can couple with cysteine, lysine, non-natural amino acids or glycosyl groups of antibody molecules. D represents the drug unit; B3 is independently selected from the branched segment; C1 is the spacer group independently; S3 and S5 are independently the hydrophilic groups or selected from the group consisting of the hydrophilic groups; F1 is selected from the direct bond or the group consisting of: optionally substituted alkylene, optionally substituted polyethylene glycol, optionally substituted alkenyl, optionally substituted ynylene, optionally substituted alicyclic, optionally substituted alicyclic, optionally substituted aryl, and optionally substituted heteroaryl; when substituted, the substituent is selected from halogen, hydroxyl, amino, carboxyl, carbonyl, sulfonic acid, sulfone, phosphate, and alkoxy. L1 is selected from either a direct key or the extended unit; the condition is that F1 and L1 are not both direct keys at the same time. d can be 1, 2, or 3 independently; a can be 0, 1, 2, or 3 independently; Preferably, wherein: F1 and L1 are not direct keys; and / or a is 0, or a is 1; and / or d is 1; (6) Wherein, in the compound of formula (II), Q1 is the functional group that can couple with cysteine, lysine, non-natural amino acids or glycosyl groups of antibody molecules. D represents the drug unit; B1 is selected from the branched segment; C1 is either a direct bond or the spacer group; S2 and S3 are each independently the hydrophilic group or selected from the group consisting of each of the hydrophilic groups; F1 is selected from the direct bond or the group consisting of: optionally substituted alkylene, optionally substituted polyethylene glycol, optionally substituted alkenyl, optionally substituted ynylene, optionally substituted alicyclic, optionally substituted alicyclic, optionally substituted aryl, and optionally substituted heteroaryl; when substituted, the substituent is selected from halogen, hydroxyl, amino, carboxyl, carbonyl, sulfonic acid, sulfone, phosphate, and alkoxy. L1 is selected from either a direct key or the extended unit; the condition is that F1 and L1 are not both direct keys at the same time. a and b are independently 1, 2, or 3; Preferably, the compound has the structure of formula (If): The connector as described in claim 7 or 8 is characterized in that, The connector includes any of the following features: (1) B1, B2 and B3, when they exist, are each keys; (2) B1, B2, and B3, when they exist, are each... in: Connection point 3 This indicates that B1, B2, or B3 are connected to S2, S4, or S5 respectively; R 8 Selected from H or R 8 It is a hydrophilic group, and R 8 The hydrophilic groups in S2, S4 or S5 are each selected from: optionally substituted polysarcosine residues, polyglycerols, polyols, glycosyl groups, cyclodextrins, substituted glycol fragments, substituted glycosylated polyethylene glycol fragments, substituted glycosylated polyglycerols, substituted cyclodextrin polyethylene glycols or combinations thereof. Preferably, wherein: The optionally substituted polysarcosine residues are Wherein n2 is an integer between 4 and 20, 4 and 16, or 8 and 12, preferably 10; R0 is selected from C1-C6 alkyl, C1-C6 cycloalkyl, and C1-C6 alkoxy, preferably methyl; preferably, the optionally substituted polysarcosine residue is And / or, the substituted glycosylated polyglycerol fragment is Where n4 is an integer between 4 and 12, or between 4 and 10; And / or, the substituted polyethylene glycol fragment is Where n5 is an integer between 4 and 24, between 7 and 20, or between 8 and 18, preferably, the substituted polyethylene glycol fragment is... And / or, the substituted glycosylated polyethylene glycol fragment is Where n3 is an integer between 4 and 18, or between 4 and 12; preferably, the substituted glycosylated polyethylene glycol fragment is And / or, the hydrophilic group is selected from the group consisting of optionally substituted polyethylene glycol fragments and substituted polysarcosine fragments, preferably. Wherein n7 is an integer between 4 and 20, 4 and 16, or 8 and 12, preferably 10; R0 is selected from C1-C6 alkyl, C1-C6 cycloalkyl, and C1-C6 alkoxy, preferably methyl; n5 is an integer between 4 and 24, 7 and 20, or 8 and 18; more preferably, the hydrophilic group is: And / or, the polyol is Preferred And / or, the glycosyl group is More preferably, B1, B2, or B, when present, -B1-[S2] b -B2-[S4] c 、or -B3-[S2] a Each part is independently selected from: (3) L1 is an optional substituted amino acid when it is present; Preferably, the optionally substituted amino acid is selected from: phenylalanine, isoleucine, leucine, tryptophan, valine, methionine, tyrosine, alanine, threonine, histidine, serine, glutamine, arginine, lysine, asparagine, glutamic acid, proline, citrulline, aspartic acid, and glycine, preferably valine, more preferably valine. Further improvements (4) L1 is an optional substituted polypeptide residue when it is present; Preferably, L1, when present, independently comprises polypeptide residues consisting of optionally substituted amino acids selected from the group consisting of: phenylalanine, isoleucine, leucine, tryptophan, valine, methionine, tyrosine, alanine, threonine, histidine, serine, glutamine, arginine, lysine, asparagine, glutamic acid, proline, citrulline, aspartic acid, and glycine. More preferably, L1, when present, independently comprises optional substituted polypeptide residues consisting of amino acids selected from the group consisting of glycine, phenylalanine, valine, alanine, arginine, citrulline, aspartic acid, asparagine, and lysine. More preferably, L1, when present, independently comprises optionally substituted polypeptide residues selected from the group consisting of: phenylalanine-lysine (Phe-Lys), valine-alanine (Val-Ala), valine-citrulline (Val-Cit), glutamic acid-valine-alanine (Glu-Val-Ala), glutamic acid-valine-citrulline (Glu-Val-Cit), valine-lysine (Val-Lys), alanine-alanine (Ala-Ala), alanine-alanine-alanine (Ala-Ala-Ala), alanine-alanine-asparagine (Ala-Ala-Asn), alanine-leucine (Ala-Leu), leucine-leucine (Leu-Leu), phenylalanine-arginine (Phe-Arg), and phenylalanine-lysine (Phe-Lys). Glycine-glycine-phenylalanine-glycine (Gly-Gly-Phe-Gly), glycine-proline (Gly-Pro); More preferably, L1, when present, is independently phenylalanine-lysine (Phe-Lys), valine-alanine (Val-Ala), valine-citrulline (Val-Cit), alanine-alanine (Ala-Ala), and glycine-glycine-phenylalanine-glycine (Gly-Gly-Phe-Gly). More preferably, L1, when present, is independently valine-alanine (Val-Ala), valine-citrulline (Val-Cit), or alanine-alanine (Ala-Ala), preferably. More (5) Each C1 is independent as follows: Preferred More Where: Connection point 1 Connect to B3 or L1, and connect point 2. Connected to the drug unit D; And / or, when a is present and not zero, each S3 is independently the glycosyl or cyclodextrin, preferably the glycosyl, more preferably the glycosyl. Further improvements Preferably, -C1-[S3] a Part of (6) When F1 exists, each is an independent direct bond; (7) F1, when present, is independently selected from direct bonds or optionally substituted polyethylene glycol groups; Preferably, the optionally substituted polyethylene glycol group is Where n6 is an integer between 1 and 18, between 1 and 12, or between 1 and 10, preferably n6 is 1, 3 or 7; More preferably, F1 exists independently as Where n6 is 1, 3, or 7, or F1 exists independently as Where n6 is 1, 3, or 7; (8) The C in the drug unit D 3~6 The cycloalkyl group can be monocyclic, spirocyclic, fused, or bridged; preferably C10. 3~6 cycloalkyl groups are selected from C 3~6 Monocyclic cycloalkyl or C 5~6 Bridged cycloalkyl; Preferably, the C 3~6 The cycloalkyl group is selected from cyclopropane, cyclobutane, cyclopentane, cyclohexane, Preferred materials include cyclopropane, cyclobutane, cyclohexane, or... And / or, the 3-6 membered heterocyclic alkyl group in the pharmaceutical unit D may be ethylene oxide, aziridinyl, aziridine, oxadiazinyl, tetrahydrofuranyl, dioxadiazinyl, pyrrolidone, imidazoalkyl, pyrazolyl, pyrrolinyl, tetrahydropyranyl, piperidinyl, morpholinyl, dithiaalkyl, thiomorpholinyl, piperazine, or trithiaalkyl; (9) The R in the drug unit D 1 Selected from halogens, -NH2, -OH, C 1-3 Alkyl or C 1-3 Alkoxy; Preferably, the R in the drug unit D 1 The components are selected from F, Cl, Br, I, -NH2, -OH, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, or propoxy, preferably methyl, methoxy, Cl, -OH, or -NH2, and more preferably methyl or methoxy. (10) The R in the drug unit D 2 Selected from halogens, -NH2, -OH, C 1-3 Alkyl or C 1-3 Alkoxy; Preferably, the R in the drug unit D 2 Selected from F, Cl, Br, I, -NH2, -OH, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, or propoxy, more preferably F; (11) The R in the drug unit D is selected from F, Cl, Br or I, preferably F; (12) The n in the drug unit D is selected from 1 or 2, preferably 1; (13) The m in the drug unit D is selected from 1 or 2, preferably 1. The connector as described in any one of claims 7-9 is characterized in that, The compounds of formula (A) are selected from those represented by formula (A-1): in: Ring A can be cyclopropane, cyclobutane, cyclopentane, or cyclohexane. said R 2 preferably F; said R 1 preferably methyl or methoxy; Preferably, the compound of formula (A) is a compound of formula (A-1-1): in: R 1 Selected from methyl, Cl, -OH or -NH2, methoxy; R 2 selected from F; Or, R 1 R 2 Composition with adjacent carbon R is selected from F; and n is selected from 1; Preferably, it is a compound of formula (AA) Alternatively, the compound of formula (A) is a compound of formula (A-1-2): in: R 1 Selected from methyl, Cl, -OH or -NH2, methoxy; R 2 Selected from F; Or, R 1 R 2 Composition with adjacent carbon R is selected from F; and n is selected from 1 Alternatively, the compound of formula (A) is a compound of formula (A-1-3): in: R 1 Selected from methyl, Cl, -OH or -NH2, methoxy; R 2 Selected from F; Or, R 1 R 2 Composition with adjacent carbon R is selected from F; and n is selected from 1; Alternatively, the compound of formula (A) is a compound of formula (A-1-4): in: R 1 Selected from methyl, Cl, -OH or -NH2, methoxy; R 2 Selected from F; and n is selected from 0. The connector as described in any one of claims 7-10 is characterized in that, The compound of formula (A) is selected from the following structures: The connector as described in any one of claims 7-11, characterized in that, The compound is selected from compounds of formulas B1-B18: An intermediate or a pharmaceutically acceptable salt, ester, stereoisomer, polymorph, solvate, N-oxide, isotopically labeled compound, metabolite, or prodrug thereof, wherein the intermediate has the structure of formula (III): in: Q1 is a functional group that can couple with cysteine, lysine, non-natural amino acids or glycosyl groups of antibody molecules. Connection point Connected to the antibody Connection point Connect to the drug delivery unit; B1, B2, and B3 are each independently selected from branched segments; C1 is an independent spacer group; S2, S3, S4 and S5 are each independently a hydrophilic group or selected from the group consisting of each of the aforementioned hydrophilic groups; F1 is selected from the direct bond or the group consisting of: optionally substituted alkylene, optionally substituted polyethylene glycol, optionally substituted alkenyl, optionally substituted ynylene, optionally substituted alicyclic, optionally substituted alicyclic, optionally substituted aryl, and optionally substituted heteroaryl; when substituted, the substituent is selected from halogen, hydroxyl, amino, carboxyl, carbonyl, sulfonic acid, sulfone, phosphate, and alkoxy. L1 is selected from either a direct bond or an extended unit; the condition is that F1 and L1 are not both direct bonds at the same time. a, b, c, and d are each independently 0, 1, 2, or 3, provided that a, b, c, and d are not all 0 at the same time; The functional groups conjugated to the cysteine, lysine, non-natural amino acids, or glycosyl groups of the antibody molecule are selected from those with optional substitutions. The intermediate as described in claim 13, characterized in that, The intermediate has any of the structures shown in the following formula: (1) The intermediate has the structure of formula (III-a): in: Q1 is the functional group that can couple with cysteine, lysine, non-natural amino acids or glycosyl groups of antibody molecules. Connection point Connected to the antibody; Connection point Connected to the drug unit; C1 is the spacer group independently; S3 is independently the hydrophilic group or selected from the group consisting of each of the hydrophilic groups; F1 is selected from the direct bond or the group consisting of: optionally substituted alkylene, optionally substituted polyethylene glycol, optionally substituted alkenyl, optionally substituted ynylene, optionally substituted alicyclic, optionally substituted alicyclic, optionally substituted aryl, and optionally substituted heteroaryl; when substituted, the substituent is selected from halogen, hydroxyl, amino, carboxyl, carbonyl, sulfonic acid, sulfone, phosphate, and alkoxy. L1 is selected from either a direct key or the extended unit; the condition being that F1 and L1 are not both direct keys. a can be 1, 2, or 3 independently; Preferably, L1 is a direct bond; and / or a is 1. (2) The intermediate has the structure of formula (III-b): in: Q1 is the functional group that can couple with cysteine, lysine, non-natural amino acids or glycosyl groups of antibody molecules. Connection point Connected to the antibody; Connection point Connected to the drug unit; B1 is selected from the branching groups mentioned above; C1 is the spacer group independently; S2 is independently the hydrophilic group or selected from the group consisting of each of the hydrophilic groups; F1 is selected from the direct bond or the group consisting of: optionally substituted alkylene, optionally substituted polyethylene glycol, optionally substituted alkenyl, optionally substituted ynylene, optionally substituted alicyclic, optionally substituted alicyclic, optionally substituted aryl, and optionally substituted heteroaryl; when substituted, the substituent is selected from halogen, hydroxyl, amino, carboxyl, carbonyl, sulfonic acid, sulfone, phosphate, and alkoxy. L1 is the extension unit; b can be 1, 2, or 3 independently; Preferably, b is 1; (3) The intermediate has the structure of formula (III-c): in: Q1 is a functional group that can couple with cysteine, lysine, non-natural amino acids or glycosyl groups of antibody molecules. B1 and B2 are independently selected from the branched segments; C1 is the spacer group independently; S3, S4 and S2 are independently the hydrophilic groups or selected from the group consisting of the hydrophilic groups; F1 is selected from the direct bond or the group consisting of: optionally substituted alkylene, optionally substituted polyethylene glycol, optionally substituted alkenyl, optionally substituted ynylene, optionally substituted alicyclic, optionally substituted alicyclic, optionally substituted aryl, and optionally substituted heteroaryl; when substituted, the substituent is selected from halogen, hydroxyl, amino, carboxyl, carbonyl, sulfonic acid, sulfone, phosphate, and alkoxy. L1 is selected from either a direct key or the extended unit; the condition is that F1 and L1 are not both direct keys at the same time. b and c can each be 1, 2, or 3 independently; a can be 0, 1, 2, or 3 independently; Preferably, wherein: F1 and L1 are not direct keys; and / or a is 0, or a is 1; and / or b is 1; and / or c is 1; (4) The intermediate has the structure of formula (III-d): in: Q1 is the functional group that can couple with cysteine, lysine, non-natural amino acids or glycosyl groups of antibody molecules. D represents the drug unit; B2 is independently selected from the branched segment; C1 is the spacer group independently; S3 and S4 are independently the hydrophilic groups or selected from the group consisting of the hydrophilic groups; F1 is selected from the direct bond or the group consisting of: optionally substituted alkylene, optionally substituted polyethylene glycol, optionally substituted alkenyl, optionally substituted ynylene, optionally substituted alicyclic, optionally substituted alicyclic, optionally substituted aryl, and optionally substituted heteroaryl; when substituted, the substituent is selected from halogen, hydroxyl, amino, carboxyl, carbonyl, sulfonic acid, sulfone, phosphate, and alkoxy. L1 is selected from either a direct key or the extended unit; the condition is that F1 and L1 are not both direct keys at the same time. c can be 1, 2, or 3 independently; a can be 0, 1, 2, or 3 independently; Preferably, wherein: F1 and L1 are not direct keys; and / or a is 0, or a is 1; and / or c is 1; (5) The intermediate has the structure of formula (III-e): in: Q1 is the functional group that can couple with cysteine, lysine, non-natural amino acids or glycosyl groups of antibody molecules. B3 is independently selected from the branched segment; C1 is the spacer group independently; S3 and S5 are independently the hydrophilic groups or selected from the group consisting of the hydrophilic groups; F1 is selected from the direct bond or the group consisting of: optionally substituted alkylene, optionally substituted polyethylene glycol, optionally substituted alkenyl, optionally substituted ynylene, optionally substituted alicyclic, optionally substituted alicyclic, optionally substituted aryl, and optionally substituted heteroaryl; when substituted, the substituent is selected from halogen, hydroxyl, amino, carboxyl, carbonyl, sulfonic acid, sulfone, phosphate, and alkoxy. L1 is selected from either a direct key or the extended unit; the condition is that F1 and L1 are not both direct keys at the same time. d can be 1, 2, or 3 independently; a can be 0, 1, 2, or 3 independently; Preferably, wherein: F1 and L1 are not direct keys; and / or a is 0, or a is 1; and / or d is 1; (6) Wherein, in the compound of formula (III), Q1 is the functional group that can couple with cysteine, lysine, non-natural amino acids or glycosyl groups of antibody molecules. B1 is selected from the branched segment; C1 is the spacer group independently; S2 and S3 are each independently the hydrophilic group or selected from the group consisting of each of the hydrophilic groups; F1 is selected from the direct bond or the group consisting of: optionally substituted alkylene, optionally substituted polyethylene glycol, optionally substituted alkenyl, optionally substituted ynylene, optionally substituted alicyclic, optionally substituted alicyclic, optionally substituted aryl, and optionally substituted heteroaryl; when substituted, the substituent is selected from halogen, hydroxyl, amino, carboxyl, carbonyl, sulfonic acid, sulfone, phosphate, and alkoxy. L1 is selected from either a direct key or the extended unit; the condition is that F1 and L1 are not both direct keys at the same time. a and b are independently 1, 2, or 3; Preferably, the intermediate has the structure of formula (III-f): The intermediate as described in claim 13 or 14, characterized in that, The intermediate contains any of the following characteristics: (1) B1, B2 and B3, when they exist, are each keys; (2) B1, B2, and B3, when they exist, are each... in: Connection point 3 This indicates that B1, B2, or B3 are connected to S2, S4, or S5 respectively; R 8 Selected from H or R 8 It is a hydrophilic group, and R 8 The hydrophilic groups in S2, S4 or S5 are each selected from: optionally substituted polysarcosine residues, polyglycerols, polyols, glycosyl groups, cyclodextrins, substituted glycol fragments, substituted glycosylated polyethylene glycol fragments, substituted glycosylated polyglycerols, substituted cyclodextrin polyethylene glycols or combinations thereof. Preferably, wherein: The optionally substituted polysarcosine residues are Wherein n2 is an integer between 4 and 20, 4 and 16, or 8 and 12, preferably 10; R0 is selected from C1-C6 alkyl, C1-C6 cycloalkyl, and C1-C6 alkoxy, preferably methyl; preferably, the optionally substituted polysarcosine residue is And / or, the substituted glycosylated polyglycerol fragment is Where n4 is an integer between 4 and 12, or between 4 and 10; And / or, the substituted polyethylene glycol fragment is Where n5 is an integer between 4 and 24, between 7 and 20, or between 8 and 18, preferably, the substituted polyethylene glycol fragment is... And / or, the substituted glycosylated polyethylene glycol fragment is Where n3 is an integer between 4 and 18, or between 4 and 12; preferably, the substituted glycosylated polyethylene glycol fragment is And / or, the hydrophilic group is selected from the group consisting of optionally substituted polyethylene glycol fragments and substituted polysarcosine fragments, preferably. Wherein n7 is an integer between 4 and 20, 4 and 16, or 8 and 12, preferably 10; R0 is selected from C1-C6 alkyl, C1-C6 cycloalkyl, and C1-C6 alkoxy, preferably methyl; n5 is an integer between 4 and 24, 7 and 20, or 8 and 18; more preferably, the hydrophilic group is: And / or, the polyol is Preferred And / or, the glycosyl group is More preferably, B1, B2, or B, when present, -B1-[S2] b -B2-[S4] c 、or -B3-[S2] a Each part is independently selected from: (3) L1 is an optional substituted amino acid when it is present; Preferably, the optionally substituted amino acid is selected from: phenylalanine, isoleucine, leucine, tryptophan, valine, methionine, tyrosine, alanine, threonine, histidine, serine, glutamine, arginine, lysine, asparagine, glutamic acid, proline, citrulline, aspartic acid, and glycine, preferably valine, more preferably valine. Further improvements (4) L1 is an optional substituted polypeptide residue when it is present; Preferably, L1, when present, independently comprises polypeptide residues consisting of optionally substituted amino acids selected from the group consisting of: phenylalanine, isoleucine, leucine, tryptophan, valine, methionine, tyrosine, alanine, threonine, histidine, serine, glutamine, arginine, lysine, asparagine, glutamic acid, proline, citrulline, aspartic acid, and glycine. More preferably, L1, when present, independently comprises optional substituted polypeptide residues consisting of amino acids selected from the group consisting of glycine, phenylalanine, valine, alanine, arginine, citrulline, aspartic acid, asparagine, and lysine. More preferably, L1, when present, independently comprises optionally substituted polypeptide residues selected from the group consisting of: phenylalanine-lysine (Phe-Lys), valine-alanine (Val-Ala), valine-citrulline (Val-Cit), glutamic acid-valine-alanine (Glu-Val-Ala), glutamic acid-valine-citrulline (Glu-Val-Cit), valine-lysine (Val-Lys), alanine-alanine (Ala-Ala), alanine-alanine-alanine (Ala-Ala-Ala), alanine-alanine-asparagine (Ala-Ala-Asn), alanine-leucine (Ala-Leu), leucine-leucine (Leu-Leu), phenylalanine-arginine (Phe-Arg), and phenylalanine-lysine (Phe-Lys). Glycine-glycine-phenylalanine-glycine (Gly-Gly-Phe-Gly), glycine-proline (Gly-Pro); More preferably, L1, when present, is independently phenylalanine-lysine (Phe-Lys), valine-alanine (Val-Ala), valine-citrulline (Val-Cit), alanine-alanine (Ala-Ala), and glycine-glycine-phenylalanine-glycine (Gly-Gly-Phe-Gly). More preferably, L1, when present, is independently valine-alanine (Val-Ala), valine-citrulline (Val-Cit), or alanine-alanine (Ala-Ala), preferably. More (5) Each C1 is independent as follows: Preferred More Where: Connection point 1 Connect to B3 or L1, and connect point 2. Connected to the drug unit D; And / or, when a is present and not zero, each S3 is independently the glycosyl or cyclodextrin, preferably the glycosyl, more preferably the glycosyl. Further improvements Preferably, -C1-[S3] a Part of (6) When F1 exists, each is an independent direct bond; (7) F1, when present, is independently selected from direct bonds or optionally substituted polyethylene glycol groups; Preferably, the optionally substituted polyethylene glycol group is Where n6 is an integer between 1 and 18, between 1 and 12, or between 1 and 10, preferably n6 is 1, 3 or 7; More preferably, F1 exists independently as Where n6 is 1, 3, or 7, or F1 exists independently as Where n6 is 1, 3 or 7. The intermediate as described in any one of claims 13-15, characterized in that, The intermediate is selected from intermediates of formulas C1 to C18: A compound or a pharmaceutically acceptable salt, ester, stereoisomer, polymorph, solvate, N-oxide, isotopically labeled compound, metabolite, or prodrug thereof, wherein the compound has the structure of formula (IV): in: Ab is an antibody molecule; q is an integer or decimal from 1 to 8; Q1 is a functional group capable of coupling with cysteine, lysine, non-natural amino acids, or glycosyl groups of the antibody molecule. D represents the drug unit; B1, B2, and B3 are each independently selected from bonded or branched segments; C1 is an independent spacer group; S2, S3, S4 and S5 are each independently a hydrophilic group or selected from the group consisting of each of the aforementioned hydrophilic groups; F1 is selected from the direct bond or the group consisting of: optionally substituted alkylene, optionally substituted polyethylene glycol, optionally substituted alkenyl, optionally substituted ynylene, optionally substituted alicyclic, optionally substituted alicyclic, optionally substituted aryl, and optionally substituted heteroaryl; when substituted, the substituent is selected from halogen, hydroxyl, amino, carboxyl, carbonyl, sulfonic acid, sulfone, phosphate, and alkoxy. L1 is selected from either a direct bond or an extended unit; the condition is that F1 and L1 are not both direct bonds at the same time. a, b, c, and d are each independently 0, 1, 2, or 3, provided that a, b, c, and d are not all 0 at the same time; The functional groups conjugated to the cysteine, lysine, non-natural amino acids, or glycosyl groups of the antibody molecule are selected from those with optional substitutions. The drug structural unit is selected from the compounds shown in formula (A): in: X is CH2 or S; Ring A is independently selected from C 3-6 cycloalkyl or 3-6 membered heterocycloalkyl; R 1 and R 2 Each is independently selected from halogens, -NH2, -OH, and C. 1-3 Alkyl or C 1-3 Alkoxy; Or, R 1 R 2 Composition with adjacent carbon R is independently selected from halogen, hydroxyl, amino, or thiol groups; n is selected from 0, 1, 2, or 3; m is selected from 1, 2, 3, or 4; ""for Or a mixture containing it. The compound as claimed in claim 17, characterized in that, The compound has any of the following structures: (1) The compound has the structure of formula (IV-a): in: Ab is the antibody molecule; q is an integer or decimal from 1 to 8; Q1 is the functional group that can couple with the cysteine, lysine, non-natural amino acid, or glycosyl group of the antibody molecule. D represents the drug unit; C1 is the spacer group independently; S3 is each independently the hydrophilic group or selected from the group consisting of each of the hydrophilic groups; F1 is selected from the direct bond or the group consisting of: optionally substituted alkylene, optionally substituted polyethylene glycol, optionally substituted alkenyl, optionally substituted ynylene, optionally substituted alicyclic, optionally substituted alicyclic, optionally substituted aryl, and optionally substituted heteroaryl; when substituted, the substituent is selected from halogen, hydroxyl, amino, carboxyl, carbonyl, sulfonic acid, sulfone, phosphate, and alkoxy. L1 is the extension unit; a can be 1, 2, or 3 independently; Preferably, L1 is a direct bond; and / or a is 1; (2) The compound has the structure of formula (IV-b): in: Ab is the antibody molecule; q is an integer or decimal from 1 to 8; Q1 is the functional group that can couple with the cysteine, lysine, non-natural amino acid, or glycosyl group of the antibody molecule. D represents the drug unit; B1 is selected from the branched segment; C1 is either a direct bond or the spacer group; S2 and S3 are each independently the hydrophilic group or selected from the group consisting of each of the hydrophilic groups; F1 is selected from the direct bond or the group consisting of: optionally substituted alkylene, optionally substituted polyethylene glycol, optionally substituted alkenyl, optionally substituted ynylene, optionally substituted alicyclic, optionally substituted alicyclic, optionally substituted aryl, and optionally substituted heteroaryl; when substituted, the substituent is selected from halogen, hydroxyl, amino, carboxyl, carbonyl, sulfonic acid, sulfone, phosphate, and alkoxy. L1 is the extension unit; b can be 1, 2, or independently; Preferably, b is 1; (3) The compound has the structure of formula (IV-c): in: Ab is the antibody molecule; q is an integer or decimal from 1 to 8; Q1 is the functional group that can couple with the cysteine, lysine, non-natural amino acid, or glycosyl group of the antibody molecule. D represents the drug unit; B1 and B2 are independently selected from the branched fragments; C1 is the spacer group independently; S3, S4 and S2 are independently the hydrophilic groups or selected from the group consisting of the hydrophilic groups; F1 is selected from the direct bond or the group consisting of: optionally substituted alkylene, optionally substituted polyethylene glycol, optionally substituted alkenyl, optionally substituted ynylene, optionally substituted alicyclic, optionally substituted alicyclic, optionally substituted aryl, and optionally substituted heteroaryl; when substituted, the substituent is selected from halogen, hydroxyl, amino, carboxyl, carbonyl, sulfonic acid, sulfone, phosphate, and alkoxy. L1 is selected from either a direct key or the extended unit; the condition is that F1 and L1 are not both direct keys at the same time. b and c can be 1, 2 or 3 independently; a can be 0, 1, 2, or 3 independently; Preferably, wherein: F1 and L1 are not direct keys; and / or a is 0, or a is 1; and / or b is 1; and / or c is 1; (4) The compound has the structure of formula (IV-d): in: Ab is the antibody molecule; q is an integer or decimal from 1 to 8; Q1 is the functional group that can couple with the cysteine, lysine, non-natural amino acid, or glycosyl group of the antibody molecule. D represents the drug unit; B2 is independently selected from the branched segment; C1 is the spacer group independently; S3 and S4 are independently the hydrophilic groups or selected from the group consisting of the hydrophilic groups; F1 is selected from the direct bond or the group consisting of: optionally substituted alkylene, optionally substituted polyethylene glycol, optionally substituted alkenyl, optionally substituted ynylene, optionally substituted alicyclic, optionally substituted alicyclic, optionally substituted aryl, and optionally substituted heteroaryl; when substituted, the substituent is selected from halogen, hydroxyl, amino, carboxyl, carbonyl, sulfonic acid, sulfone, phosphate, and alkoxy. L1 is selected from either a direct key or the extended unit; the condition is that F1 and L1 are not both direct keys at the same time. c can be 1, 2, or 3 independently; a can be 0, 1, 2, or 3 independently; Preferably, wherein: F1 and L1 are not direct keys; and / or a is 0, or a is 1; and / or c is 1; (5) The compound has the structure of formula (IV-e): in: Ab is the antibody molecule; q is an integer or decimal from 1 to 8; Q1 is the functional group that can couple with the cysteine, lysine, non-natural amino acid, or glycosyl group of the antibody molecule. D represents the drug unit; B3 is independently selected from the branched segment; C1 is the spacer group independently; S3 and S5 are independently the hydrophilic groups or selected from the group consisting of the hydrophilic groups; F1 is selected from the direct bond or the group consisting of: optionally substituted alkylene, optionally substituted polyethylene glycol, optionally substituted alkenyl, optionally substituted ynylene, optionally substituted alicyclic, optionally substituted alicyclic, optionally substituted aryl, and optionally substituted heteroaryl; when substituted, the substituent is selected from halogen, hydroxyl, amino, carboxyl, carbonyl, sulfonic acid, sulfone, phosphate, and alkoxy. L1 is selected from either a direct key or the extended unit; the condition is that F1 and L1 are not both direct keys at the same time. d can be 1, 2, or 3 independently; a can be 0, 1, 2, or 3 independently; Preferably, wherein: F1 and L1 are not direct keys; and / or a is 0, or a is 1; and / or d is 1; (6) Wherein, in the compound of formula (IV), Q1 is the functional group that can couple with the cysteine, lysine, non-natural amino acid, or glycosyl group of the antibody molecule. D represents the drug unit; B1 is selected from the branched segment; C1 is either a direct bond or the spacer group; S2 and S3 are each independently the hydrophilic group or selected from the group consisting of each of the hydrophilic groups; F1 is selected from the direct bond or the group consisting of: optionally substituted alkylene, optionally substituted polyethylene glycol, optionally substituted alkenyl, optionally substituted ynylene, optionally substituted alicyclic, optionally substituted alicyclic, optionally substituted aryl, and optionally substituted heteroaryl; when substituted, the substituent is selected from halogen, hydroxyl, amino, carboxyl, carbonyl, sulfonic acid, sulfone, phosphate, and alkoxy. L1 is the extension unit; a and b are independently 1, 2, or 3; Preferably, the compound has the structure of formula (IV-f): The compound as claimed in claim 17 or 18, characterized in that, The compound contains any of the following characteristics: (1) B1, B2 and B3, when they exist, are each keys; (2) B1, B2, and B3, when they exist, are each... in: Connection point 3 This indicates that B1, B2, or B3 are connected to S2, S4, or S5 respectively; R 8 Selected from H or R 8 It is a hydrophilic group, and R 8 The hydrophilic groups in S2, S4 or S5 are each selected from: optionally substituted polysarcosine residues, polyglycerols, polyols, glycosyl groups, cyclodextrins, substituted glycol fragments, substituted glycosylated polyethylene glycol fragments, substituted glycosylated polyglycerols, substituted cyclodextrin polyethylene glycols or combinations thereof. Preferably, wherein: The optionally substituted polysarcosine residues are Wherein n2 is an integer between 4 and 20, 4 and 16, or 8 and 12, preferably 10; R0 is selected from C1-C6 alkyl, C1-C6 cycloalkyl, and C1-C6 alkoxy, preferably methyl; preferably, the optionally substituted polysarcosine residue is And / or, the substituted glycosylated polyglycerol fragment is Where n4 is an integer between 4 and 12, or between 4 and 10; And / or, the substituted polyethylene glycol fragment is Where n5 is an integer between 4 and 24, between 7 and 20, or between 8 and 18, preferably, the substituted polyethylene glycol fragment is... And / or, the substituted glycosylated polyethylene glycol fragment is Where n3 is an integer between 4 and 18, or between 4 and 12; preferably, the substituted glycosylated polyethylene glycol fragment is And / or, the hydrophilic group is selected from the group consisting of optionally substituted polyethylene glycol fragments and substituted polysarcosine fragments, preferably. Wherein n7 is an integer between 4 and 20, 4 and 16, or 8 and 12, preferably 10; R0 is selected from C1-C6 alkyl, C1-C6 cycloalkyl, and C1-C6 alkoxy, preferably methyl; n5 is an integer between 4 and 24, 7 and 20, or 8 and 18; more preferably, the hydrophilic group is: And / or, the polyol is Preferred And / or, the glycosyl group is More preferably, B1, B2, or B, when present, -B1-[S2] b -B2-[S4] c 、or -B3-[S2] a Each part is independently selected from: (3) L1 is an optional substituted amino acid when it is present; Preferably, the optionally substituted amino acid is selected from: phenylalanine, isoleucine, leucine, tryptophan, valine, methionine, tyrosine, alanine, threonine, histidine, serine, glutamine, arginine, lysine, asparagine, glutamic acid, proline, citrulline, aspartic acid, and glycine, preferably valine, more preferably valine. Further improvements (4) L1 is an optional substituted polypeptide residue when it is present; Preferably, L1, when present, independently comprises polypeptide residues consisting of optionally substituted amino acids selected from the group consisting of: phenylalanine, isoleucine, leucine, tryptophan, valine, methionine, tyrosine, alanine, threonine, histidine, serine, glutamine, arginine, lysine, asparagine, glutamic acid, proline, citrulline, aspartic acid, and glycine. More preferably, L1, when present, independently comprises optional substituted polypeptide residues consisting of amino acids selected from the group consisting of glycine, phenylalanine, valine, alanine, arginine, citrulline, aspartic acid, asparagine, and lysine. More preferably, L1, when present, independently comprises optionally substituted polypeptide residues selected from the group consisting of: phenylalanine-lysine (Phe-Lys), valine-alanine (Val-Ala), valine-citrulline (Val-Cit), glutamic acid-valine-alanine (Glu-Val-Ala), glutamic acid-valine-citrulline (Glu-Val-Cit), valine-lysine (Val-Lys), alanine-alanine (Ala-Ala), alanine-alanine-alanine (Ala-Ala-Ala), alanine-alanine-asparagine (Ala-Ala-Asn), alanine-leucine (Ala-Leu), leucine-leucine (Leu-Leu), phenylalanine-arginine (Phe-Arg), and phenylalanine-lysine (Phe-Lys). Glycine-glycine-phenylalanine-glycine (Gly-Gly-Phe-Gly), glycine-proline (Gly-Pro); More preferably, L1, when present, is independently phenylalanine-lysine (Phe-Lys), valine-alanine (Val-Ala), valine-citrulline (Val-Cit), alanine-alanine (Ala-Ala), and glycine-glycine-phenylalanine-glycine (Gly-Gly-Phe-Gly). More preferably, L1, when present, is independently valine-alanine (Val-Ala), valine-citrulline (Val-Cit), or alanine-alanine (Ala-Ala), preferably. More (5) Each C1 is independent as follows: Preferred More Where: Connection point 1 Connect to B3 or L1, and connect point 2. Connected to the drug unit D; And / or, when a is present and not zero, each S3 is independently the glycosyl or cyclodextrin, preferably the glycosyl, more preferably the glycosyl. Further improvements Preferably, -C1-[S3] a Part of (6) When F1 exists, each is an independent direct bond; (7) F1, when present, is independently selected from direct bonds or optionally substituted polyethylene glycol groups; Preferably, the optionally substituted polyethylene glycol group is Where n6 is an integer between 1 and 18, between 1 and 12, or between 1 and 10, preferably n6 is 1, 3 or 7; More preferably, F1 exists independently as Where n6 is 1, 3, or 7, or F1 exists independently as Where n6 is 1, 3, or 7; (8) The C in the drug unit D 3~6 The cycloalkyl group can be monocyclic, spirocyclic, fused, or bridged; preferably C10. 3~6 cycloalkyl groups are selected from C 3~6 Monocyclic cycloalkyl or C 5~6 Bridged cycloalkyl; Preferably, the C 3~6 The cycloalkyl group is selected from cyclopropane, cyclobutane, cyclopentane, cyclohexane, Preferred materials include cyclopropane, cyclobutane, cyclohexane, or... And / or, the 3-6 membered heterocyclic alkyl group in the pharmaceutical unit D may be ethylene oxide, aziridinyl, aziridine, oxadiazinyl, tetrahydrofuranyl, dioxadiazinyl, pyrrolidone, imidazoalkyl, pyrazolyl, pyrrolinyl, tetrahydropyranyl, piperidinyl, morpholinyl, dithiaalkyl, thiomorpholinyl, piperazine, or trithiaalkyl; (9) The R in the drug unit D 1 Selected from halogens, -NH2, -OH, C 1-3 Alkyl or C 1-3 Alkoxy; Preferably, the R in the drug unit D 1 The components are selected from F, Cl, Br, I, -NH2, -OH, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, or propoxy, preferably methyl, methoxy, Cl, -OH, or -NH2, and more preferably methyl or methoxy. (10) The R in the drug unit D 2 Selected from halogens, -NH2, -OH, C 1-3 Alkyl or C 1-3 Alkoxy; Preferably, the R in the drug unit D 2 Selected from F, Cl, Br, I, -NH2, -OH, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, or propoxy, more preferably F; (11) The R in the drug unit D is selected from F, Cl, Br or I, preferably F; (12) The n in the drug unit D is selected from 1 or 2, preferably 1; (13) The m in the drug unit D is selected from 1 or 2, preferably 1. The compound according to any one of claims 17-19, characterized in that, The compounds of formula (A) are selected from those represented by formula (A-1): in: Ring A can be cyclopropane, cyclobutane, cyclopentane, or cyclohexane. The R 2 Preferred option: F; The R 1 Preferably methyl or methoxy; Preferably, the compound of formula (A) is a compound of formula (A-1-1): in: R 1 Selected from methyl, Cl, -OH or -NH2, methoxy; R 2 Selected from F; Or, R 1 R 2 Composition with adjacent carbon R is selected from F; and n is selected from 1; Preferably, it is a compound of formula (AA) Alternatively, the compound of formula (A) is a compound of formula (A-1-2): in: R 1 Selected from methyl, Cl, -OH or -NH2, methoxy; R 2 Selected from F; Or, R 1 R 2 Composition with adjacent carbon R is selected from F; and n is selected from 1 Alternatively, the compound of formula (A) is a compound of formula (A-1-3): in: R 1 Selected from methyl, Cl, -OH or -NH2, methoxy; R 2 Selected from F; Or, R 1 R 2 Composition with adjacent carbon R is selected from F; and n is selected from 1; Alternatively, the compound of formula (A) is a compound of formula (A-1-4): in: R 1 Selected from methyl, Cl, -OH or -NH2, methoxy; R 2 Selected from F; and n is selected from 0. The compound according to any one of claims 17-20, characterized in that, The compounds of formula (A) are selected from the following structures: The compound according to any one of claims 17-21, characterized in that, The compounds are selected from compounds of formulas D1-D17: in: q can be 1 to 7.5, 1 to 7, 1 to 6.5, 1 to 6, 1 to 5.5, 1 to 5, 1 to 4.5, 1 to 4, 1 to 3.5, 1 to 2.5, 1 to 2, 1 to 1.5, 1.5 to 9, 1.5 to 8.5, 1 to 5 to 8, 1 to 5 to 7.5, 1 to 5 to 5.5, 1.5 to 5, 1.5 to 4.5, 1.5 to 4, 1.5 to 3.5, 1.5 to 3, 1.5 to 2.5, 1.5 to 2, 2 to 7.5, 2 to 7, 2 to 6.5, 2 to 6, 2 to 5.5, 2 to 5, 2 to 4.5, 2 to 4, 2 to 3.5, 2 to 3, 2 to 2.5, 2.5 to 8, 2.5 to 7.5, 2.5 to 7, 2.5 to 6.5, 2.5 to 6, 2.5 to 5.5, 2.5 to 4.5, 2.5 to 5, 2.5 to 2.5, 2.5 to 3.5, 3 to 7.5, 3 to 7, 3 to 6.5, 3 to 6, 3 to 5.5, 3 to 4.5, 3 to 4, 3 to 3.5, 3.5 to 7.5, 3.5 to 7, 3.5 to 6, 3.5 to 5.5, 3.5 to 5, 3.5 to 4.5, 3.5 to 4, 4 to 8, 4 to 7.5, 4 to 7, 4 to 6.5, 4 to 6, 4 to 5.5, 4 to 5 or 4 to 4.5; preferably about 1, about 1.5, about 2, about 2.5, about 3, about 3.5, about 4, about 4.5, about 5, about 5.5, about 6, about 6.5, about 7, about 7.5 or about 8; Ab is a monoclonal antibody or its antigen-binding fragment, wherein preferably, the monoclonal antibody is an antibody against the following antigens: HER2, HER3, TROP2, B7-H3, B7-H4, GPC20, GPRC5D, CDH6, EGFR, EGFRvIII, AXL, Nectin-4, Tissue factor, TIM-1, PSMA, PTK7, EpCAM, MUC1, STEAP1, GPNMB, FGF2, FOLR1, c-MET, GFR, AGS-16, Guanylyl cyclase C, Mesothelin, SLC44A4, EphA2, AGS-5, GPC-3, c-KIT, ROR1, ROR2, PD-L1, CD27L, 5T4, MerTK, Mucin 16. 16) NaPi2b, STEAP, SLITRK6, ETBR, BCMA, CEACAM5, ICAM1, SC-16, SLC39A6, Delta-like protein 3, Claudin 18.2, Claudin 3, Claudin 6, Claudin9, CD19, CD20, CD22, CD30, CD33, CD37, CD45, CD56, CD66e, CD70, CD73, CD74, CD79b, CD123, CD138, CD147, CD166, CD223, MUC16, MSLN, ENPP3, SLTRK6, FGFR, LIV-1, Lewis Y, integrin αV (αv-integrin), integrin beta-6 (ITGB6), ASCT2, C4.4a, CA-IX, CD324, CD352, CD44v6, CD48a, CLL-1, Cripto, CS1, DPEP3, Ephrin-A2, Ephrin-A4, ETBR, FGFR2, FGFR3, FLT3, GD3, Globo H, GPC3, LAMP-1, LRRC15, Ly6E, TM4SF1, MFI2, NOTCH3, p-cadherin, PRLR, CLDN1, CD228, CUB domain-containing protein 1 The monoclonal antibody is indicated by the following antibodies: protein1 (CDCP1), CXCR4, LGR4, FZD7, CTR, GPR56, CCR7, DDR1, RNF43, and folate receptor α (FRα); more preferably, the monoclonal antibody is an anti-HER2 antibody, an anti-TROP2 antibody, or an anti-FRα antibody; even more preferably, the anti-HER2 antibody is trastuzumab, pertuzumab, or maglotuximab, and / or, the anti-TROP2 antibody is datopotamab or sacituzumab. A pharmaceutical composition comprising a compound of any one of claims 1-6, a linker of any one of claims 7-12, or a compound of any one of claims 17-22, or a stereoisomer, tautomer, meso compound, racemic compound, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt, ester, polymorph, solvate, N-oxide, isotopically labeled compound, metabolite, or prodrug thereof, and a pharmaceutically acceptable carrier. The use of a compound as described in any one of claims 1-6, a linker as described in any one of claims 7-12, or a compound as described in any one of claims 17-22, or a stereoisomer, tautomer, meso compound, racemic compound, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt, ester, polymorph, solvate, N-oxide, isotopically labeled compound, metabolite, or prodrug, or the use of a pharmaceutical composition as described in claim 23 in the preparation of a medicament for treating and / or preventing tumors; Preferably, the tumor is a solid tumor or a hematoma. More preferably, the tumor is a homologous recombination repair deficiency (HRD)-associated tumor. More preferably, the tumor is selected from tumors that are positive for or highly express the following targets: HER2, HER3, TROP2, B7-H3, B7-H4, GPC20, GPRC5D, CDH6, EGFR, EGFRvIII, AXL, Nectin-4, Tissue factor, TIM-1, PSMA, PTK7, EpCAM, MUC1, STEAP1, GPNMB, FGF2, FOLR1, c-MET, GFR, AGS-16, Guanylyl cyclase C, Mesothelin, SLC44A4, EphA2, AGS-5, GPC-3, c-KIT, ROR1, ROR2, PD-L1, CD27L, 5T4, MerTK, and Mucin 16. 16) NaPi2b, STEAP, SLITRK6, ETBR, BCMA, CEACAM5, ICAM1, SC-16, SLC39A6, Delta-like protein 3, Claudin 18.2, Claudin 3, Claudin 6, Claudin9, CD19, CD20, CD22, CD30, CD33, CD37, CD45, CD56, CD66e, CD70, CD73, CD74, CD79b, CD123, CD138, CD147, CD166, CD223, MUC16, MSLN, ENPP3, SLTRK6, FGFR, LIV-1, Lewis Y, integrin αV, integrin β6 beta-6, ITGB6), ASCT2, C4.4a, CA-IX, CD324, CD352, CD44v6, CD48a, CLL-1, Cripto, CS1, DPEP3, Ephrin-A2, Ephrin-A4, ETBR, FGFR2, FGFR3, FLT3, GD3, Globo H, GPC3, LAMP-1, LRRC15, Ly6E, TM4SF1, MFI2, NOTCH3, p-cadherin, PRLR, CLDN1, CD228, CUB domain-containing protein 1 (CDCP1), CXCR4, LGR4, FZD7, CTR, GPR56, CCR7, DDR1, RNF43, and folate receptor α (FRα); More preferably, the tumor is selected from breast cancer, ovarian cancer, non-Hodgkin lymphoma, Hodgkin lymphoma, acute lymphoblastic leukemia, anaplastic large cell lymphoma, multiple myeloma, prostate cancer, non-small cell lung cancer, small cell lung cancer, malignant melanoma, squamous cell carcinoma, glioblastoma, renal cell carcinoma, gastrointestinal tumors, pancreatic cancer, prostate cancer, rectal cancer, gastric cancer, bladder cancer, gastrointestinal stromal tumor, cervical cancer, esophageal cancer, peritoneal cancer, liver cancer, colon cancer, glioma, mesothelioma, rectal cancer, colorectal cancer, uterine cancer, salivary gland cancer, kidney cancer, vulvar cancer, thyroid cancer, penile cancer, malignant lymphoma, plasmacytoma, myeloma, and sarcoma.